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ABSTRACT
Carnitine supplementation has been shown to protect animals from
ammonia toxicity following an ammonium acetate infusion and to alter body
composition (i.e. increase lean mass and decrease body fat) in younger
animals. The aims of this study were to address the questions of whether:
1) carnitine lowers blood ammonia levels of rats fed high protein;
2) carnitine decreases the weight gain and body fat of older animals fed
high fat; 3) carnitine decreases glucose-induced insulin secretion; and
4) consumption o f a high fat diet increases total serum carnitine content.
Sprague Dawley retired female breeder rats (n-6 4) were stratified by weight
and randomly assigned to one o f the following 8 treatm ent groups for an 8
week study: carnitine (0%, 0.1%), protein (14%, 35%) and fa t
(4%, 35%). The study was analyzed as a 2 X 2 X 2 factorial with repeated
measures and ANOVA. At 2 and 8 weeks, serum levels o f ammonia, urea,
glucose, insulin, carnitine, and nonesterified fatty acids were obtained. An
oral glucose tolerance test was performed on week 5 and insulin and
glucose were measured. Body composition measurements were obtained
fo r all rats at the end o f the study. Inclusion o f dietary carnitine to rats fed
high protein resulted in a trend for lower serum ammonia and significantly
lower glucose at 2 but not 8 weeks, with no effect on urea nitrogen levels.
Insulin levels for these rats were lower at 2 week, but by 8 week had
become higher. Before and after the glucose load was adm inistered insulin
levels were significantly higher for these rats. Carnitine did not enhance

x
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fatty acid oxidation o r increase lean tissue, instead there was a tendency for
greater abdominal fat as percent o f body weight. We conclude that
cam itine’s effect on blood ammonia and glucose levels was short-lived and
that witn tim e carnitine may lead to weight gain and thus to a loss o f insulin
sensitivity. Consumption o f a high fat diet does not seem to lead to an
increase in total serum carnitine content. In addition the benefits o f carnitine
on body composition are not present in older non-growing animals.

xi
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CHAPTER ONE
INTRODUCTION
OBESITY
BACKGROUND
During the past two decades the prevalence o f obesity in individuals
o f diverse cultural backgrounds has increased, with the total number of
obese persons in the United States ranked among the highest in the world
(W olf and Colditz 1998, Kuczmarski et al. 1994). The Centers for Disease
Control reported an increase in the prevalence o f obesity, from 12% in 1991
to 18% in 1998. Even though a steady increase in obesity was observed
across all states, sexes, age groups, races, and educational levels, the most
drastic increase was observed in younger adults, people with some college
education, and Hispanics (Mokdad et al. 1999). Today more than 50% of
adults in the United States are overweight, based on a body mass index
(BMI) > 25 kg/m2 and 22% o f the adult population is obese (BMI > 30 kg/m2 )
(Flegal et al. 1998). Obesity is a m ajor risk factor in the development o f
chronic diseases such as coronary heart disease, type 2 diabetes, breast,
colon, and endometrial cancer, and certain musculo-skeletal disorders. In
addition, obesity can exacerbate many chronic conditions (e.g.
hypertension, dyslipidemia) that can further deteriorate the quality o f life of
the individual (W olf and Colditz 1998). In the United States, obesity related
medical conditions are the second leading cause o f death after smokingrelated illnesses with an estimated loss o f 280,000 lives each year (Allison

1
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et al. 1999a). In 1995, in the United States the total cost attributed to obesity
was $99.2 billion, with approximately $51.6 billion associated with direct
medical costs and $47.6 billion associated with indirect medical costs. Non
insulin dependent diabetes m ellitus (NIDDM) accounts for 63% ($32.5
billion) o f the direct economic cost of obesity (W olf and Colditz 1998). The
total econom ic costs o f overweight and obesity in the United States are
outrageous, with direct costs representing 5.7% of the National Health
Expenditure (W olf and Colditz 1998), which are comparable to the direct
costs o f cancer, 5% (Schuette et al. 1995). Estimates taking into account
the increased m ortality rate associated with obesity indicate that the direct
health care costs o f obesity are still high, compromising 4.32% o f the
National Health Expenditure (Allison et al. 1999b). The 4.32% does not
reflect the increased number of people who are at an increased risk of
becoming obese that are still young enough to not be seen. Thus, reducing
the costs associated with obesity and improving the health status and quality
o f life should be a primary public health concern.
The developm ent of obesity has been attributed to both genetic and
environm ental factors. However, since our genes have not changed during
the relatively short period o f tim e in which obesity has increased, it is the
changes in the environment that have led to the rise in obesity. There are
many environmental factors that can affect the components o f energy
balance, both intake and expenditure. The contributions to energy balance
observed with changes in energy expenditure seem to be small compared to

2
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those o f energy intake. There is evidence indicating that positive energy
balances are caused by loss o f appetite control and increased energy
intake, rather than by defects in energy expenditure (Grossman and
Despres 1996, Poppitt 1995). A continuous state of positive energy balance
has been shown to cause gradual weight gain that can eventually lead to
obesity (Poppitt 1995).
The composition of the diet may be an important factor contributing to
the higher incidence o f obesity in certain populations. Consumption o f highfat diets has been shown to result in overconsumption o f food, which may
lead to an increase in fat deposition, and eventually to obesity (Poppitt,
1995, Salmon and Flatt 1985). The hyperphagia associated with high fat
diets is caused by the combination o f the high fat and high energy content o f
the diets. High-energy dense diets have a greater fat content than that of
lower energy dense diets. Consumption o f a high-fat, high-energy dense
diet should be accompanied by a decrease in the total amount of food
consumed to avoid a state of positive energy balance and thus weight gain.
The amount of fat that can be oxidized is also an important determinant in
body energy regulation and is thus an im portant factor in the development of
obesity (Flatt 1995). Weight maintenance is achieved when the amount of
carbohydrate and fat oxidized is equivalent to that consumed in the diet.
Consumption o f a high carbohydrate diet during periods o f positive energy
balance reduces the amount o f fat oxidized. High fat, high energy dense
diets lead to an increase in fat oxidation, but if the amount o f calories

3
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consumed are in excess, fa t oxidation will decrease leading to increased
body fat and weight gain (Flatt 1995, Poppitt 1995). In an effort to improve
body weight, Americans are now consuming less fat as percentage o f total
calories, but the amount o f calories consumed has increased. Therefore,
although the percentage o f calories from fat is down the total amount of fat
consumed has remained the same or increased causing an increase in
energy consumption and increased weight gain (Allred 1995).
According to the Continuing Survey o f Food Intakes by Individuals
(CSFII 1994-1996) Americans consuming the typical W estern diet are eating
a diet that is still too high in fat and low in some nutrient dense foods.
Results o f the CSFII (94-96) indicated that the mean daily caloric intake
consumed by men and women ages 20 and over was 15.8% and 15.8%
from protein, 33.4% and 32% from fat, 49.3% and 51 % from carbohydrates,
and 1.5% and 1.2% from alcohol, respectively (USDA 1998). The caloric
intake was overall less then the Recommended Dietary Allowance (RDA),
with mean intake being 88% o f the RDA for calories and fem ales 30 years of
age or older having a caloric consumption in the upper range (70%) of the
recommended intake (USDA 1998). The reported energy intake o f the
participants does not reflect the observed increase in obesity. It is possible
that the RDA established fo r energy is too high o r that the survey was
skewed (Katz 1998). Furthermore, a decrease in the amount o f physical
activity could also be a contributing factor to the increase in obesity. Protein
consumption was greater than the RDA for all participants, even those

4

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

consuming the low er amounts o f protein. Females over 70 years of age
consumed 113% and both male and female children consumed more than
200% o f the RDA fo r protein (USDA 1998).
Many more Americans are now consuming diets that are approaching
a balance but there is still need for more im provem ent (Katz 1998). For
instance, individuals trying to lose weight are consuming diets, such as
“Sugar Busters”, that are high in fat and protein. The amount o f
carbohydrate and calories consumed in these diets is reduced, with most
starchy, sugary foods and desserts being elim inated. Individuals consuming
these diets seem to attribute the weight loss to the reduction in the
carbohydrate content o f the diet and an effect on glucose regulating
hormones, but in reality most o f these diets are calorie-restricted and it is the
decrease in energy consumption that leads to the weight loss. In addition,
high protein diets supplemented with additional protein sources are being
consumed in an effort to increase muscle mass and weight gain. Protein
supplements are perhaps the most common ergogenic aid or dietary
supplement used by athletes today (Applegate and G rivetti 1997). Athletes
are now consum ing not only basic protein supplem ents but are also
consuming supplem ents with specific amino acids, such as the branched
chain amino acids, arginine, and taurine, which claim to serve as an energy
source, increase levels o f growth hormone, and increase weight gain. It is
also common fo r athletes to consume protein and amino acid beverages
during and after exercise (Applegate and G rivetti 1997).

5
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HORMONAL INFLUENCES
Insulin is a peptide hormone that helps regulate the metabolism of the
macronutrients. Adequate amounts o f insulin are needed for the proper
oxidation and storage o f carbohydrates (G roff et al. 1995). In addition,
insulin helps promote uptake o f amino acids into muscle cells and prevent
breakdown o f existing protein (Karam 1997). Insulin’s actions in fat
metabolism are to provide fatty acids and glycerol for re-esterification to
triacyglycerols and to prevent the breakdown o f existing triacylglycerol
molecules (Karam 1997). Insulin functions by activating or inactivating
enzymes involved in the oxidation and synthesis of these nutrients, allowing
fo r adequate metabolic processes to occur. When the normal functions of
insulin are impaired the metabolism o f the macronutrients will be disrupted
and this may lead to the development of metabolic disorders. Decreased
insulin secretion and decreased insulin sensitivity are two defects by which
the actions o f insulin can become impaired. In addition, insulin has also
been shown to act as an adiposity signal in the central nervous system
leading to decreased food intake, weight loss, and increased thermogenesis
(Schwartz et al. 1992).
The relationship between insulin resistance and obesity has been
studied extensively. There is still controversy about whether it is the
condition o f obesity that causes insulin resistance or if the presence of
insulin resistance is what leads to the development of obesity. The
com plexity o f this relationship makes it harder to identify strategies for

6
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weight reduction and maintenance and to develop more appropriate
guidelines for people with insulin resistance.
TREATMENTS
There are many programs and strategies available fo r weight
reduction and weight maintenance, but the number o f Am erican people who
are obese is higher than before and is starting to reach epidem ic
proportions. Among the available strategies is the low carbohydrate, high
fat and high protein diet, such as Sugar Busters, Protein Power Plan, Zone
and the Atkins diet, that is being advocated by many. Eating moderate
amounts and a wide variety o f foods while increasing physical activity is
another strategy that is used. In addition, there are many drugs available
that are being used to suppress appetite, decrease fat absorption, and/or
increase metabolic rate. Furthermore, use o f supplements that are
advertised to enhance the oxidation o f fat, increase lean muscle mass, and
lead to rapid weight loss are viewed as alternative ways to treat obesity.
Carnitine, a trim ethylated quaternary amine, plays a crucial role in the
metabolism of fat and protein. L-camitine is the active isom er o f this
compound and is obtained from exogenous (diet) or endogenous (synthesis)
sources. Because o f its role in fat metabolism, the use o f L-cam itine as a
supplement to increase fat oxidation and weight loss is being evaluated. In
addition, use of supplemental L-camitine to enhance nitrogen utilization and
promote growth of lean muscle is being advocated as a means o f improving
body composition. L-cam itine has an indirect effect on the metabolism of

7
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glucose because it affects fat and protein metabolism. Therefore, Lcam itine is also being utilized as a potential treatm ent for type 2 diabetes.
L-camitine along with other supplements is being used by many as a way of
achieving rapid changes in body composition and to am eliorate metabolic
disorders associated with obesity.
OBJECTIVES
The objectives o f this study were to exam ine the effects o f
supplemental dietary L-Cam itine on ammonia levels and body composition
o f rats fed high protein and high fat diets. The specific objectives addressed
by the study were the following:
•

To determine the effects o f dietary carnitine on ammonia levels and urea
production in rats fed low and high protein diets.

•

To determine if dietary carnitine reduces weight gain and body fat in
older rats fed a high fat diet.

•

To determine if dietary carnitine reduces glucose-induced insulin
secretion in rats fed different levels o f protein and fat.

•

To determine if consumption o f a high fat diet increases the synthesis of
endogenous carnitine as indicated by total serum carnitine.

•

To determine if dietary carnitine enhances fatty acid oxidation as
measured by 3- hydroxyacyl CoA dehydrogenase (HOAD) in skeletal
muscle.

8
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HYPOTHESES
•

Inclusion o f dietary carnitine will decrease glucose oxidation and insulin
secretion.

•

Dietary carnitine w ill decrease serum ammonia levels and increase blood
serum urea production o f rats fed a high protein diet.

•

The addition o f dietary carnitine to rats fed a high fat diet w ill result in
decreased weight gain and improved insulin sensitivity.

•

Consumption of a high fat diet will increase the synthesis o f carnitine.

•

Rats on the high fat diet consuming dietary carnitine w ill have enhanced
fatty acid oxidation.

9
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CHAPTER TWO
REVIEW OF LITERATURE
CARNITINE
INTRODUCTION
Carnitine, an important constituent o f biological systems, is a smallmolecular weight water-soluble quaternary amine (p-OH-y-Ntrim ethylam inobutyric acid; see Appendix A for structure). L-camitine was
discovered in 1905, but its crucial role in metabolism was not elucidated until
1955 (Brem er 1983). Mammals and microorganisms are capable of
synthesizing carnitine from two dietary amino acids, lysine and methionine.
In humans, biosynthesis o f carnitine from deoxycamitine, the immediate
precursor o f carnitine, is limited to the liver, brain, and kidneys (Bremer
1983). In addition, foods o f animal origin such as meat and dairy products
are significant sources of exogenous L-cam itine in human nutrition (Mitchell
1978). There is no known established human dietary requirement for
carnitine, but in general consumption o f a well-balanced healthy diet
contains adequate amounts of carnitine and the two amino acids, lysine and
methionine, needed for carnitine biosynthesis (Kelly 1998). On average, the
American non-vegetarian diet provides approximately 100-300 mg (0.621.86 mmol) o f L-cam itine daily with endogenous synthesis providing about
300-600 mg/day (1.86-3.73 mmol) (Feller and Rudman 1988).
The total carnitine pool in a healthy individual is about 100 mmol, with
the biggest pool found in skeletal muscle (98%) and the remaining amounts

10
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in the liver and kidney (1.5%; Gatti et al.1998). Diet, endogenous synthesis,
and efficient reabsorption by the kidneys influence plasma carnitine levels.
Carnitine baseline levels are also influenced by gender, age and nutritional
status (Gatti et al.1998). The concentration o f carnitine varies across
species and different tissues. In mammalian tissues, the highest
concentration o f carnitine is in the heart and skeletal muscle. Tissue
carnitine concentration is related to the specific functions o f this compound.
Fatty acid and amino acid catabolism are among the metabolic pathways
dependent on carnitine for proper functioning.
The role o f L-cam itine in the oxidation o f long-chain fatty acids in
animal tissues has been well established. Carnitine has been shown to
enhance long-chain fatty acid oxidation in homogenates o f different tissues
(Fritz 1955) and in isolated mitochondria (Fritz et al.1962). Carnitine allows
long chain acyl CoA esters to cross the mitochondrial membrane, which is
impermeable to CoA compounds (Feller and Rudman 1988). Activated
long-chain fatty acids need to be transported inside the mitochondria for
beta-oxidation to occur. On the outer side o f the inner mitochondrial
membrane, long-chain fatty acylcam itine esters are formed by the enzyme
carnitine palm itoyltransferase I. These esters can then cross the inner
mitochondrial membrane. Once inside the inner mitochondrial membrane,
the fatty acyl CoA and carnitine are regenerated by the enzyme carnitine
palm itoyltransferase II.

11
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Less is known about the role o f carnitine in amino acid metabolism.
Carnitine seems to serve a facilitative role if not an obligatory role in the
catabolism o f branched chain amino acids (Borum 1983). The discovery o f
branched-chain acylcam itines lead researchers to believe that carnitine
m ight be involved in the transport o f branched chain am ino acids into the
mitochondria. Presence o f the a-keto acid dehydrogenase inside the inner
mitochondrial memebrane indicated that the branched chain am ino acids did
not need to be transported as branched-chain acylcam itine into the
mitochondria. Inside the m itochondria the branched chain 2-oxoacids
(transaminated form o f the branched chain amino acids) get converted to
their corresponding branched chain acylCoA esters. The proper oxidation o f
branched chain amino acids requires the removal of the branched chain 2oxoacids to prevent excess form ation o f CoA inside the m itochondrial matrix
(Brem er 1983, Hinsbergh et al.1978). Researchers believe that carnitine
seems to be participating in am ino acid metabolism by form ing branched
chain acylcam ities thus decreasing the branched chain acylCoA esters and
providing a buffering effect on the m itochondrial acyl-CoA/CoA ratios
(Brem er 1983, Hinsbergh et al.1978). The ability of acetyl carnitine to move
freely across subcellular membranes allows it to function as a pool from
which acetyl-CoA is regenerated (G atti et al.1998). Thus, making it possible
fo r metabolic energy to be transported between different organs.
Another role o f carnitine in metabolism is to protect cells against toxic
accumulation o f acyl-CoA compounds. Carnitine traps acyl-CoA
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compounds o f either endogenous or exogenous origin by forming carnitine
esters. These acyl carnitine esters can then be transported to the liver for
catabolism or to the kidneys for excretion (Feller and Rudman 1988).
It has been suggested that for some individuals and under certain
conditions carnitine can be considered a conditionally essential nutrient
(Kelly 1998). Therefore, therapeutic functions o f carnitine for individuals
with a nutritional deficiency or a genetic defect, are becoming more
widespread. Prim ary L-camitine deficiency was first described by Engel and
Angelini (1973) in the early 1970’s. Primary carnitine deficiency is classified,
based on the abnorm ality o f the tissue distribution o f carnitine, into two
autosomal recessive disorders, myopathic and system ic. In the myopathic
condition, the concentration of carnitine in muscle is low and plasma levels
are normal. This deficiency is characterized by muscle weakness and is
accompanied by an increase in plasma enzymes o f muscle origin. A defect
in the transport o f carnitine has been proposed as the cause for this
deficiency. In the system ic condition, carnitine concentrations are low in
plasma, liver and in skeletal and heart muscle. Symptoms include muscle
weakness and irregularities o f the liver, central nervous system and heart.
The following conditions can also be observed: encephalopathy,
hyperbilirubinemia, hyperammonemia, and cardiom yopathy. The defect
associated with this deficiency is not known (Feller and Rudman 1988).
Secondary carnitine deficiency is most commonly associated with genetic or
acquired metabolic defects and seems to occur more often than the primary
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deficiency. Some o f the current therapeutic applications o f carnitine include
treatment o f anorexia nervosa, chronic fatigue syndrome, heart disease, and
male infertility (Kelly 1998).
INTERACTION WITH MACRONUTRIENTS
P rotein
Carnitine is considered an essential compound for proper amino acid
metabolism. Research has been conducted to determine if carnitine has a
protective effect against ammonia toxicity, can affect the growth
performance o f animals and cause variations in body composition. The
underlying mechanisms o f these effects o f carnitine are not always clear.
Several hypotheses have been proposed to try to elucidate these
mechanisms.
Ammonia concentrations in nearly all-animal tissues are maintained
at very low levels. A 5 to 10 fold increase in ammonia concentration in the
blood induces toxic effects in most species. Functional disturbances of the
central nervous system accompany these toxic effects (Felipo et al.1988).
The effect o f hyperammonemia on brain function is not well understood
making it harder to develop appropriate treatments. In ureotelic species the
main mechanism used to prevent ammonia toxicity is the production of urea.
In mice, the protective effect of L-camitine on ammonia toxicity was
reported by O’Connor et al.(1984). Male Swiss albino mice fed a standard
diet were injected with a single intraperitioneal injection o f 12 mmol
ammonium acetate/kg o f body weight (LD «» = 12 mmol; 0.8 M solution).
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Thirty-m inutes prior to ammonium infusion, mice were injected
intraperitoneally with different doses o f L-camitine, 8, 16, 24 and 32 mmol/kg
o f body weight or with a saline solution. Symptoms o f ammonia toxicity
were seen rapidly after the injection for the mice who received the saline
solution. Mice given ammonium acetate with saline solution die between 10
to 15 minutes, so all o f the mice were sacrificed 10 minutes after the
ammonium acetate injection; their brains were removed and frozen in liquid
nitrogen. Enzymatic determination was done fo r the following metabolites:
ammonia, lactate, pyruvate, a-ketoglutarate, glutamate, and glutamine.
Mice fed L-cam itine had decreased levels o f ammonia in the brain and the
blood (p<0.01) when compared to saline treated mice. L-cam itine
suppressed the mortality associated with acute ammonia intoxication. A t the
lower dosages o f L-cam itine the survival rate was 60%, symptoms were
present but attenuated, and the appearance of toxicity was delayed. A t the
higher dosages, the survival rate fo r the mice was 100%. Adm inistration of
L-cam itine prevented the accumulation o f glutamine and the decrease in
glutamate levels was smaller, making the levels o f these two m etabolites
significantly (p<0.01) different than levels in mice injected with saline.
Increased glutamine synthesis from glutamate leads to an increase in ATP
consumption and thus a decrease in ATP levels. In addition, glutam ine can
eventually affect the transport o f reducing equivalents (NAOH) into the
mitochondria via the malate aspartate shuttle causing a decrease in the
amount o f ATP produced. L-cam itine also made levels o f a-ketoglutarate,
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which are slightly increased by ammonia, more normal. The increase in
glutmate m ight be due to both the decreased conversion to glutamine and
increased synthesis from a-ketoglutarate. Blood urea nitrogen levels for
both protected and unprotected mice were sim ilar at the time o f death.
O’Connor et al.(1984) concluded that the early protective effect o f Lcam itine was not caused by an increase in urea synthesis. The most
important protective effect seemed to be the increase in glutamate in the
brain, which may reflect enhanced ammonia utilization via glutamate
dehydrogenase, which converts a-ketoglutarate to glutamate. A decrease in
levels o f glutam ate, a major excitatory neurotransm itter in the brain, may
result in neurological problems, such as coma, during periods o f ammonia
intoxication.
Costell et al. (1984) examined the effects of L-cam itine on urea
synthesis follow ing acute ammonia intoxication. Male Swiss Albino mice fed
a standard diet were divided into two groups. One group received saline
with an intraperitoneal injection with a LD 100 o f ammonium acetate (12
mmol/kg). Another group received an intraperitoneal injection o f L-cam itine
(16 mmol/kg) 30 minutes before the ammonium acetate challenge. Five
minutes before receiving the ammonium acetate injection animals in both
groups received a pulse o f (14C) NaHCOa- In addition, an intracardiac
injection o f 50 ul o f an aqueous (14C) N aH C 03 solution containing 2 mCi/ml
(57.8 mCi/mmol o f specific radioactivity) was adm inistered. After the
ammonium acetate injection blood samples were drawn from the tail vein at
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designated times. Samples were analyzed for plasma 14C urea and 14C
bicarbonate determination. At sacrifice, the livers were removed and
hepatic mitochondria were isolated from which the intram itochondrial
content o f N-acetylglutmate was estimated. Anim als not given L-cam itine
exhibited symptoms o f ammonia toxicity, such as hyperexcitability and
seizures, which progressed to death in 15 minutes. A higher synthesis o f
14C urea was observed for animals protected with L-cam itine than fo r
animals given ammonium acetate only. The enhancement o f urea synthesis
observed could be due to an increase in intram itochondrial content o f acetyl
CoA and synthesis o f N-acetylglutamate caused by higher rates o f fatty acid
oxidation. In this study, the level o f N-acetylglutamate rose rapidly after the
ammonium acetate injection and the levels were the same in animals given
or not given the L-camitine. Thus, L-camitine did not induce a further
increase on the hepatic intramitochondrial levels o f N-acetylglutamate above
that induced by ammonia. To summarize, there must be some other factor
involved in the stimulation of urea synthesis by L-cam itine. Alternative
explanations could include an increase in intramitochondrial ATP or an
increase in concentration o f some urea cycle interm ediates (Saheki et
al.1980, Fritz and Marquis, 1965).
In a sim ilar study, Deshmukh and Rusk (1988) examined the effects
of L-cam itine on ammonia toxicity. Male Swiss Albino mice (n=47) were
divided into the following 4 groups: Saline (n=8), L-cam itine (n=6), Saline +
Ammonium Acetate (n=14), and L-camitine + Ammonium Acetate (n=19).
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All groups were maintained on a Purina rodent chow diet. An
intraperitioneal injection of ammonium acetate (14 mmol/kg o f an 0.8 M
solution), 30 minutes after saline or L-cam itine administration, was given to
mice in groups 3 and 4. Mice were sacrificed 5 minutes after the ammonium
acetate injection. At this time blood was collected from the heart and the
brain was removed and frozen in liquid nitrogen. Then blood samples were
analyzed three hours later for levels of ammonia and urea in serum and
plasma. This study differed from the one conducted by O’Connor et al.
(1984) where blood samples were collected from the tail vein. Preliminary
experiments had been conducted to determine the lethal dose of amonium
acetate. Mice were injected intraperitoneally with different dosages of
ammonium acetate, ranging from 1-18 mmol/kg. Contrary to the findings of
O’Connor et al. (1984), the LD 100 of ammonium acetate was observed at a
higher concentration o f ammonium acetate, 14-18 mmol/kg. The
intraperitioneal injection with L-camitine (16 mmol/kg) did not alleviate the
symptoms o f hyperammonemia. A rapid increase in serum and liver levels
o f ammonia was observed after the ammonium acetate injection for mice
given carnitine or saline, but brain levels did not increase. In contrast, the
results o f O’Connor et al. (1984) showed that brain ammonia levels did
increase rapidly in animals that received ammonium acetate. Deshmukh
and Rusk found that mice treated with ammonium acetate plus L-camitine
had higher levels of ammonia in the liver than the mice injected with saline
plus ammonium acetate (p<0.05). The researchers concluded that the
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increase was m ost probably due to a higher load o f nitrogen derived from
the carnitine. In addition, the results showed that L-cam itine failed to protect
mice against ammonia toxicity. The higher ammonium dose used by
Deshmukh and Rusk could explain the lack of an effect o f carnitine on
ammonia levels.
In a study conducted by Therrien et al. (1997) the efficacy o f Lcam itine in the prevention o f hepatic encephalopathy, a complex
neuropsychiatric disorder associated with acute or chronic liver failure, in
hypearmmonemic conditions was evaluated. Adult male Sprague-Dawley
rats (n=70) were anesthetized and an end-to-side portacaval anastomasis
(PCA) surgery was performed to create a portacaval shunt to bypass the
liver. Thirty-five rats received L-cam itine (16 mmol/kg) intraperitoneally 1
hour before a subcutaneous dose o f ammonium acetate (8.5 mmol/l/kg).
The other 35 received a saline injection with the same subcutaneous dose
o f ammonium acetate. Cerebrospinal fluid (CSF) ammonia, lactate, and
amino acid levels were measured. To collect CSF catheters were inserted
in the cistem a magna space and 24 hours after the operation silastic tubing
was connected to the catheter for CSF sampling. A 25 ul sample o f CSF
was drawn just before L-cam itine or saline was administered, 10 minutes
before adm inistration o f ammonium acetate, 30 minutes after ammonium
adm inistration, and 10 minutes later. Neurological deterioration was not
observed fo r any o f the rats in the L-camitine treated group, whereas salinetreated rats manifested severe encephalopathy progressing through the loss
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o f righting reflex to coma. The L-camitine treated group had a survival rate
o f 100% compared w ith 5% in the saline treated group. Adm inistration of
ammonium acetate increased CSF ammonia to 0.9S ± 0 .1 5 m m ol/L and 1.24
± 0.15 mmol/L at precoma and coma stages, respectively (p<.01). CSF
ammonia at both stages was significantly (p < .01) reduced in the Lcam itine-treated group when compared to the saline-treated group.
Treatment with L-cam itine did not led to a significant reduction in plasma
ammonia nor CSF o r brain glutam ine levels. However, L-cam itine led to a
significant attenuation o f the CSF lactate increase that was seen fo r the
saline treated rats at both precoma (p < .001) and coma stages (p < .001) of
encephalopathy. Increased CSF alanine levels were also decreased by
36% at precoma (p < .01) and 34% at coma (p < .05) stages fo r animals
treated with L-cam itine compared with saline-treated animals. The
attenuation observed suggests that in the L-cam itine-treated group
mitochondrial respiration had been at least partially restored. The enzyme a
ketoglutarate dehydrogenase, which converts a ketoglutarate to succinyl
CoA, is inhibited by pathophysiological concentrations o f ammonia.
Inhibition o f this enzym e results in decreased pyruvate oxidation coupled
with an increase in brain levels o f lactate and alanine. By decreasing CSF
ammonia levels, carnitine may have prevented the ammonia-induced
inhibition o f a ketoglutarate dehydrogenase. These results lead the authors
to conclude that the m ajor protective effect of L-cam itine involves a central
rather than peripheral mechanism. In addition, in patients with liver disease

20

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the use o f L-cam itine to prevent and treat ammonia-precipitated coma could
be considered a rational approach.
Hearn et al. (1989) did a series o f experiments to determine if Lcam itine had a protective effect against hyperammonemic conditions in
male W istar rats. An end-to-side portacaval shunt (PCS) was used to
induce a chronic hyperammonemic state. In experiment one, PCS
hyperammoneic rats (n=5) were injected intraperitoneally with L-cam itine
(16 mmol/kg) one hour prior to a LD 100 (12 mmol/kg) dose o f ammonium
acetate via an intraperitoneal injection. In the second experiment, rats were
given ammonium acetate (n=9), ammonium acetate plus L-cam itine 1 hr
prior to ammonium infusion (n=7), or ammonium acetate plus L-cam itine 24
hr prior to ammonium infusion (n=5). In the last experiment, rats received
either a saline injection 30 minutes (n=5) or 1 hr (n=4) prior to ammonium
acetate infusion or L-cam itine 30 minutes (n=9) or 1 hr (n=17) prior to
ammonium acetate infusion. Animals were killed by freeze-blowing, a
procedure where the forebrain is extruded through a hollow needle and
rapidly frozen. The brain tissue was deproteinized and the homogenate was
neutralized. The homogenate was analyzed for the following brain
metabolites: total acid-soluble carnitine, ammonia, free carnitine, and shortchain acylcam itines. The protein pellet was resuspended in KOH for longchain acylcam itine determination. The percentage survival rate for animals
treated with L-cam itine varied across experiments, ranging from 35 to 100%.
Results o f the first 2 experiments suggested a significant protective effect for
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L-camitine, based on the survival rate o f the animals. Results from the third
experiment suggested a protective effect that did not reach statistical
significance. The concentration o f L-camitine increases slowly in the brain,
as expected for a compound that penetrates the blood-brain barrier poorly.
Despite this accumulation was observed in moderately large amounts over
several hours. At 1, 4, and 24 hours following an L-camitine injection, total
acid soluble carnitine slowly increased in the rat forebrain and was
significantly different from baseline data, p=0.05, p=0.025, and p=0.025,
respectively. But the protective effect o f carnitine was com pletely lost when
L-camitine was given 24 hr. prior to the ammonium infusion. Thus, this
increase does not correlate with the protective effect o f L-camitine against
acute ammonia toxicity. In conclusion, the authors suggest that in rats the
protective effect o f L-camitine is short-lived; protection is maximal 1 hr after
administration and undetectable at 24 hr. Therefore, this study suggests
that protection from toxicity depends mainly on peripheral rather than central
L-camitine dependent mechanisms.
According to Felipo et al. (1994) L-camitine prevents ammonia
toxicity by preventing glutamate neurotoxicity. Primary cultured neurons
were prepared from the cerebellum o f 8 day-old W istar rats. Before addition
of glutamate (1 mM) to the cells some of the cells were pre-incubated with
carnitine. To determine the effect of L-cam itine on glutamate binding to
different types o f glutamate receptors, cells were incubated with glutamate
(labeled and unlabeled), and Tris-citrate with or without carnitine. Binding o f
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different receptors to glutam ate was determined by subtracting the binding
determined in samples containing unlabeled glutamate and unlabeled
glutam ate receptors (N-methyl-D-aspartate-NMDA, kainate, and
quisqualate). Results indicated that L-camitine prevented glutam ate toxicity,
in a dose-dependent manner, by increasing the affinity o f glutam ate for the
quisqualate receptor and decreasing the affinity for the NMDA receptor. It
has been shown that acute ammonia toxicity is mediated by activation of the
NMDA receptor (Felipo et al.1988). Activation o f the NMDA receptor by
glutam ate results in an increase in cytoplasmic levels o f Ca2+that lead to
neuronal death. Thus, L-cam itine prevents glutam ate toxicity by
preferentially activating the quisqualate receptor and preventing an increase
in cytoplasm ic Ca+2 and the neurotoxicity prompted by activation o f the
NMDA receptor. By preventing the glutamate neurotoxicity carnitine could
stop the development o f ammonia toxicity.
Results o f the studies conducted by O'Connor et al. (1984) and
Costell et al. (1984) in mice, and Therrien et al. (1997) and Heam et al.
(1989) in rats, and Felipo et al. (1994) in primary cultured neurons provide
evidence to support the protective role of carnitine in the treatm ent of
ammonia toxicity. But each study attributed the protective effect to a
different mechanism; thus the exact mechanism that affords this protective
effect remains to be elucidated. The study by Deshmukh and Rusk (1988)
in mice is the only one that found a lack of a protective effect on carnitine on
ammonia toxicity. Therefore, there seems to be some promise to support
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the use o f L-cam itine as a therapeutic treatm ent fo r conditions that alter the
normal levels o f ammonia in the blood and brain.
The effect of L-camitine on growth performance and body
composition o f animals and athletes is also being investigated. The use of
carnitine as a supplement in animal feed has drawn attention because o f its
potential to enhance the protein-sparing action o f fat and promote growth (Ji
et al.1996). In humans, studies with carnitine supplementation have been
conducted to determine the relationship between plasma carnitine
concentration and variation in body com position (G atti et al.1998, Amodio et
al.1990).
Ji et al. (1996) examined the biochemical actions o f carnitine at the
cellular and subcellular levels in Atlantic Salmon (Salmo salar). Four
hundred and eighty Atlantic Salmon fry (Penobscot-strain) were transferred
to 12 tanks (n=40). The fish were reared under simulated natural
photoperiods and were accustomed to the control diet for 2 wk. Before the
fish were assigned to dietary treatm ents they were anesthetized, blotted with
paper towels, and weighed. Body w eight and length were recorded for the
fish in each tank. Fish were fed one o f four diets fo r 6 wk: control (cam itinefree), and carnitine supplemented 4.6, 11.5 or 23 mmol/kg wet weight o f
finished diet. A daily ration of 3% o f the body weight was achieved by using
autom atic feed dispensers. Four different experiments were conducted.
Experim ent 1, was a preliminary trial to examine growth and feed conversion
in fish fed the different diets. In experim ent 2, changes in body composition
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were measured and preliminary data were collected fo r biochemical
responses. Experiment 3, included an analysis o f biochemical responses to
dietary carnitine. Experiment 4, was conducted with 2-yr old salmon and
results were compared to metabolic measurements from isolated
hepatocytes from juvenile salmon (Experiment 3). Specific growth rate and
the feed conversion coefficient were calculated for all experiments. Protein
content was determined in isolated liver mitochondria and hepatocytes by
the biuret method. Proximate analysis o f tissue composition was conducted
in three fish, randomly chosen, from each o f 2 tanks per diet. Fish were
fasted fo r 16-18 hr, scales were removed and filets and skins were excised
from both sides. The visceral organs, minus the posterior intestine were
also removed. The filets and viscera were immediately frozen and stored
until the tim e o f analysis. Samples were thawed, minced with a small
electric coffee grinder, and moisture, ash, fat (Soxhlet extraction method),
and protein (Kjeldahl method) content were determined. The following
parameters were also determined: free amino acids in blood and liver, fatty
acid oxidation in mitochondria, flux through pyruvate carboxylase (PC;
converts pyruvate to oxaloacetate) in liver mitochondria, flux through the
branched-chain a-keto acid dehydrogenase complex (BCKDH; converts aketo acid to corresponding CoA compound) in liver mitochondria, and
protein synthesis.
No significant (p>0.05) differences were observed in the body
weights, specific growth rates (percentage change in body weight/day), or
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feed conversion for juvenile salmon fed the carnitine-free or carnitine
supplemented diets. Supplemental carnitine did not have an apparent
influence on efficiency o f feed conversion (p>0.05). Proximate analysis of
the filets and visceral organs o f juvenile salmon indicated that carnitine
supplementation decreased lipid content, in a dose-dependent manner, by
as much as 73% (p< 0.005). Protein concentration increased, in a dosedependent manner, by as much as 62% fo r fish fed carnitine (p< 0.005).
Liver from 2-yr old salmon and juvenile salmon fed carnitine oxidized
palmitate at rates that were 2.5 (p<0.05) and 1.5 times (p<0.001),
respectively, the rates observed with liver from carnitine deprived cohorts.
Plasma concentrations o f proline, valine, and cysteine were significantly
(p<0.05) greater for juvenile salmon-fed the carnitine-supplemented diet.
The liver concentration o f all 3 of these amino acids plus leucine, isoleucine,
histidine, and glycine was significantly (p<0.05) greater for juvenile fish fed
carnitine. Cam itine-fed salmon had a significantly (p<0.001) greater PC flux
(81% greater), but no difference in BCKDH flux, when compared with
salmon not fed carnitine. The capacity for protein synthesis, measured by
incorporation o f radiolabeled methionine into acid-insoluble material, was
significantly greater (p<0.05) for juveniles and 2-y-old salmon fed the
carnitine diets. In conclusion, the mechanism for carnitine-induced changes
in nitrogen metabolism could be explained by the enhanced protein
synthesis and increased PC flux. By increasing the ratios o f acetyl
CoA:CoA-SH and ATP:ADP ratios carnitine might stimulate flux through PC
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and reduce flux through the BCKOH complex. Thus increasing the supply o f
carbon fo r synthesis of nonessential amino acids (via increased PC) and the
supply o f branched-chain oc-keto acid fo r re-am ination to the branched chain
amino acids (via reduced BCKDH).
The practice o f weaning pigs at a young age has motivated
nutritionists to develop feasible feeding practices that can help promote
maximum growth rate (Owen et al.1996). To evaluate the effect of dietary Lcam itine on growth performance and body com position o f early-weaned
pigs, Owen et al. (1996) conducted two experiments. In experiment 1, 120
weanling pigs were allotted into 6 groups (2X3 factorial arrangement o f
treatm ents). Each group consisted o f 4 pigs per pen with five replications
(pens) per treatment. Two levels o f soybean oil (0 or 10%) and 3 levels o f Lcam itine (0, 500, 1,000 ppm) were given from day 0 to 14 after weaning.
Fourteen to thirty-five days after weaning, levels were reduced to 0 or 5%
and 0, 250, and 500 ppm for soybean oil and L-cam itine, respectively. In
the second experiment, 180 weanling pigs were distributed in a 2X3
factorial. Each group consisted o f 6 pigs per pen and 5 replicates per
treatm ent. L-cam itine was fed at 2 different levels, 0 or 1,000 ppm, for the
first 14 days after weaning. Pigs for each o f these diets were then fed 0,
250, or 500 ppm o f L-camitine from day 14 to 35. On days 7 and 28, blood
samples were collected via vena cava puncture fo r all pigs. Plasma was
analyzed fo r urea N and nonesterified free fatty acids. To determine initial
body composition measurements, 12 pigs were selected randomly at day 0
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and carcass com position fo r the whole animal was calculated. A t the end of
the experiment, 14 pigs from the following treatm ents were slaughtered: 0 or
1,000 ppm L-cam itine from day 0 to 14 and 0 or 500 ppm L-cam itine from
day 14 to 35. Carcass com position measurements were determ ined using
the 1990 Association o f O fficial Analytical Chemists (AOAC) methods. The
average value fo r initial body composition measurements was subtracted
from composition measurements obtained at day 35 after weaning. Crude
daily lipid and protein accretion rates were calculated by dividing this
difference by 35 days.
In the first experim ent, L-cam itine and soybean oil had no significant
(p>0.10) effect on pig perform ance for the first 14 days. The gain:feed ratio
significantly (p <0.05) improved from day 14 to 35 with increasing dietary Lcamitine. Twenty eight days after weaning, plasma urea N concentrations
significantly increased (p<0.05) with increasing L-cam itine. In the second
experiment, carcass m oisture and protein percentages were not significantly
(p>0.10) influenced by dietary L-camitine. On day 35, Pigs fed 1,000 ppm
(day 0 to 14) o f L-cam itine had significantly (p<0.05) less carcass lipid and
daily lipid accretion rates whether they were fed or not fed L-cam itine from
day 14 to 35. The authors concluded that L-cam itine im proved the gaimfeed
ratio and reduced carcass lipid accretion in early-weaned pigs. But that
further investigations are needed to determine the optim al levels or
sequence o f L-cam itine supplementation.
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To investigate the relationship between plasma carnitine and acetyl
carnitine levels and body composition, Gatti et al. (1998) conducted a study
in 33 well-trained athletes, 14-49 years o f age (26 males and 7 females).
Subjects were fasted fo r 4 hours and blood samples were taken and
analyzed for plasma carnitine and acetyl carnitine concentrations.
Bioelectrical Impedance Assay (BIA) was used to determ ine body
composition measurements of the subjects. A significant negative
correlation was found between plasma acetyl carnitine and fat free mass
(FFM) in kilograms (p< 0.0001) and as percent o f body mass (p<0.01). A
significant (p<0.01) positive correlation was found between percent fat mass
(as % o f body mass) and plasma acetyl carnitine. The authors concluded
that the negative correlation between plasma acetyl carnitine and muscular
mass variation might be due to a metabolic muscle improvement in relation
to muscular FFM increment. This might provide evidence that muscle
metabolism changes in relation to plasma acetyl carnitine concentration.
Contrary to these results, a study conducted by Am odio et al. (1990) found
no relationship between triceps skinfold measurements and carnitine plasma
levels.
To determine what effects a hyperammonemic animal model has on
body composition, Miffana et al. (1989) conducted a study in male W istar
rats (150-200 g). Rats were fed for 6 wk either a diet containing 20% (w/w)
ammonium acetate (n=7) o r a standard control diet fed ad libitum (n=7) or
pair fed (n=7). Body composition measurements were obtained for rats fed
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ammonium acetate (n=4) and the standard ad libitum (n=4) diet. Moisture
content was determined by lyophilization, lipids were extracted with
chloroform/methanol, and the nitrogen content o f the defatted extract was
determined by the Kjeldahl method. Prior to body composition analysis, the
weight of the following organs was recorded: brain, liver, kidney, and
gastrocnemius muscle. In addition, the following m etabolites were
determined: Free carnitine in blood (n=5), free carnitine in liver (n-7), acetyl
carnitine and long-chain acyl carnitine in liver (n=7), acetyl CoA (n=7),
ketone bodies in blood (n=5), and ketone bodies in liver (n=7).
Rats fed the ammonium acetate diet had a lipid content (per g of wet
wt) that was reduced to about one half that of rats fed standard diet
(p< 0.001). The protein content o f rats fed the ammonium acetate was
significantly greater (p< 0.001) than for rats fed the standard diet. Relative
weights o f brain, liver and kidney increased significantly (p<0.02) for rats fed
the ammonium acetate diet. There was no s ig n ific a n t difference in the
weight of the gastrocnemius muscle. Therefore, the decrease in body
weight associated with animals fed ammonium acetate was mainly due to
loss o f adipose tissue. Levels o f blood carnitine significantly (p < 0.001)
decreased by 34% for rats fed the ammonium acetate diet when compared
to pair fed and ad libitum controls. Long-chain acylcam itine levels were
significantly (p < 0.001) increased in the liver by 60-70% in rats fed
ammonium acetate compared to levels of rats fed the control diet. Acetyl
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CoA levels were also significantly (p < 0.001) increased by 47% fo r rats fed
the ammonium acetate diet. Blood ketone bodies were significantly
(p < 0.001) higher for rats fed the ammonium acetate diet. In conclusion,
higher long-chain acylcam itine levels indicated increased transport o f longchain fatty acids into the mitochondria for oxidation. Increased betaoxidation lead to higher levels o f acetyl CoA, which when in excess can get
converted to ketone bodies and used as an energy source. Ingestion of
ammonium acetate altered the lipid metabolism o f these rats and resulted in
a significant decrease in body lipid content.
Results o f the studies conducted by Ji et al. (1996), Owens et al.
(1996) and Gatti et al. (1998) indicate that carnitine promotes changes in
body composition by increasing protein synthesis. Carnitine seems to
induce changes in nitrogen metabolism by increasing the supply o f carbon
for synthesis o f non-essential amino acids. The effect on body composition
have only been seen in younger animals, but the results o f Gatti et al. (1998)
point to an effect o f carnitine on body composition o f adult athletes.
Fat
The role o f L-cam itine in energy metabolism has prompted
researchers to evaluate its effectiveness in reducing the degree o f adiposity
in animals. An im portant factor in the regulation o f lipid metabolism is the
level of carnitine in each tissue (Shimura and Hasegawa 1993). The
condition o f obesity accelerates the rate of lipid synthesis and o r lipid
deposition, which leads to an unbalanced metabolic condition, and
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accum ulation o f lipids. Therefore, evaluation o f the effects o f compounds,
such as L-cam itine, may help improve lipid metabolism in obesity.
Shimura and Hasegawa (1993) conducted a study in rats to
determ ine the changes in lipid concentrations in the liver and serum o f rats
fed a high fat diet supplemented with L-cam itine. Two different experiments
were conducted with 4 wk old Male W istar rats. In the first experiment, 16
rats were divided into 2 groups o f eight and fed a diet high in fat (30% com
oil) w ithout or with carnitine (0.3%) for 1 week or 2 weeks. Rats on the high
fat diet with carnitine were pair-fed with intake o f rats fed the high fat without
carnitine. In experim ent 2, thirty-two rats were divided into 2 groups of
sixteen and fed one o f the following diets fo r a 3 wk period: Control diet (5%
com oil) or high fat (30% com oil). Rats on the control diet were pair-fed
with intake o f the high fat diet. H alf o f the rats (n=8) from each of these
groups were fed the following diets for 3 more wk: High fat diet with carnitine
(30% and 0.3%, respectively) or control diet with carnitine (5% and 0.3%,
respectively). A fter each feeding period, rats were fasted for 12 hours and
blood was collected and analyzed for triglyceride (TG), total cholesterol
(Choi), and phospholipids (PL). A t this tim e, the liver was removed and
assayed for total amount o f lipid. Adipose tissue around the kidneys and
epididym is was weighed and used as an index o f body fat.
In the first experiment, rats fed the high fat diet with carnitine showed
a significant (p<0.05) decrease in body weight compared with rats fed the
high fat without carnitine. At week 1, TG levels o f rats fed high fat with
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carnitine were significantly (p < 0.05) lower than levels o f rats fed high fat
without carnitine. By 2 weeks, rats fed high fat with carnitine showed a
significant (p< 0.05) decrease (25%) in the amount o f total lipids compared
with rats fed high fat without carnitine. PL levels also decreased significantly
(p< 0.05) fo r rats fed high fat with carnitine. In experim ent 2, rats fed the
high fat diet with carnitine had a significant (p < 0.05) decrease in total lipids,
TG, and Choi when compared to rats fed the high fat diet without carnitine.
Body weight was not significantly different for rats fed the high fat diet with
or without carnitine, but the weight o f body fat had a tendency to decrease
fo r rats fed the carnitine. Rats fed the control diet with carnitine had no
significant difference in total lipids and body weight when compared to rats
fed the control diet without carnitine. They concluded that, addition of
carnitine to the high fat diet depressed lipid accumulation and decreased
lipid levels in the liver and serum. The effect of carnitine was still present
even if rats were first fed a diet high in fat without carnitine fo r 3 wk.
Furthermore, rats administered the control diet did not experience a change
in their lipid levels with the addition o f carnitine.
Incorporation of L-camitine into diets o f broiler chickens is being
utilized to reduce the degree of adiposity and maximize the degree o f lean
tissue (Rabie and Szilagyi, 1998). Deposition o f fat depends to a great
extent on the appetite o f the broiler, particularly when diets o f different
energy contents are fed. Thus, nutritionists are trying to find a solution to
this problem by means of dietary manipulations. The study conducted by
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Rabie and Szilagy (1998) investigated the response to supplemental dietary
L-cam itine o f broiler chickens fed on diets with different levels o f
metabolizable energy (ME). One hundred and eighty, 1-day-old Hybro
broiler chicks were fed a commercial starter diet from day 1 to day 18.
Three isonitrogenous diets with 13.5,12.8 or 12.2 megajoules (M J)/kg o f ME
with or without supplemental L-cam itine (50 mg/ kg o f diet in the form o f
Camiking 50:50 mix L and D) were used during the experimental period, 18
to 53 days o f age. Each treatm ent group o f 10 birds was replicated three
times for a total o f 30 birds per group. The diet with 13.5 MJ ME/kg served
as the control diet. W eekly feed intake, energy intake, body weight gain,
and feed conversion were used to evaluate the performance o f broiler
chickens. To examine the effects o f L-cam itine on fa t deposition, 6 birds
from each treatment were decapitated. Measurements for carcass yield and
components (weights and percentages o f eviscerated carcass, giblets, total
edible parts, and breast yield), abdominal fat (absolute weight and
percentage o f body weight) and composition o f the edible meat o f broilers
were obtained.
L-cam itine supplementation did not affect feed or energy intake.
There was no interaction between supplemental L-cam itine and dietary
energy level with respect to feed o r energy intake throughout the
experimental period. Dietary energy level had a significant (p < 0.0001)
effect on body weight gain. Body weight gain was reduced over the
experimental period when dietary energy level was decreased from 13.5 to
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12.2 MJ ME/kg o f diet, except during the feeding period o f 46-53 days o f
age. Body weight gain was significantly (p < 0.0001) higher fo r the first 2
weeks o f the study and over the entire experimental period for broilers fed Lcarnitine. During the period from 25 to 32 days of age there was a
significant (p < 0.02) interaction between L-cam itine and dietary energy level
with respect to body weight gain and feed conversion. Carnitine caused an
increase in body weight at the higher energy level, but did not affect body
weight at the lower energy level. Body w eight gain was higher for broilers
fed the highest energy level with L-cam itine compared to broilers fed the
highest energy level w ithout L-cam itine. Feed conversion increased for
broilers fed the lowest energy level with L-cam itine. The relative weight of
abdominal fat (proportion o f total body weight) was significantly lower for
broilers fed L-cam itine (p < 0.0003) and lower dietary energy levels (p <
0 .0002 ).
The authors concluded that the reduction in absolute weight of
abdominal fat content in response to L-cam itine may be in part attributed to
an increased rate o f fatty acid oxidation within the m itochondria induced by
L-cam itine. Loss o f fatty acids could in turn result in a reduction o f hepatic
lipogenic capacity. The authors acknowledge the possibility that other
factors might also be responsible for regulation of the rate o f fat
accumulation and point out the results o f Ji et al. (1996) conducted in
Atlantic salmon as an alternative explanation. Ji et al. (1996) believed that
improved utilization o f dietary nitrogen, achieved through more efficient fat
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oxidation, could be responsible for the improved body w eight gain observed
in response to dietary L-cam itine. The lower body weight observed for birds
on the lowest level o f dietary energy compared with the higher energy levels
could be attributed to a less efficient utilization o f dietary energy or
insufficient energy intake fo r weight gain. The effect o f L-cam itine at higher
energy levels in relation to body weight gain is probably not related to the
energy level itself. Instead it might be influenced by the composition of
dietary fa t since L-cam itine is most important for the oxidation o f long-chain
fatty acids.
Gross et al. (1998) conducted a study to evaluate the effects of
supplem ental carnitine o r chromium on weight loss and body composition
during periods o f weight reduction. Thirty-six adult obese beagle dogs
(males n=24 and fem ales n=12) with > 30% body fat were used in this study.
Anim als were blocked by percent body fat and sex and random ly assigned
to 1 o f 4 dietary treatm ents. The dietary treatments were as follows: the
control diet (high fiber low calorie), control diet plus 200 ppb chromium
picolinate, control diet plus 300 ppm L-camitine, and control diet with both
chromium picolinate and carnitine. Body composition was determined using
DXA (Hologic WDR 2000). Measurements were taken at baseline, at wk 2,
4, 8 and monthly thereafter until all o f the beagles had body fat that was less
then 20%.
Energy intake, food intake, and protein intake were sim ilar for all
treatm ents. Dogs achieved a weight loss o f 2.5% o f initial body weight per
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wk over 12 wk to reach the 20% body fat. The main effect o f carnitine was
to significantly (p < 0.05) increase lean body mass and there was a trend
(p < 0.1) fo r greater body weight. The dogs supplemented with carnitine had
a significantly (p < 0.05) greater loss in fat than dogs supplemented with
chromium. Dogs fed chromium did not have a significant increase in lean
body mass. The researchers concluded that during the weight loss period
added carnitine but not chromium increased the lean body mass o f the
beagles.
The results o f Shimura and Hasegawa (1993), Rabie and Szilagyi
(1998) and Gross et al. (1998) indicate that addition o f carnitine to the diets
o f young and older animals can lead to an increase in fat oxidation causing
a reduction in the amount o f fat as percent o f body weight. Rabie and
Szilagyi (1998) and Gross et al. (1998) observed a trend for an increase in
body weight, whereas Shimura and Hasegawa (1993) found no difference in
body weight. When there was an increased weight gain observed it was
attributed to an increase in lean body mass.
C arbohydrates
Carbohydrate metabolism is a complex process that is affected by
many different factors. High levels of both protein and fat in the diet can
alter this process. Therefore, addition o f dietary L-cam itine may exert an
indirect effect on carbohydrate metabolism by enhancing the metabolism of
protein and fat.
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A relationship has been observed between high levels o f ammonia
and impaired glucose metabolism. It has been shown that
hyperammonemia causes an increase in levels of epinephrine (Schlienger et
al.1975). Epinephrine, an adrenomedullary hormone, raises plasma
glucose concentrations by stim ulating the production o f glucose and lim iting
glucose utilization in certain tissues (Marker et ai.1998). Epinephrine exerts
these metabolic effects by stim ulating glucagon release through a P2 adrenergic pathway and lim iting insulin secretion via an a 2. adrenergic
pathway (Marker et al.1998, Schlienger et al.1975).
Schlienger et al. (1975) conducted a study to evaluate the
abnormalities o f glucose metabolism observed in hyperammonemic rats.
Forty-five male W istar rats weighing 250-300 grams were divided into 3
groups (n=15). A tracheotom y was performed to obtain blood samples from
the carotid artery. In addition, a catheter was introduced in the fem oral vein
to inject the test solution, saline or ammonium acetate. The control group
received an infusion of 2 ml o f a 0.9 g/100 ml saline solution for 95 minutes.
A second group of rats received an infusion o f ammonium acetate at a low
dose (0.50 umol/kg body weight/m in NH4+). The last group was infused with
a high dose o f ammonium acetate, 1.70 umol/kg/min NH4+. Blood glucose
and plasma insulin levels were determined before and at the 60th minute o f
infusion. Blood ammonia levels were measured every 10 minutes during the
infusion period. An intravenous glucose tolerance test was performed at the
60th minute o f infusion. An injection of 1 g glucose/kg o f body weight using a
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50 g/100 ml solution was given to all groups. Blood sugar was measured
every 5 minutes for 35 minutes.
Basal ammonia levels were 51 ± 2.50 ug/100 ml for rats in the control
group with no change during the saline infusion. Rats in the low NH4+
infusion had a rapid increase in ammonia levels, 250 ± 1 2 and
275 ± 1 5 ug/100 ml, at 60 and 95 minutes respectively. Rats in the high
NH4+ had a more marked hyperammonemia that reached 926 ± 60 and
1010 ± 68 ug/100 ml at 60 and 95 minutes, respectively. Sixty-minutes after
the infusion, the blood glucose levels o f the control and low NH4+ were
unchanged. Blood glucose levels significantly (p<0.01) increased during the
high NH4+ infusion, rising from 98 ± 3 to 127 ± 7 mg/100 ml at the 60th
minute. A fter the glucose load blood glucose levels were higher for the
group o f rats receiving the NH4+ infusion. But only the blood glucose values
of the control and high NH4+ group were significantly (p < 0.01) different.
Insulin vales, 60 minutes after start of infusion, were not significantly
different from initial levels fo r all 3 groups. During the 10 and 20th minute o f
the glucose tolerance test insulin levels o f the low NH4+ group were
significantly (p<0.001) different from basal levels. There was no insulin
response to the glucose load for rats fed high NH4+ and the insulinogenic
index tended toward 0. The authors concluded that an ammonium infusion
in rats brings about an alteration in carbohydrate metabolism and its
regulation. The abnorm alities observed are dependent on the amount o f
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ammonium infused. The alteration in the metabolism o f carbohydrates may
be due to a direct effect o f NH4+ on the pancreas.
Chronic consumption o f a high protein diet by certain individuals,
such as athletes, people consuming a typical W estern diet, and people on
fad diets, could potentially affect the regulation o f carbohydrate metabolism.
Therefore, a reduction in the levels o f ammonia by supplementing the diets
o f these individuals with carnitine could possibly prevent m etabolic disorders
associated with glucose metabolism.
The functions o f carnitine in the mitochondria are essential for proper
regulation o f metabolic processes. Particularly, in the metabolism o f lipids
regarding both oxidative and synthetic processes. The consequences these
effects may have on the metabolism o f glucose have not been fully
explained, but a close relationship has been observed between metabolic
processes using fat and those oxidizing carbohydrates (Grandi et al.1997).
Thirty-years ago, the glucose fatty acid cycle was proposed to try to
explain defective glucose metabolism in NIDDM (Non-Insulin Dependent
Diabetes M ellitus) (Randle et al.1963). Randle and associates hypothesized
that elevated levels of fatty acid oxidation could interfere with the uptake and
metabolism o f glucose in muscles, resulting in glucose intolerance and
insulin insensitivity. There is now some experimental evidence that
contradicts this hypothesis.
It has been shown that L-cam itine stim ulates the activity of the
pyruvate dehydrogenase complex, which converts pyruvate to acetyl CoA,
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by decreasing the intramitochondrial ratio o f acetly-CoA/CoA via the
trapping o f acetyl groups. The concurrent decrease of acetyl-CoA in the
cytosol contributes to the activation o f the glycolytic pathway (Mingrone et
al.1999). Broderick et al. (1991) showed that the glucose oxidation rates in
control hearts were markedly decreased in the presence of fatty acids in the
perfusate. A significant increase in glucose oxidation followed by a parallel
decrease in palm itate oxidation was observed when the carnitine
concentrations were raised. This effect was not observed in the absence of
fatty acids implying that L-camitine might act to switch fuel substrate
utilization in cells (Broderick et al.1991).
There is some evidence to suggest that L-camitine, via increased
fatty acid oxidation, will interfere with glucose metabolism. There is also
some indication that acute administration of L-cam itine improves insulinmediated glucose uptake. Therefore, a better understanding o f the effects
that carnitine may have on glucose metabolism in the presence or absence
o f fatty acids could contribute to the improvement of the metabolic control o f
this macronutrient.
In a study conducted by Mingrone et al. (1999) the effects o f Lcam itine on insulin mediated glucose uptake and oxidation in type II diabetic
patients was evaluated. The subjects in the study were non-obese healthy
volunteers (n=20) and type II diabetic patients (n=15). Subjects underwent
a short-term (2 hours) euglycemic hyperinsulinemic clamp with simultaneous
constant infusion o f L-camitine (0.28 umoles/kg body weight/minute). The
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same procedure was repeated on a different day with a saline infusion
instead of L-cam itine. The order o f infusions was randomly selected. To
maintain the glycemia o f diabetic patients below 100 mg/dl a small bolus
dosage o f short-acting human insulin was administered until the study
began. Every 30 minutes arterial blood samples were collected during the
clamp and insulin, non-esterified fatty acid, and lactate concentrations were
measured. Respiratory gas exchange measured by an open-circuit
ventilated hood system was started 60 minutes before the start o f the study
and continued during the 180 minutes o f the study. Energy expenditure,
respiratory quotient (RQ) and substrate oxidation rates were calculated.
In both groups, whole body glucose uptake was significantly (p
<0.001) higher during the L-cam itine infusion when compared to the saline
infusion. The glucose uptake of healthy controls and diabetic patients was
48.66 ± 4.73 and 35.90 ± 5.00 umol/kg/minute w ithout carnitine and 52.75 ±
5.19 and 38.90 ± 5 .1 6 umol/kg/m inute with carnitine, respectively. Glucose
oxidation, measured by indirect calorimtery, was significantly (p< 0.001)
increased only in the diabetic patients with the carnitine infusion (17.61 ±
3.33 umol/kg/minute) when compared to the saline infusion (16.25 ± 2.95
umol/kg/minute). Both groups had a significantly (p < 0.001) higher glucose
storage rate (um ol/kg/m inute) with the carnitine infusion. Plasma lactate
concentrations o f the diabetic patients significantly (p < 0.0003) decreased
during L-cam itine infusion when compared to saline. In conclusion, constant
L-camitine infusion in diabetic patients led to an improvement in insulin
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sensitivity and had a significant effect on whole body insulin-m ediated
glucose uptake in normal subjects. In diabetic patients, L-cam itine
adm inistration increased glucose oxidation and glucose taken up by the
tissues appeared to be utilized immediately as a fuel. The decrease in
plasma lactate levels suggests that the effect o f carnitine may be due to
activation o f pyruvate dehydrogenase, whose activity is decreased, in insulin
resistant sates.
Grandi et al. (1997) examined the ability o f carnitine in influencing
glucose-stim ulated insulin secretion. The researchers were interested in
determ ining any potential that carnitine might have in im proving utilization o f
glucose. Twenty-five patients (17 males and 8 females, mean age=42.6 yr)
hospitalized in the Medical Clinic at Modena University fo r disorders
unrelated to m etabolic disease were used in this study. Patients with fasting
blood glucose levels below 100 mg%, with no signs o f glycosuria, and a
body mass index under 28 for men and 25 for females were enrolled in the
study. The study was divided into 2 phases that were separated by a 48-h
period. In phase 1, a 5% glucose-enriched solution was administered
intravenously with a set 2-h infusion tim e. At tim e 0 ,6 0 , and 120 minutes,
blood samples were taken from the medial cubital vein, which is found at the
junction between the elbow and the upper arm. Blood sam ples were taken
30, 60, and 120 minutes after the infusion was discontinued. Phase 2,
consisted o f the same subjects receiving the same 5% glucose solution with
the addition o f 2 g o f carnitine. Blood samples were collected fo r phase 2
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following the same protocol o f phase 1. Plasma blood glucose and insulin
levels were determined from the samples collected.
Carnitine induced a reduction in blood glucose levels that was
statistically (p <0.05) significant only in the first sample taken after
termination o f infusion (91.3 ± 6.3 vs 98.6 ± 9.9 mg/dl). The pattern of
insulin secretion was different for the 2 phases. In phase 2, carnitine
administration reduced significantly (p < 0.05) the total insulin secretion
range when compared to phase 1 (4923 ± 975 vs 5516 ± 1335 mU/ml).
During the first hour after infusion, only the subjects receiving carnitine had
a significant (p < 0.05) decrease in insulin at 30 minutes (23.4 ± 6.3 vs 30.3
± 10.0 mU/ml) and at 60 minutes (10.4 ± 2.1 vs 17.6 ± 5.6 mU/ml). In
addition, post-infusion insulin ranges were significantly (p < 0.05) lower for
subjects receiving carnitine (1004 ± 196 vs 1525 ± 454 mU/ml). In
conclusion, insulin secretion is signficantly reduced and blood gluose levels
are transiently decreased when glucose is given with an acute
adm inistration o f carnitine. Thus, laying the basis for improved peripheral
glucose utilization. The assumption was made that the increased levels of
blood carnitine led to the transport o f acetyl-CoA molecules from the inner
mitochondrial matrix to the cytosol. Consequently, the inner mitochondrial
ratio o f acetyl-CoA/CoA is reduced and the pyruvate dehydrogenase
enzyme remains active leading to an increase in glycolytic activity.
To examine the effects o f L-cam itine adm inistration on the severity of
diabetes, Paulson et al. (1984) conducted a study in male Sprague-Dawley
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rats weighing 200-250 grams. Rats were divided into the following 4 groups:
saline control (n=13), carnitine control (n=14), saline diabetic (n=22), and
carnitine diabetic (n=16). An intravenous injection o f streptozotocin (60
mg/kg) was used to induce diabetes. Twenty-four hours after the
adm inistration o f streptozotocin, either saline (0.9% NaCI) or L-camitine (3
g/kg/day) was injected intraperitoneally for 14 days. During sacrifice, blood
samples were collected and serum was assayed for glucose, triglycerides,
free fatty acids, ketones, and carnitine. Tissues were removed and freezeclamped in liquid nitrogen. Total carnitine concentrations in the heart were
assayed.
Diabetic rats treated with carnitine had a significant (p < 0.05)
decrease in serum glucose levels when compared to saline treated diabetic
rats, 398 ± 1 2 and 490 ± 1 3 mg/dl respectively. Serum levels of ketones
(0.61 ± 0.12 vs. 1.18 ± 0.13 mmol/L), triglycerides (244 ± 25 vs. 705 ±112
umol/Ldl), and free fatty acids (0.40 ± 0.04 vs. 0.73 ± 0.05 mmol/l) were
significantly (p <0.05) lower for carnitine treated diabetic rats when
compared to saline treated diabetic rats. Carnitine administration to the
nondiabetic rats had no effect on serum glucose, increased serum ketones,
and decreased triglycerides and free fatty acid levels when compared to
saline-treated nondiabetic rats. In the diabetic rats, L-cam itine prevented
the decrease in total myocardial carnitine content (p < 0.05). Paulson et al.
(1984) concluded that chronic therapy with carnitine may reduce the severity
of diabetes mellitus and improve myocardial performance.
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The results o f other researchers contradict those observed by
Mingrone et al. (1999), Grandi et al. (1997) and Paulson et al. (1984). It has
been shown that compounds that decrease lipid oxidation and the activity of
carnitine palmitoyl transferase I can decrease glucose levels in normal and
diabetic rodents and humans (Martin et al.1991, Mandarino et al.1984, W olf
etal.1982).
Barnett et al. (1992) conducted a study to examine the longitudinal
effects of inhibiting fatty acid oxidation with Etomoxir in m ildly diabetic rats.
Male Sprague Dawley rats (150 g) were randomly assigned to one o f 3
treatment groups. Two o f the groups were rendered m ildly diabetic by an
intravenous injection o f 55 mg/kg o f streptozotocin. Rats in the third group
received an injection with citrate buffer and were used as controls. The
diabetic rats were random ly assigned to a treatm ent group that received
Etoxomir (12.5 m g/kg/day) or a diabetic control group. Etoxom ir is a specific
inhibitor of long chain fatty acids that mediates its effect by inhibition of
carnitine palm itoyltransferase I. All rats were fed ad libitum a diet high in fat
composed o f butter, wholemeal flour, and skim milk powder (50% energy
from fat, 30% from carbohydrate, and 20% from protein). Rats were fasted
for 16 hours and blood was obtained to measure glucose, insulin,
triglycerides, and free fatty acids at 3 days, 1 week, and at 4 weeks o f
treatment.
At the end o f the study, diabetic rats treated with Etom oxir (n=10) had
significantly (p < 0.02) higher body weights than the diabetic control group
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(n= 10; 234 ± 11 vs 202 g ± 13). Fasting plasma glucose levels were
significantly (p < 0.001) higher throughout the study in the diabetic rats when
compared to the controls. Diabetic rats treated w ith Etoxom ir (n=22) had
significantly (p < 0.001) lower fasting plasma glucose levels over the 4 week
period when compared to the diabetic controls (n = 8; 17.6 ± 2.4 vs 22.3 ±
1.9 mmol/l). Lower glucose levels were first observed after one week of
treatm ent and this reduction was maintained for the rem ainder of the study.
Throughout the entire study, there were no significant differences in plasma
insulin levels for all groups of rats. Fasting plasma triglyceride levels were
significantly (p < 0.001) lower in the Etoxomir treated diabetic rats (n=23)
compared to the levels o f diabetic controls (n=19), 0.32 ± 0.07 and 0.98 ±
0.14 mmol/l respectively. During the 4-week period, serum free fatty acid
levels were significantly (p < 0.001) lower following treatm ent with Etoxomir
(1.52 ± 0.26 vs 3.51 ± 0.69 mEq/l). In conclusion, inhibition o f fatty acid
oxidation by Etoxom ir decreased fasting glucose concentrations without
alterations in insulin levels. This is consistent w ith an improvement in insulin
sensitivity. Inhibition of fatty acid oxidation improved the metabolism of
carbohydrate in a rodent model of diabetes.
These results are supported by sim ilar studies conducted by Barnett
et al. (1996) and Martin et al. (1991). Barnett et al. (1996) conducted a
study using a rat model that is genetically predisposed to develop NIDDM
when fed a standard chow diet. The authors concluded that an increased
rate o f lipid oxidation and glucose turnover (based on HGP-hepatic glucose

47

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

production) may be associated with the development o f NIDDM in
genetically predisposed animals. Using diabetic male Sprague Dawley rats
weighing 200*250 g, Martin et al. (1991) studied the mechanisms o f the
glucose lowering effect o f a compound (B 827-33) known to inhibit carnitine
palmitoyltransferase I. The results suggested that the decrease in glucose
observed after inhibition o f fat oxidation appears to be dependent on the
nutritional status o f the animal, the decrease being more im portant in the
starvation state than the postabsorptive state. In addition, the results
confirmed that compounds that inhibit lipid oxidation could be used to treat
some diabetic patients if their hypoglycemic action continues on a long-term
basis.
According to the results conducted by Mingrone et al. (1999), Grandi
et al. (1997) and Paulson et al. (1994) in diabetic humans and rats, carnitine
improves insulin sensitivity and peripheral utilization of glucose. The
improvement seems to be due to activation of the pyruvate dehydrogenase
enzyme, which increases the activity o f the glycolytic pathway. In the
studies conducted by Barnett et al. (1996 and 1992) and Martin et al. (1991)
inhibition o f fatty acid oxidation lead to an improvement in carbohydrate
metabolism. Thus, according to these results use o f carnitine, which
increases the oxidation o f fats, should not result in an improvement in the
metabolism o f carbohydrates.
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INSULIN
INTRODUCTION
The pancreas is made up o f two distinct organs, the exocrine
pancreas and the endocrine pancreas. The endocrine pancreas is the
source o f insulin, glucagon, somatostatin, and pancreatic polypeptide. It
consists of 0.7-1 million small endocrine glands, the islets o f Langerhans,
that are scattered within the glandular substance o f the exocrine pancreas.
The islets contain 4 ceil types, alpha (a), beta ((3), delta (5), and phi ($),
which are not distributed uniformly throughout the pancreas. The beta cells,
which are located in the innermost part o f the endocrine pancreas, are
responsible for the secretion o f insulin (Karam 1997).
Insulin is a peptide hormone consisting o f 51 amino acids found
within two peptide chains, A (21 amino acids) and B (30 amino acids). Two
disulfide bridges connect these 2 chains together and an intrachain disulfide
bridge links position 6 and 11 in the A chain (Hadley, 1996). In normal
adults the human pancreas secretes about 40-50 units o f insulin per day.
During fasting the basal concentration of insulin in the blood averages
10 uU/mL (0.4 ng/mL, or 69 pmol/L). In healthy individuals insulin
concentrations, after a standard meal, seldom rise above 100 uU/mL
(Karam 1997).
Preproinsulin, a precursor molecule o f insulin, js produced in the
rough endoplasmic reticulum o f pancreatic B cells. Almost imm ediately after
it is synthesized, microsomal enzymes cleave this precursor forming
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proinsulin. Proinsulin is a single chain containing 86 amino acids, that
includes the A and B chains o f the insulin m olecule and a connecting section
o f 35 amino acids. The proinsulin is transported to the golgi apparatus and
packaged into clathrin coated secretory granules. Maturation of the granule
is accompanied by loss o f the clathrin coating and the conversion of
proinsulin into insulin and a small connecting peptide, C-peptide. Mature
secretory granules contain equim olar amounts o f insulin and C-peptide and
small amounts o f proinsulin. The C-peptide has no known biological activity
(Karam 1997).
Insulin secretion is regulated by several factors, some which exert a
direct and immediate effect on the B-cells o f the pancreas and others that
exert a delayed and either a direct o r indirect effect on insulin release
(Malaisse, et al.1979). Factors exerting a direct and immediate effect
include certain nutritional factors (glucose), hormones (catecholamines and
gastrointestinal), and neurohumoral responses (cholinergic transmitters).
There is a delayed effect in insulin release during certain situations, such as
nutritional (fasting), endocrine (pregnancy), and ontogenic (perinatal period)
conditions (Karam 1997).
Insulin’s m ajor role is to promote the storage of ingested nutrients.
This role corresponds to the adaptive responses o f peripheral tissues to
changes in energy balance. After a meal is consumed the release of insulin
leads to the disposition o f absorbed nutrients (Schwartz et al.1992). The Bcells are capable o f detecting the following fuel molecules, glucose, amino
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acids, fatty acids, and ketone bodies. O f these molecules only glucose is
capable o f initiating insulin secretion. The other fuel m olecules can increase
insulin secretion only in the presence o f glucose (Meglasson and
Matschinsky, 1986). W hen an exogenous stimulus (e.g. ingested meal with
glucose), causes the B-ceils to release insulin the response is biphasic in
nature (Karam 1997). An increase in glucose concentration leads to an
initial short-lived increase in insulin, the early phase. The concentration of
peripheral insulin increases reaching its early phase peak concentration in
peripheral blood 30-45 minutes after a meal is ingested (Karam 1997). A
steady glucose concentration leads to a gradual decrease in insulin released
followed by an increase in the amount o f insulin released that corresponds
to the late phase o f insulin secretion (1-3 hours after ingestion o f meal).
Previous research indicated that insulin is not required for the
metabolism o f glucose in the brain. The inference was then made that
circulating insulin was incapable o f crossing the blood-brain barrier (BBB)
and therefore had no effects on the brain. While the first belief remains true,
the second one has been challenged. Both insulin and insulin receptors
have now been identified in the adult mammalian brain. Brain insulin seems
to be derived largely from the circulation and there is evidence to suggest
that its delivery into the brain may be facilitated by a specific BBB transport
system (Schwartz et al.1992, Woods et al.1990).
There is extensive data supporting the hypothesis that insulin has a
function as a peripheral adiposity signal to the CNS (Schwartz et al.1992,
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W oods et al.1990). First, plasma insulin levels are directly influenced by
changes in energy balance and adiposity. Second, there is evidence
supporting a dose-dependent entry o f circulating insulin into the central
nervous system in several species. Third, the high concentrations o f insulin
receptors in the neurons o f brain regions involved in the regulation o f
feeding have been documented. Finally, there is a marked reduction in food
intake following central or peripheral administration o f insulin causing an
increase in sympathetic nervous system activity and thermogenesis.
Therefore, peripheral insulin levels, which rise when adiposity increases,
induce a state of negative energy balance by acting within the central
nervous system causing a reduced caloric intake, increased energy
expenditure, and eventually loss o f adiposity (Schwartz et al.1992).
INTERACTIONS WITH MACRONUTRIENTS
The interactions o f insulin with the macronutrients are associated with
the endocrine effects of this hormone on three major tissues specialized for
storage o f energy: liver, muscle, and adipose tissue. Insulin acts to promote
the formation of certain substances (anabolism), while inhibiting the
breakdown of other substances (catabolism).
In the liver, insulin promotes glycogen synthesis and storage by
changing the activity of enzymes in the glycogen synthesis pathway. Insulin
triggers a pathway that dephosphorylates glycogen synthase thereby
activating the enzyme. Insulin exerts these effects via a cascade of
reactions that lead to multiple phosphorylations. The binding o f insulin to its
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tyrosine kinase receptor leads to the phosphorylation and activation o f an
insulin-sensitive protein kinase. In turn, a subunit on protein phosphatase 1
is phosphorylated. This activated protein phosphatase 1, leads to the
dephosphorylation o f glycogen synthase, phosphorylase kinase, and
phosphorylase a. The dephosphorylated forms o f phosphorylase kinase
and phosphorylase a are inactive, thereby the degradation o f glycogen is
blocked (Stryer 1995). The maximum capacity storage o f glycogen in the
liver is in the range o f 100-110 g (Karam 1997). In addition, insulin inhibits
gluconeogenesis by decreasing the activity o f specific enzymes, fructose 1,6
biphosphatase, and phosphoenol pyruvate carboxykinase and promotes
glycolysis by increasing the activity of other enzymes, glucokinase,
phospofructokinase and pyruvate kinase (Karam 1997, G roff et al.1995,
W allis et al.1985).
In the fed-state, the synthesis of protein, triglycerides, and very lowdensity lipoproteins is increased in the liver by the actions o f insulin. A
higher rate o f protein synthesis produced by insulin appears to be due to an
increase in transcription rates (Wallis et al.1985). Insulin enhances the
action of intravascular lipoprotein lipase, thus increasing the availability and
uptake of free fatty acids. Additionally, increased glycolytic activity provides
a source of glycerophosphate that can be re-esterified w ith fatty acids (Groff
et al.1995). The anticatabolic effects o f insulin include the inhibition of
hepatic glycogenolysis, ketogenesis, and gluconeogenesis (Karam 1997).
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In muscle tissue, the synthesis o f glycogen is promoted by insulin and
the newly formed glycogen replaces the stores expended by muscle activity.
The enhancement o f glycogenosis is attained by increasing the transport of
glucose into muscle cells due to an increase in the num ber o f glut 4
receptors in the plasma membrane, increasing the activity o f glycogen
synthase, and inhibiting glycogen phosphorylase a. The capacity for
glycogen storage in muscle is approximately 500-600 g. Lack o f glucose-6phosphatase lim its use o f this stored glycogen to only this tissue except
when the muscle supplies the liver with lactate that can then be converted
into glucose (Karam 1997).
Another action o f insulin in muscle cells is to promote the synthesis of
proteins by increasing the transport o f amino acids as well as stimulating
ribosomal protein synthesis. The anticatabolic actions o f insulin on protein
metabolism vary according to the different tissues (M eek et al.1998). The
predominant effect o f insulin in skeletal muscle is by an effect on translation,
where it apparently increases the rate o f initiation. However, in heart muscle
or slow twitch red muscle fiber (e.g. soleus) a deficiency in insulin does not
result in an instant change in the rate of initiation (W allis et al.1985, Karam
1997). Another effect o f insulin on protein is to control the rate o f
degradation o f intracellular protein. The rates of protein degradation in both
heart and skeletal muscle are reduced by insulin. This reduction seems to
be due to an effect o f insulin on the lysosomal system (W allis et al.1985).
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The function o f insulin in adipose cells is to promote the storage o f
triglycerides. Insulin induces the production o f endothelial bound lipoprotein
lipase, which leads to hydrolysis o f triglycerides found in circulating
lipoproteins. By augmenting the transport of glucose into fat cells insulin
increases the availability o f glycerol phosphate, which is used in the
esterification o f free fatty acids into triglycerides. Furthermore, to prevent
lipolysis o f stored triglycerides insulin inhibits the action o f horm onesensitive lipase, an intracellular enzyme. This enzyme is active in the
phosphorylated form and increased levels of cyclic AMP facilitate
phosphorylation. Insulin inhibits this enzyme by lowering the levels o f cyclic
AMP, possibly by increasing the activity o f phosphohdiesterase (cleaves
cAMP to inactive 5’AMP), which lead to diminished activity o f the adipose
tissue hormone-sensitive lipase (Karam 1997, W allis et al.1985).
INSULIN RESISTANCE
Non-insulin dependent diabetes mellitus (NIDDM) is a heterogeneous
disorder identified by abnorm alities in both the secretion and action o f insulin
(DeFronzo et al.1992, Dinneen et al, 1992). Some patients with NIDDM
may have abnormal beta cell function that leads to im pairm ent in insulin
secretion. Others may have impairment in hepatic or peripheral tissue
sensitivity to insulin (Pacoe and Storlien, 1990). Although a lot o f research
has been conducted to determ ine the etiology and pathogenesis o f this
disorder many questions remain unanswered. For example, does obesity
lead to insulin resistance or does insulin resistance lead to obesity?
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The developm ent o f obesity has been attributed to both genetic
components and lifestyle factors. Physical inactivity and consumption o f
high fat diets are among the most important lifestyle factors contributing to
the problem. Obese people are at an increased risk o f developing insulin
resistance, hypertension, dyslipidemia, heart disease, non-insulin dependent
diabetes mellitus, and certain types o f cancer (Pi-Sunyer 1993). It has been
postulated that obesity in combination with physical inactivity leads to the
development o f hyperinsulinemia. The enlargement o f adipose cells during
obesity leads to a decrease in the number o f insulin receptors present in the
cell membrane o f those cells. The body responds to the decrease in
number o f receptors by increasing the amount of insulin produced and this
induces an up-regulation in the synthesis o f insulin receptors. The higher
insulin levels eventually lead to a down-regulation o f insulin receptors, which
causes a decrease in the amount of insulin released. It is the down and up
regulation of these receptors that leads to the development of
hyperinsulinemia (Karam 1997). High levels o f insulin lead to an impaired
suppression o f hepatic glucose production and a decrease in peripheral
glucose uptake. In the presence of both o f these conditions insulin
resistance develops. There is still some debate about whether insulin
resistance develops first in peripheral (muscle) or splanchnic tissues (liver
and gastrointestinal tract). A decrease in glycogen synthesis, glucose
oxidation, glucose transport, and insulin receptor synthesis accompanies the
development o f insulin resistance (De Fronzo et al.1992). If insulin
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resistance persists the beta cells can no longer compensate and overt
impaired glucose tolerance develops. Fasting blood glucose levels
abovel 15 mg/100ml (6.4 mmol/l) are observed in people with impaired
glucose tolerance. These high fasting glucose levels eventually lead to
beta-cell damage and development o f fasting hyperglycemia. According to
Starling’s curve, fasting blood glucose levels of 140 mg/dl (7.8 mmol/l)
cause a rapid decline in insulin secretion. It is at this point that non-insulin
dependent diabetes mellitus develops. NIDDM is sustained by the condition
of increased hepatic gluconeogensis observed when fasting glucose levels
are maintained at 140 mg/dl (Harris 1996, DeFronzo et al.1992). This
hypothesis postulates that the condition o f obesity leads to the development
o f insulin resistance.
According to Thorbum et al. (1999) the opposite condition can also
be true, insulin resistance may lead to accumulation o f excess fat and
development o f obesity. Presence o f insulin resistance is associated with
development o f several aspects o f a condition known as Syndrome X.
Syndrome X has been used to characterize a cluster o f abnorm alities that
include obesity, glucose intolerance, hypertension, insulin resistance, and
dyslipidaemia (Thorbum et al.1999). Individuals with this syndrome are at a
risk of developing type II diabetes and heart disease (Ferranini et al.1991).
The features of Syndrome X were studied in transgenic and control rats of
different ages (1, 3, 6, and 17 months) who were fed either chow or cafeteria
food for 6 months (Thorbum et al.1999). Transgenic rats came from a
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homozygous colony overexpressing a non-insulin responsive
phosphoenolpyruvate carboxykinase gene. This rate-lim iting gluconeogenic
enzyme that catalyzes the conversion o f oxaloacetate to
phosphenolpyruvate is tightly regulated by insulin. Results showed that
presence o f this unresponsive gene was related to early development of
fasting and postprandial hyperinsulinem ia, fasting hypercholesterolaemia
and mild obesity. This lends support to the hypothesis that insulin
resistance can trigger the developm ent o f syndrome X. Addition o f a highfat cafeteria diet lead to an even greater manifestation o f syndrome X
possibly because consumption o f high fat induces more severe insulin
resistance. Barnard et al. (1998) observed that Fischer rats fed a high fat
diet developed insulin resistance after only 2 weeks, hypertriglycerademia at
2 months, obesity at 5 months, and hypertension at 12 months. These
results support those of Thorbum et al. (1999) and verify that insulin
resistance independent of obesity can be the principal cause o f syndrome X
and thus obesity.
GLYCEMIC INDEX
The glycemic index was initially developed as a tool for shaping the
diets o f diabetic patients. The index is based on the blood glucose level o f a
single food when compared to the blood glucose level found after
consumption o f an equivalent amount o f pure glucose. The standard used
for healthy individuals is glucose, whereas wholemeal bread and cottage
cheese is the standard for diabetic individuals. The index is reported as the
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area under the blood glucose response curve fo r a single food considered
as a percentage o f the area after the same am ount o f carbohydrate as
glucose is consumed (Crapo 1984). The overall usefulness of the glycemic
index classification is being re-evaluated in the clinical setting. Among the
controversial issues is the contention that the classification o f single foods
could not predict the glycemic response to mixed meals because other
noncarbohydrate components were not present (Hollenbeck et al.1988).
Furthermore, there is concern about the m ethodologic variables, such as
food portion size, that can markedly affect the interpretation of the response
and the glycem ic index values (W olever et al.1991). O ther researchers
believe that knowledge o f the glycem ic effects o f single foods might be of
use for studying the physiologic effects o f whole diets (Jenkins et al.1981).
Therefore, there is still debate over the clinical utility o f the glycemic index.
Studies have shown that differences in glycem ic index correspond to
differences in the rates o f digestion and absorption o f carbohydrates from
different foods (O'Dea et al.1981, Bymes et al. 1995). Starchy foods with a
high amylopectin (branched-chain form o f starch) content have been shown
to promote the development of insulin resistance in rats. These foods are
digested and absorbed more quickly than starches containing a high
amylose (straight chain form of starch) content and thus produce a greater
postprandial insulin and glucose response (Bym es et al. 1995). Foods that
are absorbed more slowly delay gastric emptying and this results in more
constant blood glucose and insulin responses. Reductions in blood glucose
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levels after a meal seem to have only a modest effect on overall blood
glucose levels, but these changes may be beneficial for some diabetic
patients. Therefore, the use o f high carbohydrate diets with low glycemic
index starchy foods with fiber may be beneficial for individuals with diabetes
(Wolever et al.1991).
ORAL GLUCOSE TOLERANCE TEST
The oral glucose tolerance test (OGTT) is used to determine the state
of impaired glucose tolerance and non-insulin dependent diabetes. Glucose
tolerance is the result o f two conditions, delivery o f insulin to the target cells
and the sensitivity o f those cells to the actions o f insulin. The poor
reproducibility and lack o f a controlled physiological stim ulus limits the
usefulness o f the OGTT in the determination of the pathophysiology of
diabetes (Phillips et al.1994).
Other methods available that can be used to measure insulin
secretion and insulin resistance include the intravenous glucose tolerance
test and the euglycaem ic clamp, respectively. But the com plexity,
invasiveness, and labor intensity o f these methods make them difficult to
conduct in large-scale studies. Therefore, researchers have had to depend
on the OGTT to evaluate the degree of insulin sensitivity and insulin
secretion (Phillips et al.1994). The results of a study conducted by Phillips
et al. (1994) indicated that measurements o f insulin and glucose during the
OGTT can be used to estimate the roles of insulin secretion and insulin
resistance.
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Reaven et al. (1983) conducted a study to examine the effects o f diet
on insulin secretion and action in 12 month old male Sprague-Dawley rats.
Rats were randomly assigned to one of the following 3 dietary treatments
(n=13): standard chow (4.2 kcal/g), calorie-restricted diet (1.4 kcal/g),
sucrose diet (3.6 kcal/g) with 60% o f the calories from sucrose, 29% from
protein, and 11% fat. Rats were maintained on the diets for 10-11 months.
An oral glucose tolerance test was performed with the glucose load (0.9 g)
administered based on an approximation o f lean body mass. Blood from the
tail vein was obtained at baseline and at 30, 60,120, and 180 minutes after
the load. Plasma glucose and insulin concentrations were determined.
Baseline plasma glucose levels were comparable for all 3 groups.
The pattern o f change in plasma glucose levels was sim ilar for rats in all
groups. At 60 minutes, the glucose levels o f the rats fed the calorierestricted diet were significantly (p < 0.01) lower than that of the other 2
groups. Rats fed the sucrose diet had higher plasma glucose levels at the
individual tim e points when compared to rats fed chow but the levels did not
reach statistical significance. Baseline insulin concentrations were
significantly different among the groups, with rats on the calorie restricted
diet having the lowest and rats on the sucrose diet having the highest
concentrations. Rats in all 3 groups had a sim ilar pattern o f insulin response
after the glucose load. Levels o f insulin for rats fed the sucrose diet were
higher at every time point when compared to rats fed chow. Total insulin
response was significantly (p < 0.01) different among groups, the values for
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chow-fed, sucrose-fed, and calorie-restricted rats were, 525 ± 61, 831 ± 68,
and 306 ± 25 uU/ml, respectively. The authors concluded that rats fed a
calorie-restricted diet were more insulin sensitive than both rats fed a chow
and sucrose diet. Rats fed a sucrose diet were more insulin resistant.
DIET COMPOSITION
ENERGY BALANCE
The increase in the incidence o f obesity worldwide has raised
concern about the adverse effects o f this condition and has made the
regulation o f body w eight a major public health issue (Flatt 1995). Body
weight maintenance can be attained by achieving a balance between energy
intake and energy expenditure. Although on a day to day basis nutrient
intake and physical activity vary greatly weight m aintenance is still achieved.
Because, variations in daily energy expenditure are small, it is the changes
in food intake that greatly affect energy balance. Therefore, the major
mechanism responsible for weight maintenance is the adjustm ent o f food
intake to energy expenditure (Flatt 1995). There are many factors that may
influence food intake in individuals, but it is not clear as to which o f these
play dominant roles in the regulation o f food intake (Poppitt and Prentice
1996, Duncan et al.1983).
Despite the variations in nutrient intake body com position remains
relatively stable indicating that some compensatory changes are occurring.
Three types o f com pensatory responses are possible: changes in food
intake, changes in the composition o f the fuel mix oxidized, and changes in
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energy expenditure (Flatt 1987). Factors affecting food intake include the
amount and type o f fat in the diet indicating that the energy density o f the
diet can affect energy intake, satiety, and eating tim e (Horton et al.1995,
Duncan et al.1983). Changes in substrate and hormone concentrations
influence the distribution o f the fuel mix oxidized which affects the amount
and type o f nutrients stored (Flatt 1995).
To meet the body’s energy requirements the com position o f the fuel
mixture oxidized changes throughout the day. The human body tries to
minimize variations in protein content and to maintain glycogen stores within
a specific range. Because the body has the capacity to store more fat than
glycogen and protein, energy balance can be offset by gains or losses o f fat
(Flatt 1995).
The relative proportion o f the fuel mixture oxidized determines the
respiratory quotient (RQ). Carbohydrate oxidation results in a RQ close to
1, whereas oxidation o f fat results in a RQ o f 0.7. Consumption o f a diet
high in fat or carbohydrate decreases o r increases, the RQ, respectively.
For the RQ to equal the FQ (food quotient) the individual has to oxidize the
same amount o f fat and carbohydrate as he or she is consuming.
Consumption o f a diet that produces a RQ > FQ leads to storage of fat and
weight gain, since less fat is oxidized than consumed. Consumption o f a
diet that produces a RQ < FQ leads to a reduction in body fat and weight
loss because more fat is being oxidized than what is consumed (Westeterp,
K.R., 1993).
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According to J. P. Flatt (1995), the oxidation o f carbohydrate and
protein is adjusted for intake, whereas fat oxidation is determined by the gap
between total energy expenditure and amount o f energy provided by protein
and carbohydrate. Fat oxidation is impaired in individuals after consumption
o f meals even if the fat content is greater than the carbohydrate content.
The fuel mixture oxidized contains a lesser proportion of fat than that
present in the diet leading to storage o f the remaining amount. Flatt’s theory
does not take into account the concept o f energy balance and how this can
affect the type of macronutrient that is oxidized. Other research indicates
that it is during periods o f positive energy balance that consumption of a
high fat diet will cause a decrease in the amount o f fat oxidized.
Consumption of high fat diets during periods o f energy balance do cause an
increase in the amount o f fat oxidized (Horton et al. 1995).
Diet composition is an im portant determ inant of body weight
maintenance. In rats, long term consumption o f diets high in fat has been
shown to cause obesity regardless of total energy intake (W arwick and
Schiffman 1992). Short-term (2 weeks) consumption o f a high fat diet during
periods o f energy balance in humans caused a shift in substrate oxidation
so that oxidation more closely reflected the composition o f the diet, thus
preventing weight gain (Hill 1991). Anim als consuming diets o f different
caloric densities adjust by eating more on a low-calorie diet and less on a
high calorie diet. Rats fed a high energy dense diet experience a rapid
increase in body weight before these compensatory changes take place
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causing a higher weight gain overall (Johnson et al.1986, Roy et al.1999
unpublished manuscript). Horton et al. (1995) conducted a study in lean
and obese men to determine how energy balance and fuel oxidation change
with fat and carbohydrate overfeeding. Consumption o f high carbohydrate,
as well as consumption of high fat, led to increased carbohydrate and fat
oxidation, respectively, and increased total energy expenditure. Excess
consumption o f calories from fat had an effect on fat fuel oxidation, but lead
to a greater and faster accumulation o f fat then when carbohydrates were
consumed in excess. Once glycogen stores are filled excess carbohydrate
consumption does lead to fat accumulation. Horton et al. (1995) observed
that obese subjects, when compared to their lean counterparts, had a higher
RQ when both fat and carbohydrate was consumed in excess, indicating a
higher proportion o f carbohydrate oxidation.
AMMONIA CONCENTRATION
Conditions, such as cirrhosis, that have been shown to affect normal
functioning o f the liver are associated with increased levels o f ammonia in
the brain and blood. Abnormalities in glucose metabolism have also been
reported in these patients. In addition, studies conducted in
hyperammonemic rats showed that high levels o f ammonia altered
peripheral glucose uptake and inhibited endogenous insulin secretion
(Schlienger and Im ler 1978, Schlienger et al.1975). Levels o f ammonia
were increased for rats rendered hyperammonemic by either an exogenous
infusion o f ammonium acetate or with a chronic endogenous portal stricture,
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when compared to levels in the controls. Ammonium infused rats had blood
ammonia levels o f 385 ± 40 ug/100 ml (226.4 ± 23.52 um ol/l) 10 minutes
after infusion and then the level rose progressively to 550 ± 70 ug/ml (323 ±
41.1 um ol/l) 60 minutes after infusion. For portal-strictured rats, basal
hyperammonemia was observed with high ammonia levels remaining
constant throughout the study, 216 ± 28 ug/100 ml (127 ± 16.5 umol/l).
High dietary protein intakes may lead to the developm ent o f a
hyperammonemic condition sim ilar to that observed in the portal-strictured
rats. There exists the possibility that if high protein diets and/or amino acid
supplements are consumed fo r prolonged periods o f time blood ammonia
may increase to levels that can possibly alter glucose metabolism. In the
United States, individuals who eat the typical W estern diet consume protein
in amounts that exceed the recommended dietary allowance fo r this nutrient
(USDA 1998). Furthermore, people consuming fad diets such as, “Sugar
Busters", “The Zone”, and “The Protein Power Plan”, may be affected by
increased ammonia concentrations. In addition, athletes consuming protein
or amino acid supplements in an effort to increase lean body mass accretion
could also be affected by chronic exposure to elevated levels o f ammonia.
These levels may not be as high as ammonium infusions in animals but
long-term effects could be damaging to health.
SYNTHESIS OF CARNITINE
Studies have indicated that the composition o f the diet can have an
effect on blood levels o f free and esterified carnitine and on the excretion of
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urinary carnitine. Results o f studies conducted in both animals and humans
indicate that there may be an increased need fo r carnitine in the tissues
when the fat content o f the diet is increased.
Cederbald (1987) observed that healthy males consuming a high fat
diet (54% o f energy) (n -7 ) had increased levels o f free carnitine in plasma
and urinary excretion o f both free and acyl carnitine. These levels were
significantly (p < 0.05) greater than the levels obtained when a high
carbohydrate diet was consumed (51%). Cederbald concluded that the high
fat content o f the diet could have increased the absorption o f dietary
carnitine. In addition, an increase in endogenous synthesis of carnitine
could have resulted from the higher lipid load provided by the high fa t diet.
The tissue demand for carnitine could have been increased on the high fat
diet to allow for higher rates o f fatty acid oxidation and compensate fo r the
loss o f urinary carnitine.
Seccombe et al. (1978) conducted a study in young white W istar rats
to determ ine the effect o f different diets on blood levels of free and esterified
carnitine. Animals were exposed to either a high fat diet, with long-chain
triglycerides (n=8, cottonseed oil) o r medium-chain triglycerides (n=10,
coconut oil), or a diet high in carbohydrates (n -8 ). Serum free carnitine
levels were significantly (p < 0.0001) lower in rats fed either the long-chain
triglyceride diet (20 ± 2.2 uM) or the medium-chain triglyceride diet (19.4 ±
1.1 uM) compared to animals fed the high carbohydrate diet (39.2 ± 2.2 uM).
Total serum carnitine content was significantly (p < 0.001) lower for rats fed
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the long-chain triglyceride diet (34.4 ± 1.9 uM) than those fed the mediumchain triglyceride (47.5 ± 2.5 uM) or the high carbohydrate diet (51.6 ± 2.9
uM). The authors concluded that the decrease in total carnitine seen with
the long-chain triglyceride diet might be due to a greater demand by the
tissues for carnitine so that fatty acids can be oxidized.
These results do not necessarily indicate that supplemental dietary
carnitine is required under high dietary fat conditions. An additional
exogenous source o f carnitine may not be required because synthesis of
carnitine in the body may always be adequate. However, studies continue
to address this possibility.
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CHAPTER 3
METHODOLOGY
EXPERIMENTAL DESIGN
STUDY DESIGN
The study was a com pletely randomized design with 2 X 2 X 2
factorial arrangements o f treatments. The study was undertaken to
determine the effects o f dietary carnitine on glucose, fat, and protein
metabolism o f rats that were fed either high fat and/or high protein. Female
retired breeder rats (9 months old) were used as an animal model since
weight gain and changes in glucose and fat metabolism are most commonly
associated with older adults. Furthermore, rats fed a diet high in fat become
obese and are recognized as models o f the effects of a high fat diet on
insulin resistance (Storiien, 1986). Treatment groups are shown in Table
3.1.
Table 3.1 Dietary treatm ent groups by percent weight o f diet
Protein
Carnitine
Dietary Treatment
NLL
NLF
NPL
NPF
CLL
CLF
CPL
CPF

No Carnitine,Low Protein, Low Fat
No Carnitine, Low Protein,High Fat
No Carnitine, High Protein, Low Fat
No Carnitine, High Protein, High Fat
Carnitine, Low Protein, Low Fat
Carnitine, Low Protein, High Fat
Carnitine, High Protein, Low Fat
Carnitine, High Protein, High Fat

0%
0%
0%
0%
0.1%
0.1%
0.1%
0.1%

14%
14%
35%
35%
14%
14%
35%
35%

Fat
4%
35%
4%
35%
4%
35%
4%
35%

ANIMALS
Seventy-two 9 month old fem ale retired breeder rats (Harlan Sprague
Dawley, Madison, W isconsin), from the same colony, age and weight
matched, were used in this study. The study protocol was approved by the
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Louisiana State University Institutional Anim al Care and Use Committee
(see Appendix B). The rats were housed individually in w ire cages
containing a food cup and a w ater bottle and were maintained on a 12:12
lighting schedule, with lights coming on at 7:00 a.m. and off at 7:00 p.m..
The rats were allowed to adapt to their new environment for 2 days and
were fed the standard AIN-93M diet during this period. On the third day the
rats were weighed and randomly assigned to one o f nine treatm ent groups
(eight dietary and one baseline). The rats were stratified from the heaviest
to the lightest and divided into eight weight groups o f nine rats each, i.e. the
first heaviest nine rats were one group, the next heaviest nine rats were
another group and so on. After this stratification by weight, one rat from
each o f the 8 groups was then assigned to one o f nine groups, labeled A-I.
Then the A -I groups were randomly assigned to one of the nine treatm ent
groups. The mean body weight o f the treatm ent groups (n=9) was 307.3 ±
4.60 g, with weights ranging from 243 to 356 g.
Baseline rats were maintained on the standard diet fo r a total o f six
days and were sacrificed on the 7th day. Before sacrifice an oral glucose
tolerance test was performed to determ ine the amount o f tim e needed for
glucose and insulin levels to decline. The baseline carcasses were frozen
(-20°C) for future body composition measurements. One o f the baseline
rats died the day of the oral glucose tolerance test and a small tum or in the
neck region was detected in another.
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EXPERIMENTAL METHODOLOGY
Diet
The rats were randomly assigned to a low fat/low protein, a low
fat/high protein, a high fat/low protein, or a high fat/high protein diets with or
without carnitine. The low fat/low protein diet was the basic diet for this
experiment and is the AIN-93M diet formulated for maintenance o f adult
rodents (Table 3 .2 ).
The carbohydrate content (sucrose and cornstarch) o f the other diets
was adjusted from this basic diet to allow for increased protein in the high
protein diet (35% by wt) o r increased fat in the high fat diet (35% by wt).
Amounts o f all other nutrients were a fixed amount so that they remained at
AIN-93M concentrations (by wt). The other diets are illustrated in tables 3.33.5. The level o f L-cam itine (0.1%) used in this study was determined from
a previous rat study (Rebouche 1983). Rats fed diets that were
supplemented with 0.1% to 1.0% of L-camitine had increased L-camitine
concentrations in serum and all tissues; however, at higher levels (0.5%2.0%) the L-cam itine produced diarrhea in these rats (Rebouche 1983).
To obtain a carnitine concentration o f 0.1%, 2 gram s o f Camiking
(50% mixture D and L) was added to every kilogram o f diet prepared. The
sucrose content o f the diet was reduced by the amount o f Camiking added
to the diets (i.e. 2 g). To avoid confusion among the different dietary
treatments a small amount o f blue dye (.33 g/kilo o f diet) was added to the
carnitine diets.
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Table 3.2. Basic diet for experiment- AIN 93 M diet.
1
In g r e d ie n t
Am ount needed per kilo
Sucrose

Grams
100

Amount for study

%
10.0

1.8 kilograms

Casein

140

14.0

2.52 kilograms

Cornstarch

466

46.6

8.39 kilograms

Dextrinized Cornstarch

155

15.5

2.79 kilograms

Soybean Oil (with BHT)

40

4.0

Crisco

■■■■

Cellulose Fiber

50

5.0

900 grams

Methionine

1.8

.18

32.4 kilograms

Mineral Mix (AIN 93)

35

3.5

630 grams

Vitamin Mix (AIN 93)

10

1.0

180 grams

Choline Bitartrate

2.5

720 grams
-

.25

45 grams
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Table 3.3. High protein and low fat diet.
Am ount needed per kilo
I n g r e d ie n t

Am ount for study

Sucrose

Grams
71

%
7.1

Casein

350

35.0

3.15 kilograms

Cornstarch

330

33.0

2.97 kilograms

Dextrinized Cornstarch

110

11.0

.99 kilograms

40

4.0

360 grams

Cellulose Fiber

50

5.0

900 grams

Methionine

1.8

.18

32.4 kilograms

Mineral Mix (AIN 93)

35

3.5

630 grams

Vitamin Mix (AIN 93)

10

1.0

180 grams

Choline Bitartrate

2.5

.25

45 grams

Soybean Oil (with BHT)

.64 kilograms

Crisco
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Table 3.4 Low protein and high fat diet.
Am ount needed per kilo
I n g r e d ie n t
Sucrose

Grams
57

%
5.1

Am ount for study
1.8 kilograms

Casein

140

14.0

2.52 kilograms

Cornstarch

266

26.6

8.39 kilograms

Dextrinized Cornstarch

88

8.8

2.79 kilograms

Soybean Oil (with BHT)

40

4.0

720 grams

310

31.0

Cellulose Fiber

50

5.0

900 grams

Methionine

1.8

.18

32.4 kilograms

Mineral Mix (AIN 93)

35

3.5

630 grams

Vitamin Mix (AIN 93)

10

1.0

180 grams

2.5

.25

45 grams

Crisco

1Choline Bitartrate

6.2 kilograms
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Table 3.5. High protein and high fat diet.
I n g r e d ie n t
Am ount needed per kilo

Am ount for study

Grams
28

%
2.8

.56 kilograms

Casein

350

35

7 kilograms

Cornstarch

130

13

2.6 kilograms

Dextrinized Cornstarch

43

4.3

.86 kilograms

Soybean Oil (with BHT)

40

4.0

.80 kilograms

310

31.0

6.2 kilograms

Cellulose Fiber

50

5.0

900 grams

Methionine

1.8

.18

32.4 kilograms

Mineral Mix (AIN 93)

35

3.5

630 grams

Vitamin Mix (AIN 93)

10

1.0

180 grams

2.5

.25

45 grams

Sucrose

Crisco

1Choline Bitartrate
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To prepare the basic AIN-93M diet the macronutrients were weighed
and added to a large mixing bowl. The micronutrients were sieved
sequentially into a large bowl and combined with the macronutrients.
Specific instructions on how to prepare the basic AIN-93M diet can be found
in Appendix C. The same procedure was used to prepare the low fat/high
protein diet with or without carnitine and the low fat/low protein diet with
carnitine. For the carnitine diets the Camiking was added with the
micronutrients.
To prepare the high fat diets each m acronutrient was weighed and
placed in its own container. The individual micronutrients (vitamins,
minerals, etc.) were weighed and sieved sequentially into a large bowl. The
macronutrients (except the fat) and micronutrients were then sieved
sequentially into a large bowl and mixed together (See Appendix C).
The diets were stored frozen (-20°C) in either Rubbermaid containers
or in Ziploc bags. The-low fat diets were prepared in 6-kilogram batches,
whereas the high fat diets were prepared in 1-kilogram batches. Three sixkilogram batches o f the low fat diets and 11 one-kilogram batches of the
high fat diets were prepared for this eight-week study.
The amount o f kilocalories per gram of diet fo r the low fat diets and
the high fat diets are shown in Table 3.6. The percentage o f kilocalories
coming from the macronutrients for the low protein low fat diet, the high
protien low fat, the low protein high fat diet, and the high protein high fat diet
are listed in Table 3.7.
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Table 3.6 Amount of energy per gram of diet.
Kilocalories per Gram diet
Name o f diet
3.9
NLL, NPL, CLL & CPL
I

5.4

NLF, NPF.CLF & CPF

Table 3.7 Percentage o f kilocalories from the macronutrienl s in each diet.
% Protein
% Fat
% Carbohydrate
Name o f diet
9.3
76.2
14.5
NLL & CLL
9.3
36.1
54.6
NPL & CPL
58.1
31.6
10.3
NLF & CLF
58.1
16.1
25.8
NPF & CPF
EXPERIMENTAL PROCEDURES
Food intake and body weight was recorded three tim es a week for the
entire length o f the study. The weight o f the food cup plus food was
recorded before and after each feeding. To determ ine the am ount o f food
consumed the difference was calculated. To weigh the rats, a bucket was
placed on a balance, the balance was brought to zero using small weights,
and then rats were individually placed in the bucket and weighed. At week
2, blood (1.5 ml) was obtained from the orbital sinus while rats were under
isoflurane anesthesia using an anesthesia cham ber followed by a nose cone
to effect following the technique used by Dr. Stout from the LSU School of
Veterinary Medicine. The blood was spun down in the centrifuge and the
serum was aliquoted into 3 different centrifuge tubes. Serum samples were
analyzed for L-cam itine, glucose, insulin, nonesterified fatty acids, ammonia,
and urea nitrogen.
During week 5 o f the study, an oral glucose tolerance test was
performed, blood (0.7 ml) was obtained from the orbital sinus before and
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120 m inutes after the glucose load and the serum was analyzed fo r insulin
and glucose. The rats were anesthetized with isoflurane using an
anesthesia chamber followed by a nose cone to effect. An oral gavage was
performed using an oral glucose load (3.0 g/kg of body weight) that was
given via an 18 gauge 3 ” ball tipped, gavage needle.
A t the end o f the study (wk 8), the rats were anesthetized using
isoflurane and blood (1.3 ml) was obtained from the orbital sinus. The blood
collected was used to measure end point levels o f L-cam itine, glucose,
insulin, nonesterified fatty acids, ammonia, and urea nitrogen. Rats were
sacrificied by cardiac puncture using a syringe and needle. After sacrifice,
the heart, soleus, liver, gastrointestinal tract and right and left fem ur were
removed. Abdominal fa t was removed, weighed, and returned to the
carcass for future body com position analysis. Carcasses were frozen (20°C) and body composition measurements were made 6 months later.
Different intervals were used to report different measurements
because all rats were not sacrificed on the same day. Data for
measurements that were recorded on a weekly basis was reported as a 7
week interval. Blood was taken fo r measurement o f hormones and
m etabolites during sacrifice, week 8, therefore these values were reported
as an 8 week interval. Rats were sacrificed on three different days so the
intake and weight data recorded during sacrifice week was not documented
for the same length o f tim e for all rats. Thus, these measurements could not
be used to calculate an 8 week interval period.
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LABORATORY ANALYSIS
Enzyme Analysis
To determ ine the rate of beta-oxidation in skeletal muscle (soleus)
the enzyme activity o f 3-hydroxyacyl CoA Dehydrogenase was determined.
During sacrifice the right soleus muscle was removed, weighed, wrapped in
labeled aluminum foil, frozen in liquid nitrogen, and stored at - 40°C for 6
months.
Two days prior to the analysis, a homogenizing buffer was prepared
and stored in the refrigerator (4°C). Enough buffer was prepared to analyze
64 samples (150 ml o f buffer) by using 175 mM KCL, 2 mM EDTA and 10
mM Tris stock. The mixture was stored in the refrigerator to obtain a final
temperature o f 4°C. The pH o f the buffer was brought up to 7.4 by adding
acid or base as needed.
To prepare the homogenate the soleus muscle was thawed, cleaned
(connective tissue removed) and > .03 grams of tissue were weighed. The
tissue was placed in a 16 X 100 mm glass tube to which the homogenizing
buffer was added to prepare a 5% homogenate (w/v). To determ ine the
amount o f homogenizing buffer needed the weight o f the sample was
multiplied by 19, fo r a 1/20 dilution. To homogenize the samples a
Brinkman Homogenizer (Model PCU-11) was used. The blade o f the
homogenizer was placed all the way to the bottom o f the sample and the
knob was rotated clockwise. A beaker o f ice was kept under the test tube to
keep the sample chilled at all times. The sample was homogenized until an
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opaque white liquid sample was obtained (Askew et al. 1975, W illiamson et
al. 1971). To prevent the breaking down of proteins in the tissue the
samples were carefully homogenized and not allowed to foam very much.
The homogenized samples were parafilmed and stored in the freezer until
the next day (one entire day was needed to homogenize 64 samples).
The day the analysis was conducted, a 100 mM potassium
phosphate buffer, NADH solution, and acetoacetyl CoA solution were
prepared. A 5-cuvette holder spectrophotometer (Spectronic 601, Milton
Roy, Chicago, IL.) was used to run the assay. The spectrophotometer was
turned on at least 30 minutes prior to the first reading to allow fo r warm up.
For every run only two homogenized samples were thawed. The samples
were run in duplicate. A specific amount of phosphate buffer, which
depended on the concentration o f the homogenate, was added to a labeled
test tube. Based on the protocol the amount of buffer added to obtain the
dilution factor for the specific muscle sample analyzed was either 1.4 or 1.9
ml. The homogenized sample was vortexed, 100 pi were pipeted 3 times,
the sample was vortexed, and then 100 pi were added to the labeled test
tube. Again the sample was vortexed. To a 1.6 ml cuvette, 700 pi o f 100
mM phosphate buffer, 100 pi o f NAOH, and 10 pi o f diluted homegenate
were added. The samples were then placed in the spectrophotometer and
allowed to equilibrate for 2 minutes. The reaction was initiated by adding 10
pi of 2 mM acetoacetyl CoA and inverting the cuvette (a parafilm strip was
used to cover the top). The absorbance was recorded at 340 nm every 15
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seconds for 5 minutes. The average change in optical density per minute
was determined (pm oles/g/m in) (Askew et al. 1975, W illiam son et al. 1971).
Refer to Appendix D for detailed explanations of the procedures and
calculations used in this analysis.
Serum Carnitine Analysis
H ill’s Science and Technology Center (Lonza, Topeka, Kansas)
analyzed the samples for total serum L-cam itine concentrations.
Serum Insulin Analysis
Insulin was measured using Coat-A-Count® Insulin, a solid-phase 1251
radioimmunoassay (Diagnostic Product Corporation, Los Angeles, CA).
Insulin antibody is immobilized to the wall o f a polypropylene tube used in
this assay. In this procedure,125 l-labeled insulin compete? fo r sites, on
insulin-specific antibody, with insulin in the rat blood sample. Decanting the
supernatant terminates the com petition and allows for isolation o f the
antibody-bound fraction o f the radiolabeled insulin. The coated tubes can
be decanted without loss o f antibody-bound material and thus results in a
good separation. See Appendix D fo r serum insulin assay protocol.
Serum Ammonia Analysis
Ammonia was measured using a Sigma Diagnostic Kit (Sigma
Diagnostics Procedure No. 170-UV, Sigma Diagnostics, St., Louis Missouri)
which provides a quantitative enzym atic determination o f ammonia at 340
nm. Ammonia levels reflect urea cycle activity in relation to glucose, protein
and nucleic acid metabolism. The procedure is based on the reductive
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am ination o f 2-oxoglutarate using reduced nicotinamide adeninde
dinucleotide phosphate (NADPH). The end products o f the reaction are
glutam ate and nicotinamide adenine phosphate (NAD) and the enzyme
involved is glutamate dehydrogenase (GLDH). The oxidation o f NADPH
decreases the absorbance at 340 nm, the decrease being proportional to
serum ammonia concentrations. Refer to Appendix D fo r serum ammonia
assay protocol.
Serum Glucose Analysis
Glucose concentration was measured with the Beckman DU-640
Spectrophotom eter (Beckman Instruments, Inc.) utilizing the glucose
oxidase method. Glucose is first oxidized to gluconic acid and hydrogen
peroxide. In the presence of peroxidase, the hydrogen peroxide reacts with
4-am inoantipyrine and p-hydroxybenzene sulfonate to form a quinoneimine
dye. The dye has a maximal absorbance at 505 nm and the intensity of the
color produced is directly proportional to the glucose concentration in the
sample. See Appendix D for serum glucose assay protocol.
Serum Nonesterified Fatty Acid analysis
The concentration o f nonesterified fatty acids in serum was obtained
using the colorim teric ACS-ACOD method (Wako Chemicals USA, Inc.,
Richmond Virginia). Refer to Appendix D for serum nonesterified fatty acid
assay protocol.
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Serum Urea Nitrogen analysis
Serum urea nitrogen was measured using the Beckman DU-640
spectrophotometer following the method reported by Laborde et al. (1995).
Refer to Appendix D for serum urea nitrogen assay protocol.
BODY COMPOSITION ANAYSIS
Body composition analysis was performed to determine the percent
fat, protein, moisture and ash on the baseline rats (n=7) and on the rats
(n=8) assigned to the eight dietary treatments. The methods utilized for
preparing the rat carcasses for body composition analysis were those
reported by Klinger et al. (1996). Frozen carcasses minus the liver, heart,
right soleus, gastrointestinal tract, and right and left fem ur were used for this
analysis. To prepare the carcasses for body composition analysis the
frozen carcasses were thawed 24 hours prior to the start o f the analysis.
Each carcass was individually wrapped in a biohazard bag that had been
labeled with the rat ID number. The carcasses were then autoclaved for 60
minutes at 125°C at the Life Science facilities. The autoclaved carcasses
were left at room temperature fo r approximately 30 minutes to allow for cool
down.
The carcasses were then cut into small pieces using scissors. First,
the fur and skin were removed and cut into small thin strips. Care was taken
to ensure that the sizes of the pieces were o f equal length. Secondly, the
muscle and abdominal fat were cut into fine pieces. This procedure was
much easier due to the nature o f the material being cut, but likewise care
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was taken to ensure that pieces were small enough to grind in the omni
mixer. Lastly, the bones were cut into small pieces to make it easier for the
mixer to break down the remaining bone fragments.
The cut carcasses were placed in plastic jars that fit onto the mouth
o f the omni mixer. Deionized water was added to each container before the
mixture was homogenized. The total amount o f deionized water added
consisted of the weight of the rat carcass plus 50 ml. This amount o f water
was needed to ensure that the blades of the homogenizer could reach the
carcass material, mix the contents o f the jar, and produce a homogenous
mixture. The carcass material plus deionzed water corresponding to the
weight of the carcass was first homogenized for two minutes. The contents
on the side o f the ja r were then washed down with 50 ml o f deionzed water.
This was done to guarantee that the material that was forced to the upper
part of the ja r was washed down into the homogenate. The mixture was
homogenized for another 2 minutes. The homogenate was poured into two
pre-labeled tubes and placed in the freezer (-20°C) until the different
analyses were performed (approximately one week). Glass jars containing
some extra homogenate were stored in the freezer and the remaining liquid
was discarded. The nature of the homogenate was liquid and o f brownish
color.
To determine the percent moisture content, one o f the tubes that
contained the frozen homogenate was thawed for six hours. Small beakers
were labeled with the rat ID number and weighed. Five grams of sample
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were placed in each beaker and the contents were dried in the oven, set at
105°C for 18 hours. The amount o f tim e that the sam ples remained in the
oven was determined from a test sample. The tim e at which the beaker
weight no longer changed was used as the time needed to dry the samples
and determine percent moisture. The following form ulas were used to
calculate the percent moisture: 1) W eight o f beaker plus the 5 gram sample
- W eight of beaker w ith dried sample/W eight of original sam ple (5 grams) X
100 = Percent m oisture. To take into account the w ater added during
homogenziation the follow ing formulas were used: 1) Percent
moisture*[Carcass w eight + water added (grams)] = total gram s o f water
associated with carcass. 2) Total grams o f w ater associated with carcass grams of water added to carcass = grams o f water in carcass 3) Grams of
w ater in carcass/carcass weight in grams = Percent m oisture in carcass
accounting for dilution.
To determine the percent ash content of the sam ple a wet ashing
procedure was conducted on the dried samples used for moisture
determination (Keenan et al. 1991). To char the samples, the samples were
placed in the muffle furnace (Lindberg General Signal P48038) overnight
(500°C). Each beaker was labeled and a diagram with the location of each
sample was prepared. The beakers were removed from the furnace and
allowed to cool. Approxim ately one ml o f nitric acid was added in a fume
hood to the samples and samples were set on a hot plate fo r a few hours
until the samples dried. The beakers were once again placed in the muffle
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furnace overnight and the process was repeated until the ash was no longer
black or gray in color. The following formulas were used to calculate the
percent ash o f the sample: 1) W eight o f beaker plus 5 gram sample W eight of beaker with ashed sample = grams left in sample after ashing
procedure. 2) W eight o f original sample (5 gram s) - grams left in sample
after ashing/W eight o f original sample (5 g) X 100 = percent ash o f aliquoted
sample. The calculation of percent ash has to take into account the water
added during the preparation o f the homogenate. The following formulas
were used to calculate the percent: 1) Percent ash*[Carcass weight + water
added (gram s)] = Grams of ash in carcass. 2) Grams o f ash in
carcass/W eight o f carcass (grams) = Percent ash accounting for dilution.
To determine the percent fat content the Soxtec method o f extraction
was used (Soxtec Instrument HT-1043 extraction unit) following the Offical
Methods of Analysis o f the Association o f Offical Analytical Chemists (1990).
Two to three grams o f sample were weighed and placed in a pre-weighed
aluminum tube containing a thimble. The samples were covered with sand
and a piece of cotton was placed on top o f each tube. In addition, aluminum
cups used to collect the fat extract were pre-weighed for all samples. The
tubes with samples were placed on the instrum ent with the collecting cups
underneath. To each tube 40 ml o f solution containing ethyl ether were
added. The tubes were boiled for 30 minutes, rinsed with solution for 45
minutes, and the final extraction procedure was conducted in 15 minutes.
The aluminum cups with the extract were then weighed. To calculate the fat
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percent the following formulas were used: 1) Aluminum cup weight with fat
extract - original aluminum cup weight = total grams o f fat extracted.

2

)

Total grams o f fat extracted/weight o f the sample = percent fat in the
sample. To account for the dilution factor the following formulas were used:
1) Percent fat*[Carcass weight+water added (gram s)] - Grams o f fat in
carcass. 2) Grams of fat in carcass/W eight o f carcass (grams) = Percent fat
accounting for water dilution.
To determine the percent o f protein in the sample a blot digestion
method accompanied by auto analysis was performed according to
procedure 976.06 in the Offical Methods o f Analysis o f the Association of
Official Analytical Chemists (1990). The sample, 1 to 2 grams, was weighed
onto white filter circular paper, folded and dropped into big test tubes.
Sulfuric acid, 20 mis, was added to each tube and brought up to volume with
water. Immediately after the water was added the tubes were lightly shaken
to ensure that the paper and sample were dissolved. The tubes were
placed in a rack and pre-digested fo r 15 minutes using the Digester 2020
(Tecator Prestorp Analytical Co.) at 400°C. The tubes were removed and
cooled for 15 minutes. To each tube the following was added: 1) 3.75 ml of
Hydrogen peroxide (30%) and 2) 12 g o f Catalyst (10 g o f K2SO4 and 0.3 g
of C0 SO 4 )- The tubes were placed on the digester fo r 1.5 hours and allowed
to cool for 15 minutes. To ensure that a homogenous sample was taken
rubber stoppers were placed on each tube and the tubes were shaken. The
samples were poured into small test tubes and analyzed with the auto
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analyzer. A printout with the percent protein o f the 1 to 2 g sample was
generated. To calculate the percent of protein in the carcass accounting for
the water added the following formulas were used: 1) Percent
protein*[Carcass weight+water added (grams)] - Grams o f protein in
carcass. 2) Grams o f protein in carcass/W eight o f carcass (grams) Percent protein accounting fo r dilution.
STATISTICAL ANALYSIS
The study was analyzed using the Statistical Analysis Systems
statistical software package version 6.12 (SAS Institute, Cary, NC, USA). A
multivariate technique, Multiple Analysis o f Variance (MANOVA) was used
to examine the interdependence o f the dependent variables and the effects
o f the independent factors, carnitine, protein and fat on this relationship.
Separate MANOVA’s were run for the following groups of dependent
variables: 1) Carnitine, ammonia, urea nitrogen, glucose, insulin, and
nonesterified fatty acids, 2) Food intake, energy intake, energy efficiency,
body weight, and weight gain, 3) Percent moisture, ash, protein, and fat,
final body weight, total weight gain, and abdominal fat. A univariate
technique, Analysis o f Variance (ANOVA), was used to analyze the data for
the oral glucose tolerance test and the enzyme analysis.
Due to the data handling characteristics o f the MANOVA technique
subjects with one missing value (e.g. no carnitine value for week 2) were
completely removed from the analysis. Too many observations were lost
when the MANOVA technique was applied to this data set. Therefore, the
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use of the ANOVA technique was considered more appropriate. The data
set was re-analyzed using the ANOVA technique. ANOVA with repeated
measures was used fo r the data collected at 2 and 8 weeks. ANOVA was
used for single measurements that were collected during week 8 o f the
study (end point data).
The data was also analyzed for potential outlier values using
univariate analysis. Each observation that was considered a potential outlier
was evaluated individually to determine if the observation should be
included in the data set.
Results were considered significantly different when p < .05. P
values greater than .05 and less than or equal to .1 were considered a trend
(.1 > p > .05). Results were summarized in a graphical form at where the
main and interaction effects are specified and error bars indicating the
pooled standard error o f the mean are included.
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CHAPTER 4
RESULTS
FOOD INTAKE AND BODY WEIGHT
Initially, food intake for rats fed the low and high fat diet was not
different, but after 2 weeks intake o f rats on the high fat diet decreased and
remained lower (fat*tim e, p = 0.0001) fo r the rest o f the study when
compared to rats fed low fat diets (Figure 4.1; values for all figures can be
found in Appendix E). This lead to an overall greater food intake for rats fed
the low fat diets (fat, p = 0.0001). There was no difference in the pattern of
food intake and overall intake for rats fed the high and low protein diets
(protein*tim e, p = 0.67; protein, p = 0.60) and the diets with or without
carnitine (cam itine*tim e, p = 0.38; carnitine, p = 0.95).
During the first 2 weeks of the study, energy intake for rats fed the
high fat diets was greater than intake for rats fed the low fat diets, with
intake becoming sim ilar to that o f rats fed the low fat diets for the rest o f the
study (fat*tim e, p = 0.0001, Figure 4.2). There was a trend for rats fed the
no carnitine low fat diets to have lower energy intakes (cam itine*fat*tim e, p =
0.06, Figure 4.3) than rats fed the carnitine low fat diets. The trend was
caused by the intake during weeks 2 and 3, where mean energy intake was
346.5 ± 16.3 and 363.8 ± 13.9 kcal fo r rats not fed carnitine with low fat and
398.0 ± 15.7 kcal and 390.7 ± 13.4 kcal fo r rats fed the carnitine with low fat
diets. As shown in figure 4.4, rats in all eight dietary treatment groups
began the study with sim ilar body weights (p s 1.00). One week after
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Figure 4.2 Energy intake for rats fed high and low fat diets.
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Figure 4.4 Initial and weekly body weight for all dietary treatments.
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assignm ent to the dietary treatments, rats fed high fat had overall a higher
body w eight (fat, p = 0.0001) that remained higher (fat*tim e, p = 0.0001) for
the rest o f the study (Figure 4.5). It was the greater energy intake during the
first 2 weeks o f the study that caused the body weight o f rats fed high fat to
increase and remain higher than that o f rats fed low fat. There was no
difference in the pattern and overall body weight for rats fed different levels
of protein (protein*tim e, p = 0.6; protein, p = 0.5) and carnitine
(cam itine*tim e, p = 0.8; carnitine, p = 0.97).
For the first 2 weeks o f the study, rats fed the high fat diet gained
more w eight than rats fed the low fat diet, but with tim e the am ount o f weight
gained became sim ilar to that o f rats fed low fat (fat*tim e, p = 0.0001; Figure
4.6). The initial weight gained caused rats fed high fat to have an overall
greater weight gain than rats fed low fat (fat, p = 0.0001).
O verall, rats fed the high fat diet were more energy efficient than rats
fed the low fat diet (fat, p = 0.0001, Figure 4.7). During the first 2 weeks of
the study, rats fed the high fat diet were more energy efficient than rats fed
the low fa t diet, but energy efficiency fo r both groups became sim ilar for the
rem ainder o f the study (fat*tim e, p = 0.0001).
SERUM METABOLITES AND HORMONES
CARNITINE
A t 2 and 8 weeks, serum carnitine concentrations were higher
(p = 0.0001) for rats on the carnitine diets when compared to rats not fed
carnitine (Figure 4.8). Serum carnitine concentrations were also higher
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for rats fed the low protein (p = 0.0001, Figure 4.9) and low fat (p = 0.0001,
Figure 4.10) diets compared to rats fed the high protein and high fat diets,
respectively. Mean carnitine concentrations for rats fed low protein were
47.6 ± 1.7 nmol/ml at 2 weeks and 51.5 ± 2.2 nmol/ml at 8 weeks; mean
carnitine concentrations for rats fed high protein were 41.3 ± 1.8 nmo/ml at 2
weeks and 39.1 ± 2.4 mol/ml at 8 weeks. Mean carnitine concentrations for
rats fed low fat were 47.4 ± 1 .7 nmol/ml at 2 weeks and 50.8 ± 2.4nmol/ml at
8 weeks; mean carnitine concentrations for rats fed high fat were 41.5 ± 1.7
nmol/ml at 2 weeks and 39.9 ± 2.2 nmol/ml at 8 weeks. Overall, the serum
carnitine concentrations of rats fed carnitine with high protein and high fat
and low protein and low fat were higher than the concentrations o f rats not
fed carnitine with high protein and high fat and low protein and low fat
(cam itine*protein*fat, p = 0.01, figure 4.11). As shown in figure 4.12, there
was a trend fo r rats that were not fed carnitine with high and low fat to have
a decrease o r an increase, respectively, in carnitine values over time
(cam itine*fat*tim e, p = 0.07).
AMMONIA
As shown in figure 4.13, with time serum ammonia concentrations
decreased for anim als fed both the high and low protein diets (time, p 0.0001). At week 2, the ammonia levels fo r rats fed the high protein diets
(134.8 ± 5.3 pm ol/l), was higher than levels for rats fed the low protein diets
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(116.1 ± 5.4 pmol/l). The higher ammonia level at week 2, but not week 8
made the overall serum ammonia concentrations higher fo r rats fed high
protein (protein, p = 0.007). As shown in figure 4.14, there was a trend for
rats that were fed carnitine with high protein to have lower levels o f
ammonia than rats fed high protein without carnitine (cam itine*protein, p =
0.11). A t 2 weeks, the mean levels o f ammonia fo r rats fed carnitine with
high and low protein were 122.4 ± 7.5 pmol/l and 117.2 ± 7.5 pm ol/l,
respectively. By 8 weeks, the levels were 103.8 ± 8.5 umol/l and 96.6 ± 8.5
pmol/l, respectively. At 2 weeks, the mean levels o f ammonia fo r rats not
fed carnitine with high and low protein were 147.2 ± 7.5 pmol/l and 115.0
pmol/l ± 7.7, respectively. By 8 weeks, the levels were 104.3 ± 8.5 pmol/l
and 89.5 ± 8.8 pmol/l, respectively. The difference between serum
ammonia concentration for rats fed the high and low protein diets was
greater for the diets w ithout carnitine than with carnitine. Carnitine lowered
ammonia levels for rats on the high protein diet at 2 weeks, but no longer did
so during week 8. Carnitine did not decrease ammonia fo r low protein diets.
The trend was dominated by the individual ANOVA at 2 weeks
(cam itine*protein, p = 0.08), where animals on the diet with high protein and
carnitine had ammonia levels that were much lower than those o f rats fed
high protein without carnitine. The ammonia levels o f rats fed high protein
with carnitine were sim ilar to those of rats fed low protein with o r without
carnitine. As shown in Figure 4.15, the difference in ammonia concentration
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between rats fed high protein low fat with or without carnitine was
numerically greater than the difference between rats fed low protein high fat
with or without carnitine. There was a trend for ammonia levels to be
positively correlated at 2 weeks (r = 0.3, p - 0.06) with serum glucose levels
and a stronger positive correlation was observed at 8 weeks (r = 0.4,
p = 0.003).
GLUCOSE
At 2 weeks, rats fed carnitine had lower serum glucose
concentrations than rats not fed carnitine 8.66 ± 0.31 mmol/l, and 9.24 ±
0.31 mmol/l, respectively, but by 8 weeks this had reversed, and rats fed
carnitine had higher serum glucose concentrations than rats not fed
carnitine, 8.64 ± 0.24 mmol/l and 8.16 ± 0.24 mmol/l, respectively
(camitine*time, p = 0.02, Figure 4.16). There was a trend for serum glucose
concentration to be negatively correlated (r = -0.2, p = 0.08) with carnitine
concentration at 2 weeks. Serum glucose concentrations o f rats fed the
high protein diets were overall significantly (protein, p = 0.03) higher than the
levels o f rats fed the low protein diets (Figure 4.17). Rats fed high protein
had a mean glucose concentration of 9.41 ± 0.30 mmol/l at 2 weeks and
8.63 ± 0.23 mmol/l at 8 weeks; mean glucose concentration for rats fed low
protein were 8.49 ± 0.31 mmol/l at 2 weeks and 8.17 ± 0.24 mmol/l at 8
weeks.
A t 2 and 8 weeks, glucose concentrations fo r rats fed carnitine with
high protein (8.86 ± 0.44 mmol/l; 9.09 ± 0.34 mmol/l) remained nearly stable,
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but glucose concentrations for rats not fed carnitine with high protein
decreased from 2 to 8 weeks (9.97 ± 0.42 mmol/l; 8.17 ± 0.32 mmol/l;
cam itine*protein*tim e. p = 0.03, Figure 4.18). By 8 weeks, serum glucose
concentrations for rats not fed carnitine with high protein were comparable
to the levels o f rats fed low protein with or without carnitine. Rats fed the
high fat diet had num erically greater glucose levels than rats fed the low fat
diet (p = 0.17).
UREA NITROGEN
As shown in figure 4.19, urea nitrogen levels were significantly higher
(p = 0.0001) for rats fed high protein than for rats fed low protein at 2 weeks
(6.48 ± 0.16 mmol/ vs. 5.53 ± 0.16 mmol/l) and 8 weeks (7.77 ± 0.21 mmol/l
vs. 5.76 ± 0.22 mmol/l). Rats fed high protein had a greater increase in urea
nitrogen than rats fed low protein (protein*time, p = 0.0001). There was no
difference in the pattern (cam itine*tim e, p = 0.96) and overall (carnitine, p =
0.75) urea nitrogen levels fo r rats fed a diet with or without carnitine (Figure
4.20). Both groups had a slight increase in urea nitrogen levels from 2 to 8
weeks. At 2 weeks, mean urea nitrogen concentration was 6.04 ± 0 .1 6
mmol/l for rats fed carnitine and 6.00 ± 0 .1 6 mmol/l fo r rats not fed carnitine.
By 8 weeks, concentrations were 6.80 ± 0.21 mmol/l and 6.73 ± 0.22 mmol/l,
respectively.
Overall, serum levels o f urea nitrogen for rats fed the low fat diets
were greater than levels fo r rats fed the high fat diets (fat, p = 0.001,
Figure 4.21).
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Urea nitrogen levels for rats fed the low fat diets were 6.25 ± 0.16 mmol/l
and 7.26 ± 0.22 mmol/l at 2 and 8 weeks, respectively. Rats fed the high fat
diets had urea nitrogen levels o f 5.76 ± 0.16 mmol/l at 2 weeks and 6.27 ±
0.21 mmol/l at 8 weeks. There was a trend over tim e for rats on the low fat
diets to have greater urea nitrogen levels than rats on the high fat diets
(fat*tim e, p = 0.11). Urea nitrogen levels increased, from 2 to 8 weeks, for
rats on the low fat diets, but remained nearly stable for rats fed the high fat
diets. There was also a trend for rats fed low fat without carnitine to have
higher urea nitrogen concentrations, and the difference in urea nitrogen for
rats fed high and low fat was greater for the diets without carnitine than with
carnitine (cam itine*fat, p = 0.09, Figure 4.22). Rats fed the carnitine low fat
diets had lower urea nitrogen concentration than rats fed the no carnitine
low fat diets, but rats fed the carnitine high fat diets had greater urea
nitrogen concentrations than rats fed the no carnitine high fat diets. Urea
nitrogen concentrations for rats fed carnitine with high fat were 5.95 ± 0.22
mmol/l at 2 weeks and 6.53 ± 0.30 mmol/l at 8 weeks. Urea nitrogen
concentrations for rats fed no carnitine with high fat were 5.58 ± 0.22 mmol/l
at 2 weeks and 6.01 mmol/l ± 0.31 at 8 weeks.
The difference in serum urea nitrogen concentration of rats fed high
protein with high and low fat was greater than the difference in serum urea
nitrogen o f rats fed low protein with high and low fat (protein*fat, p = 0.02,
Figure 4.23). The interaction was dominated by the high protein-low protein
effect (p < 0.0001) as rats fed high protein with low fat had higher urea
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nitrogen levels than rats fed low protein with low fat. G reater urea nitrogen
levels were observed fo r rats on the high protein high fat diet than fo r rats
fed the low protein diet with high fat.
INSULIN
As shown in figure 4.24, rats fed the high protein diets had overall
higher serum insulin concentrations than rats fed the low protein diets
(protein, p = 0.03). Mean insulin values for rats fed high protein were 6.7 ±
0.5 pU/ml (1 I.U. = 0.04167 mg international standard) at 2 weeks and 5.9 ±
0.5 pU/ml at 8 weeks; mean insulin values for rats fed low protein at 2 and 8
weeks were 5.4 ± 0.5 pU/ml and 4.7 ± 0.5 pU/ml. At 2 weeks, there was a
trend for serum insulin levels to correlate (r =0.22, p = 0.1) w ith ammonia
levels. By 8 weeks, there was a stronger positive correlation (r = 0.44, p =
0.0004) between insulin and ammonia concentrations. As shown in figure
4.25, there was a trend with tim e for rats fed carnitine with high protein to
have greater serum insulin, whereas rats not fed carnitine with high protein
had a lower serum insulin (cam itine*protein*tim e, p = 0.07). Serum insulin
concentrations fo r rats fed carnitine with low protein decreased slightly from
2 to 8 weeks, but levels fo r rats not fed carnitine with low protein remained
nearly stable. Rats who were fed the no carnitine diets with high and low fat
had a numerically greater difference in serum insulin concentration than rats
fed carnitine with high and low fat (camitine*fat, p = 0.15, Figure 4.26). The
serum insulin concentration o f rats fed low fat without carnitine was
num erically higher than the concentration for rats fed low fat with carnitine.
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But the insulin concentration o f rats fed high fa t without carnitine was
num erically lower than levels o f rats fed carnitine with high fat. Serum
insulin levels for rats fed carnitine with high fat decreased from 2 to 8 weeks
(6.6 ± 0.7 pU/ml; 5.0 ± 0.7 pU/ml), but levels for rats not fed carnitine with
high fat remained constant (4.8 ± 0.8 pU/ml; 5.0 ± 0.7 pU/ml;
cam itine*fat*tim e, p = 0.009). Serum insulin concentrations for rats fed the
no carnitine low fat diets decreased from 2 to 8 weeks (7.4 ± 0.7 p(J/ml; 5.3
± 0.7 pU/ml), whereas serum insulin concentration fo r rats fed the carnitine
low fat diets increased (5.4 ± 0.7 pU/ml; 5.8 ± 0.7 pU/ml).
As shown in figure 4.27, the difference in serum insulin
concentrations for rats on high protein diets with high and low fa t was
greater than the difference for rats fed low protein diets with high and low fat
(protein*fat, p = 0.01). Mean insulin values for rats fed high and low protein
with low fat were 7.8 ± 0.7 pU/ml and 5.0 ± 0.7 pU/ml at 2 weeks and 6.9 ±
0.7pU/ml and 4.3 ± 0.7 pU/ml at 8 weeks, respectively. Rats fed high
protein with high fat had insulin values o f 5.5 ± 0.7 pU/ml at 2 weeks and 5.0
± 0.7 pU/ml at 8 weeks. At 2 and 8 weeks, rats fed a diet with low protein
and high fa t had insulin values o f 5.8 pU/ml ± 0.8 and 5.1 pU/ml ± 0.7,
respectively. Rats on a high protein diet with low fat had higher insulin than
rats on a low protein diet with low fat. Insulin values were sim ilar for rats fed
the low and high protein diet with high fat.
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NONESTERIFIED FATTY ACIDS
Serum nonesterified fatty acid concentrations were overall
significantly lower in rats fed the high fat diets (p = 0.0004, Figure 4.28).
Mean nonesterified fatty acid concentrations for rats fed high fat were 636.7
± 42.7 pEq/l at 2 weeks and 628.8 ± 42.5 pEq/l at 8 weeks. For rats fed
low fat, mean nonesterified fatty acid concentrations were 792.2 ± 43.4 pEq/l
at 2 weeks and 820.1 ± 43.2 pEq/l at 8 weeks. There was a trend for
nonesterified fatty acid concentrations to slightly increase or decrease from
2 to 8 weeks for rats fed carnitine o r no carnitine, respectively
(camitine*time, p = 0.16, Figure 4.29). At 8 weeks, there was a positive
correlation (r = 0.29, p = 0.03) between nonesterified fatty acids and
carnitine.
ENZYME ANALYSIS
The activity o f 3-hydroxy-acyl CoA dehydrogenase was not
statistically different for rats fed diets with (5.40 ± 0.49 pmol/g/min) or
without carnitine (6.11 + 0.49 pmol/g/min; p = 0.3), high (5.63 ± 0.49
pmol/g/min) or low protein (5.87 ± 0.49 pmol/g/min, p = 0.7) and high (5.86 ±
0.49 pmol/g/min) or low fat (5.64 ± 0.49 pmol/g/min, p = 0.8). As indicated
in Figure 4.30, there was a trend for rats fed the no carnitine diet with high
and low protein to have a greater difference in enzyme activity than rats fed
carnitine with high and low protein (cam itine*protein, p = 0.12). Rats fed
carnitine with high protein (5.82 ± 0.70 pmol/g/min) had numercially greater
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enzyme activity than rats fed carnitine with low protein (4.97 ± 0.68
pmol/g/min). Rats not fed carnitine with high protein had num erically lower
enzyme activity than rats not fed carnitine with low protein, 5.44 ± 0.68
umol/g/min and 6.77 ± 0.72 pmol/g/min, respectively.
BODY COMPOSITION
The results for body composition analysis indicated that percent fat,
protein, moisture, and ash were not affected by the am ount o f carnitine in
the diet. As shown in figure 4.31, rats fed the carnitine and no carnitine diet
had sim ilar percentages fo r fat (carnitine, p = 0.2), protein (carnitine, p - 0.2)
moisture (carnitine, p = 0.6), and ash (carnitine, p = 0.5). However, rats fed
the high and low fat diet had significantly different percentages o f body
protein, fat, and m oisture (Figure 4.32). The percentage o f protein in the
body o f rats fed the high fa t diet, 20.3%, was significantly (fat, p - 0.05)
lower than the percentage found in rats fed the low fat diet, 21.5% . Rats fed
the high fat diet had a significantly higher percentage o f fa t than rats fed the
low fat diet (24.7% vs. 16.7%; fat, p = 0.0001). The m oisture content of rats
fed the high fat diet was significantly lower than that o f rats on the low fat
diet (54.2% vs. 59.8%; fat, p = 0.0001). There were no significant
differences in body com position for rats fed different amounts o f protein (fat
percent, p = 0.9; protein percent, p = 0.4; moisture percent, p = 0.4; and ash
percent, p = 0.6). Percentages for body composition o f all eight dietary
treatments groups are shown in Table 4.1.
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Table 4.1. Body composition analysis for all eight dietary treatments
Diet
Fat
Protein
Moisture
(% ± SE)
(% ± SE)
(% ± SE)
CLL
17.71 ±1.64
20.33 ± 0.84
57.75 ±1.45
(n=8)
CPL
17.10 ±1.64
21.45 ±0.84
60.96 ±1.45
(n=8)
CLF
25.69 ±1.64
19.45 ±0.84
55.24 ±1.45
(n=8)
CPF
25.20 ±1.64
20.86 ±0.84
52.91 ±1.45
(n=8)
NLL
15.72 ±1.75
22.15 ±0.89
61.40 ±1.55
(n=7)
NPL
16.12 ±1.64
22.06 ±0.84
59.03 ±1.45
(n=8)
NLF
23.04 ±1.75
20.67 ± 0.89
55.52 ±1.55
(n=7)
NPF
20.12 ±0.84
24.67 ±1.64
53.26 ±1.45
(n—8)

Ash
(% ± SE)
4.82 ±0.30

Total
(% ± SE)
100.61 ±1.06

4.50 ±0.30

104.00 ±1.06

4.72 ±0.30

105.10 ±1.06

4.42 ±0.30

103.39 ±1.06

4.49 ±0.33

103.76 ±1.14

4.82 ±0.30

102.04 ±1.06

4.38 ±0.33

103.61 ±1.14

4.15 ±0.30

102.20 ±1.06

END POINT DATA ANALYSIS
As shown in Figure 4.33, rats fed the high fat diet had a significantly
greater final body w eight (fat, p = 0.0001). Final body weights fo r rats fed
the high and low fat diet were 342 ± 5 g and 304 ± 5 g, respectively. Final
body weight was not significantly different for rats fed the diet with (323 ± 5
g) or without carnitine (324 ± 5 g; carnitine, p = 0.95). The am ount o f total
weight gained was significantly (p = 0.0001) greater fo r rats fed the high fat
diet. Rats fed the high fat diet had a total weight gain o f 35 ± 3 g, whereas
rats fed the low fat diet had a total weight gain o f -2 .5 ± 3 g. Rats that were
fed a diet high in fat had significantly (fat, p = 0.0001) more abdominal fat
than rats fed low fat, 25.4 ± 1.1 g and 13.4 ±1.1 g, respectively. As shown
in figure 4.34, abdom inal fat was not significantly different fo r rats fed the
carnitine diet (20.4 ± 1.1 g) than for rats not fed carnitine (18.4 ± 1.2 g, p 0.2). But there was a trend (p = 0.08) for rats fed carnitine to have a greater
amount of abdominal fat as percent o f body weight when compared to rats
not fed carnitine, 6.2 ± 0.3% and 5.5 ± 0.3%, respectively (Figure 4.35).
Final body weight was positively correlated with total w eight gain (r - 0.78,
p = 0.0001), abdominal fa t (r = 0.9, p = 0.0001) and percent fat in body
composition analysis (r = 0.8, p - 0.0001). Abdominal fa t was also
significantly correlated (r=0.9, p=0.0001) with percent fa t in body
composition.
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Figure 4.33 Final body weight fo r rats fed high and low fat diets.
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Figure 4.34 Abdominal fat for rats fed diet with or without carnitine.
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Figure 4.35 Abdominal fat as percent o f body weight for rats fed diet
with or without carnitine
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ORAL GLUCOSE TOLERANCE TEST
During the oral glucose tolerance test, rats fed the high protein diet
had overall numerically greater glucose concentrations (protein, p = 0.18).
At 0 minutes, rats fed high and low protein had a glucose concentration o f
10.59 ± 0.36 mmol/l and 10.68 ± 0.36 mmol/l, respectively. Glucose
concentration at 120 minutes was 15.83 ± 0.66 mmol/l for rats fed high
protein and 14.06 ± 0.64 mmol/l for rats fed low protein. Rats on the high fat
diet had overall greater serum glucose concentrations than rats fed the low
fat diet (fat, p = 0.0001). Glucose concentration at 0 minutes was 10.43 ±
0.35 mmol/l for rats fed high fat and 10.83 ± 0.37 mmol/l for rats fed low fat.
At 120 minutes, the glucose concentration o f rats fed high and low fat was
16.80 ± 0.63 mmol/l and 13.09 ± 0.67 mmol/l, respectively. As shown in
Table 4.2, rats on all eight dietary treatment groups experienced an increase
in glucose levels 120 minutes after administration o f the glucose solution
(time, p = 0.0001). At this point, rats on the high fat and high protein diets
experienced a significantly greater increase in serum glucose concentrations
than rats fed the low fat and low protein diets, fat*tim e, p = 0.01, and
protein*time, p = 0.03, respectively (figures 4.36 and 4.37).
There was a trend for insulin levels to be greater at both 0 and 120
minutes for rats fed the high protein diet (protein, p = 0.06, Figure 4.37).
Insulin levels for rats fed the high protein diet were 5.6 ± 0.6 pU/ml at 0
minutes and 4.3 ± 0.3 pU/ml at 120 minutes.
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Table 4.2. Serum glucose evels fo r oral glucose tolerance test.
Dietary Treatment
Glucose - 12 0 min.
Glucose - O min.
(mmol/L ± SE)
(mmol/L ± SE)
CLL
10.45 ± 0 .6 8
12.85 ± 1.24
CPL

11.07 ± 0 .7 9

14.73 ± 1.43

CLF

9.74 ± 0.68

14.95 ± 1.24

CPF

10.33 ± 0 .7 3

17.71 ± 1.32

NLL

11.49 ± 0 .7 9

11.67 ± 1.43

NPL

10.32 ± 0 .6 8

13.11 ± 1.24

NLF

11.03 ± 0.68

16.78 ± 1.24

NPF

10.63 ±0.68

17.76 ± 1.24
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Figure 4.36 Serum glucose and insulin levels for rats fed high (A) and
low fat (B) diets before (0 min) and after (120 min)
glucose administration.
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Figure 4.37 Serum glucose and insulin levels for rats fed high (A) and
low protein (B) before (0 min) and after (120 min) glucose
adm inistration.

126

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Rats fed the low protein diet had insulin levels o f 4.3 ± 03 pU/ml and 3.8 ±
0.3 pU/ml at 0 and 120 minutes, respectively. As shown in figure 4.38, there
was a greater difference in insulin concentrations for rats fed high and low
protein with carnitine than for rats fed high and low protein w ith no carnitine
(camitine*protein, p = 0.02). At 0 and 120 minutes, rats fed the high protein
diet with carnitine (6.4 ± 0.8 pU/ml and 4.7 ± 0.5 pU/ml) had greater serum
insulin concentrations than rats fed the low protein diet with carnitine (3.5 ±
0.8 pU/ml and 3.3 ± 0.5 pU/ml). But serum insulin concentrations for rats
not fed carnitine with high protein (4.9 ± 0.8 pU/ml and 3.9 ± 0.5 pU/ml) were
lower than levels for rats not fed carnitine with low protein (5.1 ± 0.9 p U/ml
and 4.2 ± 0.5 pU/ml).
As shown in figure 4.36, serum insulin concentrations fo r rats on the
low fat diet decreased significantly over time (fat'tim e, p = 0.005). Rats fed
the high fat diet had serum insulin concentrations o f 4.4 ± 0.6 pU/ml and 4.8
± 0.3 pU/ml at 0 and 120 minutes, respectively. At 0 and 120 minutes, rats
fed the low fat diet had serum insulin concentrations of 5.5 ± 0.6 pU/ml and
3.3 ± 0.3 pU/ml. Serum insulin concentrations for rats fed high and low
protein with different amounts o f fat are shown in figure 4.39. At 0 and 120
minutes, serum insulin concentrations for rats fed high protein with high fat
were 4.4 ± 0.8 pU/ml and 5.3 ± 0.5 p ll/m l and for rats fed high protein with
low fat concentrations were 6.9 ± 0.8 pU/ml and 3.3 ± 0.5 pU/ml. Rats fed
low protein with high fat had serum insulin concentrations o f 4.4 ± 0.8 pU/ml
at 0 minutes and 4.2 ± 0.5 pU/ml at 120 minutes. Rats fed low protein with
127

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

20

10

8 _

15

6
10

u
3

_

.Glucose i
.Insulin !

_

4i

,1

5

<5

I3

0

0

0

120

M nuki

B
.G lu c o se
. Insulin

120

Minutes

20

10

8 _

15

1

6 5
3

3
u
3
o

5

4

I

2

-

.Glucose
.Insulin

2

0
0

120

Minutes
10

20

8

*■ 10

0

4

E
3

2

-

.Glucose;
. Insulin

120

Minutes

Figure 4.38. Serum glucose and insulin levels fo r rats fed high and low
protein with or without carnitine before (0 min) and after (120 min) glucose
adm inistration; A=Cam Hi Pro, B -C am Lo Pro, C=No Cam Hi Pro, D=No
Cam Lo Pro
128

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

20

10

8

15

6;

. Glucose I

4

;

.Insulin

2

■

10

5

0

0
120

Minutes
10

20

B

15

_Glucose i

10

. Insulin

5

0
120

Minutes

.G Lucose
. Insulin

j

120

Minutes
20

10

e

15

6i
10

I
3
o

4

:

2

'

.G lucose i
. Insulin

0

0

120

Minutes

Figure 4.39 Serum glucose and insulin levels for rats fed high and low
protein and fat before (0 min) and after (120 min) glucose administration;
A= Hi Pro Hi Fat, B=Hi Pro Lo Fat, C= Lo Pro Hi Fat, D= Lo Pro Lo Fat

129

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

low fa t had serum insulin concentrations o f 4.1 ± 0.9 pU/ml and 3.3 ± 0.5
pU/ml at 0 and 120 minutes, respectively. With time, the difference in insulin
levels fo r rats fed the high protein diet with high and low fat was greater than
that o f rats fed the low protein diets with high and low fat (protein*fat*time, p
= 0.03).
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CHAPTER FIVE
DISCUSSION
We investigated the effects o f supplemental dietary carnitine on rats
fed high and low protein and fat diets. The study was conducted because of
reported benefits o f carnitine. We hypothesized that carnitine would protect
rats from the negative effects of high ammonia and reduce obesity caused
by a high fat diet.
Previous studies have been performed using ammonium infusions
rather than high dietary protein. These studies have been conducted to look
at the changes in ammonia concentrations and the symptoms that
accompany these changes during liver failure. Patients with acute or
chronic liver disease may experience an increase in levels o f ammonia in
the blood and brain. This can lead to the development o f hepatic
encephalopathy, a complex neuropsychiatric disorder. High levels of blood
ammonia during hepatic encephalopathy will eventually lead to stupor and
coma (Schlienger et al. 1975). Although it is unlikely that consumption of a
high protein diet will cause these serious complications it is not known if
prolonged consumption o f a high protein diet may lead to high enough levels
o f ammonia in the blood, which could potentially increase the levels in the
brain. Today many athletes consume a high protein diet that is also
supplemented with protein and amino acids and many people are now
following high protein weight loss diets. Therefore, we fe lt it was important

131

Reproduced with permission o f the copyright owner. Further reproduction prohibited without permission.

to determ ine if carnitine has a protective effect when a high protein diet is
consumed.
Although carnitine has been shown effective in increasing lean mass
and decreasing fat conflicting results from previous reports made us
uncertain o f the effects o f carnitine on glucose and insulin metabolism. We
had hypothesized that carnitine would decrease weight gain by causing an
increase in fat oxidation and that the increase in fat oxidation would lead to a
decrease in glucose induced insulin secretion. An increase in fat oxidation
has been proposed to lead to diabetes (Barnett et al. 1996, Randle et al.
1963).
In addition, supplementation w ith carnitine has been shown to
increase lean mass and decrease body fa t leading to lower w eight gain in
younger animals. Since studies w ith carnitine are rarely conducted with
older anim als we wanted to determ ine if carnitine’s effects on body
com position would be the same as those observed in younger animals.
In our study, we found a tendency fo r carnitine to lower ammonia two
weeks into the study leading to a beneficial effect on glucose metabolism,
but we observed no effect o f carnitine on fa t oxidation, body fat, or lean
mass. In fact, we observed a tendency towards obesity in carnitine fed rats
at the point o f sacrifice at eight weeks with dietary carnitine. This greater
body fa t many have been responsible fo r the changes we observed in the
response o f glucose to insulin between two and eight weeks.
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Schlienger and Imler (1978) found that blood ammonia levels o f rats
increase rapidly when an endogenous hyperammonemic state is produced
via a portal stricture. At 2 weeks, the blood ammonia concentration
observed in rats in our study who consumed high protein (135 pmol/l) was
higher than that o f the hyperammonemic rat model created by Schlienger
and Im ler (1978) via a portal stricture (127 pm ol/l). Two weeks into the
study rats consuming high protein had already increased ammonia levels,
but by 8 weeks (the second ammonia measurement) rats were able to adapt
to the higher protein intake with lower ammonia levels. The decrease in
ammonia levels observed at 8 weeks fo r rats fed high protein was
accompanied by a significant increase in serum urea nitrogen levels.
Therefore, rats seem to have compensated by increasing the production of
urea, possibly by synthesizing more enzymes and intermediates needed in
the urea cycle. Although there are no reports indicating that consumption of
high protein can greatly increase blood levels o f ammonia our results
dem onstrate that this occurs, at least initially. Thus, the possibility exists
that in humans short term consumption o f a high protein diet can lead to
increased ammonia concentrations. Consumption o f a high protein diet is
expected to increase the urea production rate (Forslund et al. 1998).
Although these levels of ammonia are probably not high enough to cause
toxicity, they may lead to a disruption in the metabolism o f other nutrients.
As reported by Schlienger et al. (1975) high levels o f ammonia inhibit the
release o f insulin from the pancreas and thus decrease glucose oxidation.
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In addition, the length o f the adaptive process in rats and humans needs to
be determined. This process may be longer than the 2 week period
observed in our rats, since our next measurement was at 8 weeks. Thus
blood ammonia levels may remain elevated for several weeks.
Previous studies conducted to look at the effects o f carnitine in the
treatm ent o f ammonia toxicity have used either an intraperitoneai injection of
ammonium acetate o r a portacaval shunt to induce a hyperammonemic
condition. O ’Connor et al. (1984) and Hearn et al. (1989) observed, under
these types o f conditions, a protective effect o f carnitine at lethal doses of
ammonia in mice. The protective effect observed by Hearn et al. (1989) was
short-lived, with protection being maximal only when carnitine was given 1
hour prior to an ammonium acetate injection. Carnitine given 24 hours prior
to the injection no longer had a protective effect. Contrary to these findings,
Deshmuk & Rusk (1988) and Therrien et al. (1997) found that carnitine had
no effect on blood levels o f ammonia. The lack of a beneficial effect of
carnitine observed by Deshmuk & Rusk (1988) may have been due to the
higher lethal dose o f ammonium acetate used in their study. Rats in our
study were rendered hyperammonemic via a method that is less invasive
and can be induced by consumption of a high protein diet. Therefore, the
results of our study have more applicability to human studies that will
examine the effects o f carnitine supplementation on the treatment o f
conditions, such as insulin resistance, that may be induced by changes in
dietary protein and fat levels. As hypothesized, dietary carnitine did
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decrease serum ammonia levels o f rats fed high protein, but because the
rats were able to adapt to the high protein diet they did not need the
supplemental carnitine by 8 weeks, making the protective effect o f carnitine
limited to a few weeks.
Rats in our study who were fed high protein did compensate by
increasing urea nitrogen levels by 8 weeks or possibly earlier, but urea
synthesis was not greater when carnitine was added to the high protein diet.
Contrary to what we had hypothesized, the benefits of carnitine were not
due to its ability to enhance urea nitrogen synthesis as measured by blood
urea nitrogen levels. These results are also supported by those o f O'Connor
et al. (1984) who observed sim ilar urea nitrogen levels for mice given saline
or carnitine after an intraperitoneal ammonium acetate injection. However,
urinary nitrogen was not measured in our study or that o f O’Connor et al.
(1984) so increases in urea nitrogen formation may have lead to shunting
any increased urea nitrogen to the urine. It is important to mention that in
our study rats fed the diet high in fat and protein with carnitine had
numerically greater urea nitrogen concentrations than rats fed the diet high
in fat and protein without carnitine. Therefore, the possibility exists that the
effects o f carnitine on urea nitrogen concentration for rats fed high protein
were masked by the presence o f high or low levels o f fat. Contrary to our
findings and those o f O’Connor et al. (1984), the results of Costell et al.
(1984) showed that mice given carnitine after an ammonium acetate
injection had a higher synthesis of blood urea nitrogen, but the mechanism
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responsible for this increase was not elucidated. Use o f an ammonium
acetate injection probably resulted in a faster increase in blood ammonia
levels and a greater need for the production o f urea, thereby causing the
body’s requirem ent for carnitine to be increased.
We conclude that carnitine seems to protect the rats from developing
elevated ammonia which may be necessary until they are capable of
adapting to the high protein load. However, more studies are needed to
determ ine the mechanism responsible for this decrease. It is possible that
the mechanism for this protective effect involves increased urinary excretion
o f urea, but we did not measure these levels in our study. Previous
research has also suggested that the protective effect o f carnitine on
ammonia levels could be due to: enhanced use o f ammonia, via glutamate
dehydrogenase, for the formation o f glutam ate (O’Connor et al.1984),
decreased cerebrospinal fluid ammonia (Therrien et al.1997) or by
preferential activation of glutamate receptors (i.e., quisqualate) in the brain
which prevents the increase in cystolic calcium levels and the cell death
accompanied by this increase (Felipo et al.1994).
Animal and human studies evaluating the indirect effects o f carnitine
on glucose and insulin metabolism have been relatively short, ranging from
2 to 24 hours. These studies have not looked at the effects o f carnitine on
glucose metabolism when a diet high in either protein or fat or both high
protein and high fat is consumed. Am ericans consum ing the typical
W estern diet tend to eat high amounts o f both o f these macronutrients.
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Body builders and other athletes eat lower fat but often supplement their
high protein diet with a protein or amino acid supplement. Rats in our study
were maintained on either a high fat o r a high protein diet o r both high
protein and fat for an 8 week period, thus making it more plausible to study
these indirect effects and making the results more generalizable to humans
consuming a Western type diet and to athletes. We had hypothesized that
inclusion of dietary carnitine would enhance fatty acid oxidation and
decrease the oxidation o f glucose and the secretion of insulin. Increased fat
oxidation leads to a decrease in glucose intermediates, which are needed
for insulin to be released. The hypothesis was based on previous research
and studies that indicated that inclusion of supplemental dietary carnitine
would lead to enhanced fatty acid oxidation in younger animals (Shimura &
Hasegawa, 1993, Rabie & Szilagyi, 1998). According to the Randle
hypothesis (Randle et al. 1963) the increase in fatty acid oxidation could
interfere with the uptake and metabolism of glucose in muscles, resulting in
glucose intolerance and insulin insensitivity. In our study, we did not
observe an increase in fat oxidation at 8 weeks with dietary carnitine added
to the diet. Thus, we can assume that the main indirect effect o f carnitine on
glucose metabolism observed in our study was due to its function in protein
metabolism. Contrary to what we had hypothesized, inclusion o f dietary
carnitine to the high protein diets initially did decrease glucose induced
insulin secretion, but with tim e there was a tendency for carnitine to increase
the secretion o f insulin.
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After 2 weeks of consumption o f the high protein diet, rats had higher
glucose and insulin concentrations, with the increased glucose
concentration associated with high ammonia levels. According to the results
o f the study conducted by Schlienger et al.(1975) the hyperammonemic
state observed in our rats at 2 weeks could have led to higher epinephrine
levels lim iting insulin secretion and glucose utilization, thus increasing blood
glucose levels. Although we observed higher insulin levels for rats fed high
protein it is possible that insulin function was blunted by high ammonia and
the amount o f insulin released was insufficient to handle the amount of
glucose present in the blood. Alternatively, the rats fed high protein may
have been less sensitive to the insulin secreted compared to low protein fed
rats.
Glucose levels were lower at 2 weeks if the high protein diet was
supplemented with carnitine and there was a tendency for the insulin levels
o f these rats to be lower. This supports our latter hypothesis on insulin
insensitivity with high ammonia caused by feeding of the high protein diet.
These results are also in agreement with those of o f Mingrone et al.(1999),
Grandi et al.(1997), and Paulson et al.(1984) who observed a decrease in
glucose levels in diabetic humans or diabetic rats that were treated with
carnitine. The decrease in blood glucose and insulin levels observed in our
study and in the one conducted by Grandi et al.(1997) was transient,
indicating that the beneficial effect o f carnitine could be short-lived. Contrary
to these findings, other researchers have reported that compounds that
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inhibit carnitine paimitoyi transferase I have a glucose lowering effect in
diabetic rats or rats genetically predisposed to develop NIDDM (Barnett et
al.1996, Barnett et al.1992, Martin et al.1991).
Glucose levels decreased for rats fed high protein so that by 8 weeks
levels were sim ilar to those o f rats fed low protein. Because rats fed high
protein had com pletely adapted to the higher protein load, the levels of
ammonia were no longer different than levels o f rats fed low protein, thus
making their glucose levels sim ilar and elim inating the effect o f carnitine on
blood glucose levels. Rats fed high protein diets still had higher insulin
levels when compared to rats fed low protein diets at 8 weeks, but levels
were lower than at 2 weeks. Presence o f dietary carnitine caused an
increase, by 8 weeks, in the levels o f insulin fo r rats consuming the high
protein diet, reaching levels that were higher than all other groups.
Two weeks into the study, levels o f glucose and insulin of rats fed
high protein with carnitine were lower than levels for rats fed high protein
without carnitine. Therefore, at this tim e carnitine seemed to make rats fed
high protein more insulin sensitive. Mingrone et al. (1999) also found that
an L-cam itine infusion led to an improvement in insulin sensitivity and whole
body insulin mediated glucose uptake in diabetic and normal subjects,
respectively. This effect of carnitine was attributed to its ability to decrease
plasma lactate levels thereby increasing the activity o f pyruvate
dehydrogenase. Because we did not measure the level o f lactate or the
activity o f this enzyme we cannot conclude that the effect o f carnitine
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observed in our study was due to these changes. Grandi et al. (1997) also
observed a transient effect on insulin secretion with an acute adm inistration
o f carnitine that led to lower blood glucose levels. The assum ption was
made that carnitine increased pyruvate dehydrogenase activity and this lead
to improved peripheral glucose utilization. In our study, the indirect effect of
carnitine on glucose m etabolism was most probably due to its early
protective effect on blood ammonia levels. Sometime after 2 weeks, it
seems that carnitine is no longer needed to improve the hyperammonemic
conditions created by the high protein load, thus making carnitine more
available to perform other m etabolic functions (i.e., enhance fat oxidation).
Therefore, addition o f carnitine to the high protein diet did not result in lower
glucose levels at 8 weeks, but insulin levels for these rats were greater than
those observed at 2 weeks. Higher insulin levels for these rats may be
indicative o f a transition, from a condition o f normal glucose tolerance with
insulin sensitive tissues to one o f impaired glucose tolerance and less
insulin sensitive tissues.

This is supported by the tendency towards obesity

observed at the end o f the study in rats fed carnitine. Because w e only took
measurements at 2 and 8 weeks, we cannot determ ine when carnitine
started to have a negative effect on insulin and glucose metabolism. Future
studies are needed to determ ine the period at which supplem enting high
protein diets with carnitine will cause a tendency towards a decrease in
insulin sensitivity.
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We conclude that despite carnitine’s ability to initially decrease the
glucose and insulin levels of rats fed high protein, our results seem to
indicate not only that the benefit is short-lived but that with tim e rats
consuming carnitine become less insulin sensitive. The decrease in insulin
sensitivity can lead to lower glucose disposal rates and thus higher glucose
levels in the blood. Furthermore, if the decrease in insulin sensitivity leads
to impaired glucose tolerance and to the development o f insulin resistance
and increased serum insulin, there w ill be a greater tendency for increased
fat mass and body weight.
The measurement o f insulin and glucose during an oral glucose
tolerance test has been previously used to evaluate the degree o f insulin
sensitivity and determine the state o f impaired glucose tolerance (Phillips et
al.1994). Studies looking at the effects o f diet on insulin secretion and
sensitivity seem to indicate that consumption o f high fat causes obesity
which may eventually lead to the developm ent o f NIDDM (Pi-Suyner, 1993).
It has been shown that after only 2 weeks, rats fed high fat developed insulin
resistance (Barnard et al.1998). Feeding a high sucrose diet to rats also
seemed to result in the development o f insulin resistance (Reaven et
al.1983). In our study, we originally wanted to conduct an oral glucose
tolerance test to determine if rats fed high fat with or without carnitine were
less insulin sensitive. A previous study conducted in rats observed that
blood glucose levels started to decline between two and two and half hours,
but that insulin levels had already returned to levels observed at baseline
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(unpublished data, personal communication with Boudreaux, M). To avoid
interfering with measurements taken during week 8 we decided to conduct
the oral glucose tolerance test during week 5. In addition, because multiple
blood measurements from the orbital sinus are hard to obtain we did not
want to cause problems with the animals, which may affect their
participation for the remainder o f the study. Therefore, we decided to
determine if two hours after a glucose challenge, glucose levels for rats fed
high fat took longer to decline when compared to levels o f rats fed low fat
and if carnitine would decrease insulin sensitivity. But use o f this time frame
did not allow us to determine at what tim e point glucose levels increased. In
addition, the biphasic insulin response curve could not be determined.
Therefore, we feel that we cannot make conclusions about the state of
insulin resistance based on the results from our oral glucose tolerance test,
but can make general statements about differences in glucose metabolism
observed for the various dietary treatments.
Two hours after the glucose load, glucose levels for rats fed high fat
and high protein were higher than levels fo r rats fed low fat and low protein.
The higher glucose levels observed for rats fed high fat with high or low
protein indicates that it is the fat content o f the diet that is causing the
glucose levels to be higher. Addition o f carnitine to the high protein diets
resulted in higher glucose levels two hours after the glucose load. This
effect o f carnitine was not observed when rats were fed low protein. It is
possible that at the time of the oral glucose tolerance test (week 5) carnitine
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was no longer having the beneficial effect o f lowering glucose levels, instead
carnitine seemed to be causing an increase in glucose levels for rats fed
high protein. More research needs to be done to determ ine the change in
glucose metabolism during carnitine supplem entation when a diet high in
protein and/or protein supplements is consumed.
Animal nutritionists are supplementing the feed of young animals with
carnitine to try to reduce their lipid accretion rate and improve their growth
performance. Contrary to what we hypothesized, our results seem to
indicate that dietary carnitine does not enhance fatty acid oxidation or
decrease weight gain or fat gain in older rats. If older rats are sim ilar to
adult humans the use of carnitine by adult humans, such as athletes and
obese people who wish to improve their body com position, may need to be
further evaluated before carnitine can be recommended as a dietary
supplement. This may apply only to adult humans but a study with high
protein and younger rats is necessary before we can conclusively state this.
Previous research has indicated that addition o f carnitine to the diet
o f young growing animals will enhance fatty acid oxidation (Rabie & Szilagyi,
1999, Owens et al.1996, Shimura & Hasegawa, 1993), but we did not
observe an increase in the enzyme activity o f HOAD fo r our older retired
breeder rats who were fed carnitine. In addition, higher non esterified fatty
acid levels observed at 8 weeks for rats fed carnitine supports this enzyme
results that carnitine does not increase fat oxidation. This is also supported
by the num erically greater abdominal fat, and total body fat o f older rats fed
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carnitine. The increased fa t oxidation with carnitine treatm ent observed in
younger animals could be because o f an interaction with the higher energy
requirem ent and changes in body composition that are experienced during
periods of growth.
In our study, rats that were fed carnitine had a greater numerical
am ount of total abdominal fa t (p = 0.2) and abdominal fat as percent o f body
weight (p = 0.08) than those that were not fed carnitine. Regardless o f the
am ount of fat (low or high levels) being consumed, carnitine seemed to
increase the percentage o f total body fat in the carcass leading to fatter rats,
but there was no decrease o r increase in final body weight (p = 0.9) or total
weight gain (p = 0.8). The increase in body fat observed with no change in
body weight was offset by a num erically lower protein content (p = 0.2) of
carcasses from rats that were fed carnitine.
Contrary to our findings, Shimura & Hasegawa (1993) observed a
tendency fo r the weight o f body fat to decrease for 4 week old rats fed high
fat with carnitine. Previous rat studies have demonstrated that after 2 weeks
rats can compensate for increased energy density by decreasing the
amount of food consumed. Our study results support those of Roy et al.
1999 (unpublished manuscript) and Peterson & Baumgardt (1971) and
strengthen the hypothesis that rats can adapt to changes in the energy
density of the diet. Despite the fact that rats fed high fat in our study
compensated by decreasing food intake, final body weight, abdominal fat,
total body fat, and weight gain were greater at the end o f the study. Thus,
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one can speculate that consumption o f a high fat high-energy dense diet can
lead to increased body weight and fat before the compensation changes
occur. Reversal o f dietary-induced obesity is the not the norm in humans,
but this has been observed when the diet is replaced with a low fat low
energy dense one combined with physical activity (Shick et al.1998. Bell et
al.1995). Because at the tim e the study was designed we were unaware
that rats can adapt to changes in the energy density o f the diets, rats in our
study were not pair-fed. We did not pair-feed the rats on the low fat diet with
carnitine with intake o f rats fed high fat with carnitine. The lower food intake
observed after 2 weeks for rats fed high fat resulted in less carnitine being
consumed (p = 0.0001). Therefore, rats consuming the high fa t diet with
carnitine may have not obtained the additional am ount o f carnitine needed
to oxidize the excess fat. Had we pair-fed the low fat rats with the amount of
diet for rats fed high fat then carnitine would have been the same, but it is
possible that this equalization would not have been high enough to cause
changes in fat oxidation for rats fed high fat.
Similar to our findings, Shimura and Hasegawa (1993) observed no
effect of carnitine on body weight, but Rabie and Szilagyi (1999) observed a
higher weight gain when carnitine was added to the diets o f broiler chickens.
The greater body weight gain reported by Rabie and Szilagyi (1999) was
attributed to an increase in lean mass that may have been achieved through
more efficient fat oxidation and improved utilization o f dietary nitrogen. In
our study, inclusion of dietary carnitine did not result in a greater percentage
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o f the carcass composition from protein indicating that there was no
increase in the amount o f lean mass o f the rats. By increasing the ratio of
acetylCoA:CoA-SH, carnitine seems to increase the supply o f carbon and
branched chain a-keto acids fo r synthesis o f non essential and branched
chain amino acids. O ur results in older animals do not support this
occurrence.
Results, sim ilar to those o f Rabie and Szilagyi (1999) o f carnitine on
body composition (i.e. decreased lipid content and increased protein) were
reported in juvenile salmon (Ji et al.1996) and young pigs (Owens et
al.1996). These same effects were observed by Gross et al. (1998) in adult
obese beagle dogs. According to the results o f these studies, the effects of
carnitine on body composition seem to be limited to younger growing
animals, with the exception o f the study conducted in adult dogs. Gross et
al. (1998) observed a beneficial effect of carnitine on body com position of
older animals, but unlike our older rats the dogs were consuming a high fiber
low calorie diet. Thus, it is possible that for carnitine to be beneficial in older
animals the type of diet consumed should not be high in fat or protein and/or
the level of physical activity needs to be increased. The results o f the study
conducted in athletes by Gatti et al. (1998) seem to support the latter point.
In well-trained athletes the observed increment in fat free mass was
associated with a metabolic muscle improvement due to higher levels of
carnitine in the tissue.
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Rats in our study were fed either a diet high in fat or protein or both.
According to a study conducted in rats by M ifiana et al. (1989) a
hyperammonemic state can lead to a decrease in the lipid content and an
increase in protein content o f the carcass, which can be due to an increase
in blood levels o f long-chain acylcam itine. Higher levels of long-chain
acylcam itine seemed to have resulted in an increase in transport o f longchain fatty acids for oxidation. Although we only measured total serum
carnitine, rats in our study who were fed high protein had lower total
carnitine concentrations at 2 and 8 weeks, and thus it is unlikely that levels
o f long-chain acylcam itine were higher at 2 weeks when our rats were
hyperammonemic. Therefore, we would not expect that the rats fed high
protein without carnitine experienced a decrease in their lipid content and an
increase in their protein content due to hyperammonemia. Thereby,
elim inating the possibility that no effect o f carnitine on fat oxidation was
observed because of changes in body com position that could have resulted
from the condition o f hyperammonemia.
W e hypothesized that feeding a high fat diet would promote the
synthesis o f endogenous carnitine. Because of carnitine’s function in fat
metabolism, one could speculate that higher amounts o f carnitine are
needed to handle the excess fat. Contrary to what we had hypothesized,
rats fed high fat had lower total serum carnitine concentrations, at 2 and 8
weeks, than rats fed low fat. It is possible that the tissue requirement for
carnitine for rats fed high fat was higher, thus causing a decrease in the total
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serum carnitine concentration. O ur results are in agreem ent with those of
Seccombe et al. (1978) who observed that total and free serum carnitine
concentrations were lower in rats fed high fat when compared to rats fed a
high carbohydrate diet. In the study conducted by Cederbald (1987) healthy
males had an increase in the levels o f free carnitine in plasma after
consumption o f a high fat diet (54% of energy). The percentage o f energy
coming from fat was sim ilar to what we used in our study (58% ), but we did
not measure free carnitine levels. Thus, making it hard to com pare our
results to those of Cederbald (1987).
Consumption o f a high fat diet may have led to increased
endogenous synthesis of carnitine, but if the tissue demand fo r carnitine
increases, the levels o f serum carnitine may actually decrease. In our study,
the lack o f an effect of carnitine on fat oxidation as measured by HOAD,
amount o f abdominal and total fat, and weight gain indicates that the tissue
demand for carnitine was probably not higher. Unfortunately, Seccombe et
al. (1978) did not measure rates o f fatty acid oxidation, thus making it hard
to determine if the tissue requirem ent for their rats was increased when the
high fat diet was consumed. An alternative explanation may be that the
lower total blood serum carnitine for rats fed high fat was due to the lower
food intake observed for these rats. We conclude that synthesis o f carnitine
is not always enhanced due to consumption o f a high fat diet.
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CONCLUSIONS
In our study, we tested whether carnitine would protect older rats
from high ammonia and reduce weight gain for rats fed high protein and/or
high fat. The beneficial effect o f carnitine on ammonia was evident at two
weeks but not at eight weeks, and instead o f observing the expected
decrease in weight gain, we observed opposite effects, a tendency towards
weight gain.
In our study, we used older rats as an animal model because the
changes in weight and macronutrient metabolism observed in these rats are
also frequently seen in older humans. People consuming a high protein diet
may initially benefit if they supplement their diets with carnitine. The initial
decrease in ammonia levels may help prevent the development of
hyperammonemia and future abnormalities in glucose and insulin
metabolism, but further rat studies and then human studies are needed to
determine the period for which carnitine supplementation may be beneficial.
Our results suggest that the benefit of carnitine on glucose and insulin
metabolism for people consuming a high protein diet w ill probably be short
lived. An athlete consuming a diet high in protein that is supplemented with
carnitine for long periods may become less insulin sensitive and gain weight.
The increase in body weight will be accompanied by greater accumulation of
fat and a decrease in lean mass. Furthermore, use o f supplemental
carnitine by people with NIOOM (type II diabetes) may worsen the condition
o f insulin resistance and lead to greater weight gain. The recommendation
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for people who are diabetic or consuming high protein diets that want to use
carnitine as a supplement would be to use it on a short-term basis and/or
cycle its use. The worldwide increase in the prevalence o f obesity is
alarming. Therefore, to avoid future weight problems we recommend that
studies be conducted before carnitine is added to the long list o f alternative
weight treatm ent options (i.e. instead of prevention).
Over the years many measures have been adapted to promote
weight loss. These include fat free products and/or supplements. In the
past several years consumption o f low fat and fat-free products has
increased in the United States, but the incidence o f obesity is on the rise.
Consumption o f these products by many Americans who are trying to lose
weight, has not proven to be the magic solution many were hoping for.
Achieving a healthy weight and weight maintenance requires a combination
of different approaches. Carnitine is promoted by companies as a weight
loss agent. More animal and human studies are required to determine if
carnitine can be used as an alternative approach for weight loss.
Older people who are obese and want to use supplemental carnitine
as a weight loss aid may need to also consume a diet that is low in calories
and not high in fat or protein. It may be possible that carnitine can help
reduce body fat and increase lean mass in older people if a well balanced
diet is consumed. Consumption of a high fat diet may not always lead to
increased endogenous synthesis o f carnitine. An additional exogenous
source o f carnitine on this type o f diet may not be necessary because a high
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fat diet is probably already high in animal products, which contain ample
amounts o f carnitine.
LIMITATIONS
In addition to the oral glucose tolerance test conducted at five weeks,
inclusion o f analysis o f other biological parameters at this same tim e point,
such as serum ammonia and urea nitrogen, may have provided a clearer
representation o f the changes that were taking place during the middle of
the study. This would have made the interpretation o f the results obtained
by week eight clearer. Furthermore, to obtain adequate inform ation about
changes in insulin sensitivity, glucose and insulin measurements would have
to be made at 0, 30, 60, 90 and 120 minutes after the glucose load. Our
single tim e point only allowed us to determine fo r which dietary group did
serum glucose decrease faster or slower two hours after the glucose load.
Measurement o f enzymes in the glycolytic pathway would have
provided a better understanding o f the effects o f carnitine on glucose
metabolism. It has been speculated that carnitine increases glycolysis by
enhancing the activity o f pyruvate dehydrogenase. Measuring the levels of
that enzyme at two and eight weeks could have supported our conclusion
that carnitine’s beneficial effect on glucose and insulin metabolism is short
lived and no longer present at eight weeks.
To determ ine if increased urea in the urine is the mechanism by
which carnitine lowers the levels o f ammonia, m etabolic cages fo r housing
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rats fo r collection o f urine during the study could have been used. The urine
collected could have been analyzed fo r levels o f urinary urea nitrogen.
FUTURE STUDIES
The m ajor question raised by our study is if carnitine use is
appropriate for older animals and humans. Carnitine supplem ent use may
be beneficial in the short term, several weeks, but nonbeneficial if used for
many weeks at a time. Future studies are required that frequently measure
the effect o f carnitine during consumption o f a high protein diet and obesity
for several weeks. These studies then need to be continued on a long-term
basis to observe possible significant obesity indicators (i.e., a continuos
increase in body fat and weight). Anim al studies can initially be used to
determ ine the long-term effects o f carnitine. The results o f these
investigations can then be used to develop studies to examine these effects
o f carnitine in humans.
To delineate differences o f carnitine as a supplem ent for older and
younger anim als consuming high protein diets, a study looking at the effects
of carnitine on younger and older animals consuming this type of diet is
needed. O ur results seem to indicate that prolonged used o f supplemental
carnitine may make older rats more obese and thus less insulin sensitive.
Therefore, comparing the effects o f carnitine on younger and older animals
may help establish at what age carnitine supplementation may be beneficial.
The key factor may be that carnitine interacts with the growth process to
enhance lean mass.
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Future studies addressing the mechanism for the protective effect of
carnitine on ammonia levels need to be conducted. A comprehensive study
needs to be conducted where urea levels in the blood and urine, ammonia
levels in the brain and blood, enzymes involved in the urea cycle, and levels
of amino acids are measured. This type o f study can also be used to
determine if consumption o f a high protein diet in humans can lead to
increased levels o f ammonia in the blood and brain and if so the length of
time required for this to happen.
A long-term human study that looks at the effects o f carnitine on
glucose and insulin metabolism where the type o f diet consumed is
recorded, glucose and insulin levels are measured, and amount o f physical
activity is recorded needs to be conducted. This type o f study would provide
answers to some o f the questions that were raised in our study.
Furthermore, this type of study would indicate whether or not carnitine
should be used in the treatment for diabetes.
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DIET PREPARATION
To prepare the basic AIN-93M diet the macronutrients were weighed
and added to a large mixing bowl. These ingredients were then mixed for
10 minutes at low speed and then mixed again for 5 minutes (the bowl was
scraped down between mixes). The micronutrients were sieved sequentially
into a large bowl. Any crystals left were ground up with a mortar and pestle
and added to the mixture. The ingredients were then mixed by hand until a
uniform distribution was obtained. The micronutrients were added to the
large mixing bowl and combined with the macronutrients. The
macronutrients and micronutrients were mixed for 10 minutes, the bowl was
scraped down and then the ingredients were mixed for another 5 minutes.
The soybean oil was added to this mixture and mixed for 10 minutes,
scraped down, and mixed for another 5 minutes. The diet was then stored
frozen in either Rubbermaid containers or in Ziploc bags. Each was labeled
with the diet type, date, batch number and initials o fth e person who
prepared the diet. A small amount o f sample from the last bag or container
for each diet batch was placed in a tiny plastic bag and labeled for future
diet analysis.
To prepare the high fat diets each macronutrient was weighed and
placed in its own container. The individual micronutrients (vitamins,
minerals, etc.) were weighed and sieved sequentially into a bowl. Any
crystals left were ground up with a mortar and pestle and added to the
mixture. The micronutrients were then mixed by hand until a uniform
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distribution was obtained. A small amount o f each o f the dry ingredients
(each macronutrient and the micronutrient m ix) was sieved sequentially
through a small mesh into a large bowl. This was done 3 tim es so that there
was 3 layers, each one consisting o f a small amount o f each ingredient.
This was done to ensure adequate mixing later. Crystals, from the
m acronutrients, that remained in the mesh were crushed and added to the
mixture. The ingredients were mixed using a spoon and then sieved with a
larger diam eter screen into the metal bowl o f a small mixer. The metal bowl
was placed on a large balance and the desired amount o f Crisco was then
carefully added to top o f this mixture. The specified am ount o f soybean oil
was then added to this pre-weighed mixture. The ingredients were then
hand mixed until the mixture was uniform. The metal bowl was placed on a
heavy-duty Kitchen Aid m ixer and mixed, at a setting o f 4 o r 6, for 1 minute.
A rubber spatula was used to scrape down the sides and bottom o fth e bowl.
This process was repeated 2 more times and then the m ixture was
transferred to another mixing bowl. This was done to ensure proper mixing
o f both the top and bottom parts o f the mixture. The m ixture was then mixed
2 more tim es in the Kitchen Aid Mixer. After the fifth mixing, the diet was
very uniform in consistency. The diets were stored and labeled the same
way as the low fat diets. A small sample was also taken fo r future diet
analysis.
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ENZYME AND BLOOD ANALYSIS
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HOAD ANALYSIS
1) Preparation of homogenizing buffer
a) Prepare 150 mis o f buffer (this volume is enough for 72 samples)
b) Need a 175mMKCL, 2mM EDTA and 10mM Tris concentration
c) For KCL the molecular weight is multiplied by .15 liters to get amount
o f grams you need (1.95 grams o f KCL/150 mis)
d) For EDTA you can use the disodium salt since it will go into solution
more readily. The m olecular weight o fth e salt is 336.2 so 1Mole =
336.2 so Im iiliM ole = .3362. To get a 2mM solution m ultiply .3362 by
2 which = .6724g/l. To prepare .15liters m ultiply .6724g/l X .15liters
which = .10086g/150mls.
e) For Tris make up 100 mis o f tris stock solution by weighing 1.322 g of
Trizma HCL and .194 g o f Trizma base. Fill a 150-ml beaker with
approximately 70 mis o f ultra pure water. Mix acid and base and bring
up to volume using a volum etric flask. Note the ph o fth e solution.
f)

Dissolve the KCL and EDTA in approxim ately 85 mis o f ultra pure
water. Add to that 15 mis o fth e tris stock solution. Store the mixture
in the refrigeratior fo r about 30 minutes (temperature o f mixture
should be 4 °C.

g) Bring the ph o fth e solution to 7.4 by adding acid or base as needed
(Note our ph was 7.54).
h) Transfer the solution into two volum etric flasks (100mls and 50 mis)
and bring them up to volume.
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i)

Place the solution back into the beaker and remix using a stirrer and
stir bar.

j)

Recheck the ph o f the solution (Note our ph was 7.42).

2) Preparation o f Homogenate
a) Thaw out sample
b) Clean muscle by removing any connective tissue. Cut with scissors
perpendicular to muscle and pull away connective tissue using
tweezers.
c) Weigh muscle, (need at least .03 g o f tissue)
d) To determ ine amount o f homogenizing buffer m ultiply weight o f
muscle (g) X 19. (this is a 5% homogenate o fth e tissue)
e) Place muscle and buffer in a test tube (Need a tube that is wide
enough to be used with homogenizer. Can use 16X100 mm tubes)
f)

Homogenize sample by placing blade of homogenizer all the way to
the bottom o f sample. Turn the homogenizer on by rotating knob
clockwise and carefully move tube up and down. If necessary turn
knob to get more grinding. Be careful not to cause too much foaming
of the sample. Keep a beaker of ice under the test tube when
homogenizing to keep the sample chilled at all times.

g) Place homogenized samples in ice bucket if the assay will be
conducted immediately after, otherwise parafilm the test tubes and
store in freezer.
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3) Preparation o f 100mM Potassium Phosphate buffer
a) Weigh 7.242 g o f K2H P 04
b) Weigh 1.1424 g o f KH2P04
c) Take a 500 ml beaker and add 500 mis o f ultra pure w ater and a stir
bar
d) Place beaker in a magnetic stirrer and gradually add the chemicals
e) Stir until they dissolve
f)

Bring ph up to 7.4 at room temperature by adding acid o r base as
needed

4) Preparation o f NADH
a) Make 2 mg o f NAOH/ml o f phosphate buffer
b) The first day o fth e assay we prepared 20 mg o f NADH by adding 10
mis o f phosphate buffer prepared in step 3 (this was enough to run 46
samples and some was left)
c) The second day o f the assay we prepared 30 mg o f NADH by adding
15 mis o f phosphate buffer
d) You can make larger quantities of the NADH and store frozen for later
use
5) Preparation o f Acetoacetyl CoA
a) To prepare dissolve 1.834 mg of acetoacetyl/ ml o f phosphate buffer
b) The first day of the assay we prepared the 10 mg acetoacetyl bottle
by adding 5.45 ml o fth e phosphate buffer. W eigh out the phosphate
buffer and with a pipet add to the bottle a couple o f drops o f the buffer
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(the acetoacetyl is hydroscopic). Continue to do this until you have
added enough buffer to mix the contents of the bottle. Transfer this
mixture to a beaker and add the rest o fth e buffer. 10 mg of
acetoacetyl was enough to run approxim ately 46 samples.
c) For the second day o f the assay we prepared the 25 mg bottle in the
same way except this time we used 13.63 ml o f phosphate buffer.
6) Running the assay
a) Allow 30 minutes for the spectrophotom eter to warm up
b) Thaw out two homogenized samples
c) Place 1.4 ml of phosphate buffer in two labeled test tubes
d) Vortex the homogenized sample
e) Pipet amount of sample that will be used (100 pi) three times before
using
f) Vortex sample again and pipet 100 pi o f sample into tube with
phosphate buffer (1:15 dilution) Note: This dilution can change. We
started with a 1:15 but then used a 1:10 dilution (100 pi of sample
and .9 ml o f phosphate buffer).
g) Vortex again
h) Add to a 1.6 ml cuvette 700 pi o f 100 mM phosphate buffer, 100 pi of
NADH, and 100 pi of diluted homogenate (1:10 dilution).
i)

Place samples in spectrophotometer and allow to equilibrate (couple
o f minutes)

j)

Initiate reaction by adding 100 pi o f 2 mM acetoacetyl CoA.
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k) To start the reaction, invert the samples using a piece o f parafilm.
I)

Record absorbance every 15 seconds for 5 minutes

m) Determine average change in OD/min by subtracting T i -Ts/4m inutes
n) Calculations: Net change in OD/min X 10 X 10 X 20/6.22
uMoles/g/min o f activity
•
•
•

10 = cuvette dilution
10 = homogenate dilution (phospphate buffer)
20 - homogenate dilution (homogenizing buffer)

SERUM INSULIN ANALYSIS
Three plain uncoated tubes (12X75 mm) were labeled (tubes 1-3) for
the total counts. Insulin Ab-Coated tubes, for the calibrators, were labeled A
(maximum binding, tubes 4-6) and B through G (tubes 7-24) in triplicate.
Calibrators were prepared with lyophilized processed human serum. The
calibrators were reconstituted at least 30 minutes prior to the assay by
adding 6.0 ml o f distilled water to the zero calibrator (A) and 30 ml o f distilled
water to the remaining calibrators. Table 3.7 illustrates the amount o f
micro-units of insulin per m illiliter added to the calibrator tubes. Two coated
tubes (tubes 25-26) containing rat serum were labeled as pool 1 and 2.
Four rat standards, in duplicate, were used for this assay and the coated
tubes were labeled 27-34 (table 3.7). For the samples, only one coated tube
(tubes 35-294) was labeled for each rat with its designated I.D. code. Week
2 and 8 serum samples were analyzed the same day.
To the respective tubes, 200 pi o f calibrator, 200 pi o f control, and
100 pi of sample was added. To ail tubes 1 ml o f 1251was added and the
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tubes were vortexed. The tubes were incubated fo r 18 hours at room
temperature and the supernatant was decanted thoroughly except for tubes
1, 2 and 3. A gamma counter was used to determine the amount o f insulin
present in the sample.
Table 3.7 Calibrator and rat standard labeled tubes for insulin analysis.
Concentration (uU/ml)
|
Tube Number
Content
Total counts
1,2,3
Calibrator A
0
4,5,6
Calibrator B
5
7,8,9
Calibrator C
10,11,12
15
Calibrator 0
50
13,14,15
Calibrator E
100
16,17,18
Calibrator F
200
19,20,21
Calibrator G
400
22,23,24
Pool i
25
------26
Pool 2
12.5
Rat standard
| 27,28
Rat standard
25
29,30
Rat standard
50
31,32
Rat standard
125
33,34

SERUM AMMONIA ANALYSIS
Ammonia samples fo r week 2 and 8 were each analyzed 24 hours
after the blood was collected. To run the assay two blank and control cuvets
were labeled. To the blank cuvets, 1 ml of Ammonia Assay Solution (3.4
mmol/l o f 2-oxoglutarate and .23 mmol/l o f NADPH) and .1ml o f water were
added. To the control cuvettes, 1 ml of Ammonia Assay Solution and .1ml
of Ammonia Control Solution (5 pg/ml of ammonia) were added. Ammonia
Assay Solution (1 ml) and serum (100 pi) were added to the sample cuvets.
The samples were run in singles. The cuvets were covered with parafilm
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and mixed by gentle inversion. The initial absorbance o f each cuvet was
recorded versus water, 100 pi o f L-glutamate dehydrogenase was added
and the cuvets were mixed by gentle inversion. To allow fo r the reaction to
proceed, approxim ately 5 minutes elapsed before the final absorbance was
read. Final absorbance was read for each cuvet versus water.
To determ ine the ammonia concentration the change in absorbance
was calculated (Final - Initial). The change was then subtracted from the
change in blank absorbance and multiplied by a factor, 30.3. The factor was
calculated using the following formula:
Factor=Volume of liouid cuvet (1.11 ml) x Weight (ua) of 1 umol of NADPH (17)
Millimolar absorptivity (6.22) x Volume of specimen (100 pi)
SERUM GLUCOSE ANALYSIS
The sampling interval used was determined based on the number o f
samples in the assay. In this study, a 15 second sampling interval was used
(three standards plus 64 samples). Borosilicate glass tubes (12X75 mm)
were labeled for standards and samples as shown in Table 3.8. The ICN
DIGIFLEX pipetter was set in the sample/dispense mode. The syringes
were set at 1.25 ml and 6.25 pi, left and right syringes respectively. The
glucose trinder reagent, adjusted to room temperature was used to prime
the samples. To the corresponding tubes 6.25 pi of w ater (blank), glucose
(standards) or sample were added. The tubes were im m ediately vortexed
and incubated at room temperature for 18 minutes. Samples were read in
the spectrophotometer.
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Table 3.8 Standard concentrations for glucose analysis.
Tube Number
Content
Concentration(mmol/L)
A-1
Standard
0
A-2
Standard
0
B-1
Standard
5.56
B-2
Standard
5.56
C-1
Standard
16.68
C-2
Standard
16.68
------1-64
Samples

SERUM NONESTERIFIED FATTY ACID ANALYSIS
A standard curve was obtained using a 10 ml solution containing oleic
acid at 1 mmol/l (Table 3.9). Borosilicate glass tubes (12X75 mm) for
standards (A-F) and samples were labeled. To each tube, 300 pi of
Reagent A (acyl-CoA synthetase, ascorbate oxidase, CoA, ATP, 4am inoantipyrine) was added, the tubes were vortexed and incubated for 20
minutes in a w ater bath at 37°C. Reagent B (acyl-CoA oxidase, peroxidase,
MEHA; 750 pi) was added, the tubes were vortexed and incubated for 20
minutes in the same water bath. The tubes w ere allowed to cool at room
tem perature for 5 minutes and then read on the spectrophotom eter at 550
nm. The concentrations of the samples were determ ined using the standard
curve.
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Table 3.9 Standard Curve for nonesterified fatty acids
Tube Standard Concentration Stock NEFA Std (|il)
m Eq/L* mmol/L

Distilled w ater (pi)

A
B
C
D
E
F

1000.0
900.0
750.0
250.0
100.0
0.0

0.000
0.100
0.250
0.500
.750
1.000

0.0
100.0
250.0
250.0
300.0
500.0

SERUM UREA NITROGEN ANALYSIS
Brosilicate glass tubes (12X75 mm) were labeled fo r 3 standards
(Table 3.10) and for each sample. The ICN DIGIFLEX pipetter was placed
in the sample/dispense mode, with the left syringe set at 100 pi and right
syringe at 5 uL. To the respective tubes, 5 uL o f standard o r sample was
added and 100 uL o f deionized water. The Urease Buffer Reagent (100 pi;
Sigma catalog No. 640-5; each 30-ml vial contains 100 units o f buffered
ureased from jack beans and sodium azide is the preservative) was added,
the tubes were vortexed and incubated for 10 minutes in a water bath at
37°C. To each tube, 250 pi o f phenol-nitroprusside Solution (50 grams
Phenol and .25 grams sodium nitroprusside) was added and the tubes were
vortexed. Hypochlorite solution (250 pi; 25 grams sodium hydroxide and
fresh 40 ml clorox bleach) was added and once again the tubes were
vortexed. An additional 1000 pi of deionized water was added to all tubes.
The tubes were incubated for 30 minutes at room temperature and the
assay was read at 570 nm using the spectrophotometer.
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Table 3.10 Standard concentrations for urea-Nitrogen analysis
1
Tube Identification Number
Urea-Nitrogen mmol/l
|
Standard 1
0
|
Standard 2
3.57
|
Standard 3
10.71
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Figure 4.1 data: Food intake for rats fed high and low fat diets.
High fat
Low fat
Food Intake
(Grams ± SE)
(Grams ± SE)
Food Intake 1
153.67 ± 3 .6 6
155.19 ± 3 .6 6
(n=32)
(n=32)
Food Intake 2
90.10 ± 2 .2 5
102.82 ± 2 .2 5
(n=32)
(n=31)
Food Intake 3
75.62 ± 2.14
97.54 ± 2 .1 4
(n=32)
(n=31)
Food Intake 4
78.94 ± 1.89
109.68 ± 1 .8 9
(n=32)
(n=31)
Food Intake 5
78.37 ± 1.83
106.93 ± 1 .8 3
(n=31)
(n=31)
Food Intake 6
95.51 ± 1.79
63.92 ± 1 .7 9
(n -3 1 )
(n=31)
Food Intake 7
69.05 ± 2 .1 0
104.88 ± 2 .1 0
(n=31)
(n=31)

Figure 4.2 data: Energy intake fo r rats fed high and low fa t diets.
High fat
Low fat
Energy Intake
(Kcal ± SE)
(Kcal ± SE)
I Energy Intake 1
832.5 ± 17.6
600.18 ± 17.6
(n=32)
(n=32)
Energy Intake 2
372.27 ± 11.3
488.1 ±11.31
(n=32)
(n=31)
Energy Intake 3
409.7 ± 9.7
377.22 ± 9.7
(n=32)
(n=31)
Energy Intake 4
424.18
± 8 .6
427.8 ± 8.6
(n=32)
(n=31)
413.57 ± 8 .6
Energy Intake 5
424.6 ± 8.6
(n -3 1 )
(n=31)
Energy Intake 6
346.3 ± 7.6
369.38 ± 7.6
(n=31)
(n=31)
Energy Intake 7
374.1 ± 9 .2
405.63 ± 9.2
(n=31)
(n=31)
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Figure 4.3 data: Energy intake for rats fed low and high fat with or without
carnitine.
Energy Intake
No Carnitine
No Carnitine
Carnitine
Carnitine
Low Fat
High Fat
Low Fat
High Fat
(Kcal ± SE)
(Kcal ± SE)
(Kcal ± SE)
(Kcal ± SE)
Energy Intake 1 601.5 ± 2 5 .3
826 ± 25.3
598.9 ± 24.5
839.0 ± 4 .5
(n=16)
(n=16)
(n=16)
(n=16)
Energy Intake 2 346.5 ± 16 .3
505.4 ± 16.3
398.0 ±15.7
470.8 ± 15.7
(n=16)
(n -1 6)
(n=15)
(n=16)
Energy Intake 3 363.8 ± 1 3 .9 404.8 ± 13.9
390.7 ± 13.4
414.6 ± 13.4
(n=15)
(n=16)
(n=16)
(n=16)
Energy Intake 4 426.2 ± 12 .4 417.4 ± 12.4
422.2 ± 12.0
437.9 ± 12.0
(n=15)
(n=16)
(n=16)
(n-16)
Energy Intake 5
420.5 ± 1 2 .4
420.7 ± 2.4
406.5 ± 12 .0
428.6 ±12.0
(n=15)
(n=15)
(n=16)
(n=16)
Energy Intake 6 375.0 ± 10.9
343.1 ± 10.9
363.7 ±10 .5
349.5 ±10.5
(n=15)
(n=15)
(n=16)
(n=16)
Energy Intake 7 421.8 ±13 .3 362.3 ± 1 3 .3
389.4 ± 12.8
385.8 ±12.8
(n=15)
(n=15)
(n=16)
(n=16)

Figure 4.4 data (a): Initial and weekly body weig i t fo r all dietary reatments.
Body W eight
CLF
CLL
CPL
CPF
(Grams ± SE) (Grams ± SE) (Grams ± SE) (Grams ± SE)
I Body W eight 0
307 ± 7
307 ± 7
308 ± 7
308 ± 7
(n=8)
(n=8)
(n=8)
(n=8)
I Body W eight 1
317 ± 8
320 ± 8
340 ± 8
340 ± 8
(n=8)
(n=8)
(n=8)
(n=8)
I Body W eight 2
314 ± 7
316 ± 7
314 ± 7
349 ± 7
(n=8)
(n=8)
(n=8)
(n=8)
I Body W eight 3
315 ± 9
321 ± 9
349 ± 9
350 ± 9
(n=8)
(n=8)
(n=8)
(n=8)
Body W eight 4
314 ± 9
320 ± 9
352 ± 9
352 ± 9
(n=8)
(n=8)
(n=8)
(n=8)
Body W eight 5
315 ± 10
319 ± 10
351 ± 10
357 ± 10
(n=8)
(n=8)
(n=8)
(n=8)
Body W eight 6
309 ± 9
346 ± 9
352 ± 9
312 ± 9
(n=8)
(n=8)
(n=8)
(n=8)
Body W eight 7
309 ± 1 0
346 ± 1 0
348 ± 1 0
314 ± 1 0
(n=8)
(n=8)
(n=8)
(n=8)
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Figure 4.4 data (b): Initial and weekly body weig ht fo r all dietary reatments.
NLL
Body W eight
NPL
NLF
NPF
(Grams ± SE) (Grams ± SE) (Grams ± SE) (Grams ± SE)
Body W eight 0
307 ± 7
308 ± 7
307 ± 7
307 ± 7
(n=8)
(n=8)
(n -8 )
(n=8)
Body W eight 1
319 ± 8
320 ± 8
342 ± 8
339 ± 8
(n=8)
(n=8)
(n -8 )
(n -8 )
Body W eight 2
312 ± 7
312 ± 7
353 ± 7
354 ± 7
(n=7)
(n -8 )
(n -8 )
(n -8 )
Body W eight 3
315 ± 10
313 ± 9
348 ± 1 0
356 ± 9
(n=7)
(n
-8
)
(n -8 )
(n -8 )
Body W eight 4
315 ± 10
314 ± 9
351 ± 1 0
358 ± 9
(n=7)
(n -8 )
(n -8 )
(n -8 )
Body W eight 5
312 ± 1 0
317 ± 1 0
359 ± 1 0
352 ± 1 0
(n=7)
(n -8 )
(n -8 )
(n=7)
Body W eight 6
304 ± 1 0
311 ± 9
345 ± 1 0
353 ± 9
(n=7)
(n -8 )
(n -8 )
(n *7 )
Body W eight 7
308 ± 11
315 ± 10
341 ±11
357 ± 1 0
(n=7)
(n -8 )
(n -7 )
(n -8 )

Figure 4.5 data: Body weight for rats fed high and low fat diets .
I Body weight
High fat
Low fat
(Grams ± SE)
(Grams ± SE)
Body weight 0
307 ± 4
307 ± 4
(n=32)
(n=32)
j Body weight 1
340 ± 4
319 ± 4
(n=32)
(n=31)
Body weight 2
350 ± 4
314 ± 4
(n=32)
(n=31)
Body weight 3
351 ± 5
316 ± 5
(n=32)
(n=31)
Body weight 4
353 ± 5
316 ± 5
(n=32)
(n=31)
Body weight 5
355 ± 5
315 ± 5
(n=31)
(n=31)
Body weight 6
349 ± 5
309 ± 5
(n=31)
(n=31)
Body weight 7
348 ± 5
312 ± 5
(n=31)
(n=31)
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Figure 4.6 data: Weic ht gain for rats fed high and low fa t diets.
| W eight Gain
High Fat
Low Fat
(Grams ± SE)
(Grams ± SE)
W eight Gain 1
33.03 ± 1 .6
12.14 ± 1 .6
(n=32)
(n=32)
W eight Gain 2
9.75 ± 2 .1 8
-5.44 ± 2 .1 8
(n=32)
(n=31)
W eight Gain 3
2.60 ± 2 .1 5
0.69 ± 2 .1 5
(n=32)
(n=31)
W eight Gain 4
2.70 ± 1 .1 3
-0.51 ± 1 .1 3
(n=32)
(n=31)
W eight Gain 5
1.40 ± 1 .0 3
-0.10 ± 1.03
(n=31)
(n=31)
W eight Gain 6
-6.42 ± 1 .0 5
-5.67 ±1.05
(n=31)
(n=31)
W eight Gain 7
2.56 ± 1 .4 5
-0.98 ±1.45
(n=31)
(n=31)
Figure 4.7 data. Energy efficiency fo r rats fed high and low fat.
Energy Efficiency
High Fat
Low Fat
(wt gn/1000 kcal ± SE)
(wt gn/1000 kcal ± SE)
Energy Efficiency 1
39.42 ± 2.0
19.90 ± 2 .0
(n=32)
(n=32)
Energy Efficiency 2
-16.93 ± 5 .8
17.67 ± 5 .8
(n=32)
(n=31)
Energy Efficiency 3
4.74 ± 5.3
-1.35 ± 5 .3
(n=32)
(n=31)
Energy Efficiency 4
5.45 ± 2.6
-1.7 ± 2 .6
(n=32)
(n=31)
Energy Efficiency 5
2.06 ± 2.44
-0.62 ± 2.44
(n=31)
(n=31)
Energy Efficiency 6
-18.26 ± 3 .1 6
-17.62 ±3.16
(n=31)
(n=31)
Energy Efficiency 7
-4.81 ± 3.61
4.71 ±3.61
(n=31)
(n=31)

I
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Figure 4.8 data: Serum carnitine levels for rats fed diet with or without
carnitine.
Dietary Treatm ent
Serum Carnitine W k 8
Serum Carnitine W k 2
(nmol/ml ± SE)
(nmol/ml ± SE)
Carnitine
59.63 ± 1.78
58.75 ± 2.35
(n=30)
(n=30)
31.90 ± 2 .2 4
No Carnitine
29.27 ± 1 .7 0
(n=30)
(n=31)
Figure 4.9 data: Serum carnitine levels for rats fed high and low protein.
Dietary Treatm ent
Serum Carnitine Wk 8
Serum Carnitine W k 2
(nmol/ml ± SE)
(nmol/ml ± SE)
High Protein
39.12 ± 2 .3 5
41.27 ± 1 .7 8
(n=30)
(n=30)
51.52 ± 2 .2 4
Low Protein
47.63 ± 1 .7 0
(n=30)
(n=31)
Figure 4.10 data: Serum carnitine levels fo r rats fed hiejh and low fat.
Dietary Treatm ent
Serum Carnitine W k 8
Serum Carnitine Wk 2
(nmol/ml ± SE)
(nm ol/m l ± SE)
High Fat
41.50 ± 1 .7 0
39.86 ± 2.23
(n=29)
(n=33)
Low Fat
47.40 ± 1 .7 8
50.78 ± 2.35
(n=30)
(n=30)
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Figure 4.11 data. Serum carnitine levels for all dietary treatment groups.
Carnitine Wk 2
j Dietary Treatment
Carnitine W k 8
(nmol/ml ± SE)
(nmol/ml ± SE)
CLL
60.22 ± 3.28
65.11 4.33
(n=8)
(n=8)
CPL
61.79 ±4.14
60.03 ± 5.47
(n=6)
(n=7)
CLF
60.22 ± 3.28
67.38 ±4.33
(n=8)
(n=8)
CPF
48.67 ± 3.50
42.49 ±4.62
(n=8)
(n=7)
NLL
32.71 ± 3.50
47.26 ±4.62
(n=7)
(n=7)
NPL
27.29 ± 3.28
30.73 ± 4.33
(n=8)
(n=8)
NLF
29.77 ± 3.50
26.34 ±4.62
(n=8)
(n=7)
NPF
27.33 ± 3.28
23.24 ± 4 .3 3
(n=8)
(n=8)
Figure 4.12 data: Serum carnitine levels for rats fed high and low fat with or
without carnitine.
Dietary Treatment
Carnitine Wk 2
Carnitine Wk 8
(nmol/ml ± SE)
(nmol/ml ± SE)
54.93 ±3.17
Carnitine High Fat
54.44 ± 2.40
(n=31)
(n= 32)
62.57 ± 3.49
Carnitine Low Fat
64.81 ± 2.64
(n=32)
(n=30)
No Carnitine High Fat
24.79 ±3.17
28.55 ± 2.40
(n=32)
(n=31)
39.0 ±3.17
j No Carnitine Low Fat
30.00 ± 2.40
(n=31)
(n=31)
Figure 4.13 data: Serum ammonia levels for rats fed high and low protein
diets.
Ammonia Wk 8
Dietary Treatment
Ammonia Wk 2
(umol ± SE)
(umol/l ± SE)
High Protein
104.0 ± 6 .0
134.8 ± 5 .3
(n=31)
(n=31)
Low Protein
116.1 ± 5 .4
93.1 ±6.1
(n=29)
(n=31)

I
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Figure 4.14 data: Serum ammonia levels for rats fed high and low protein
with or without carnitine.
Amm onia Wk 8
Dietary treatment
Ammonia W k 2
(um ol ± SE)
(umol/l ± SE)
Carnitine High Protein
122.4 ± 7 .4
103.8 ± 8 .5
(n=16)
(n=15)
117.2 ± 7 .4
96.6 ± 8.5
Carnitine Low Protein
(n -1 5 )
(n=16)
No Carnitine High Protein
147.2 ± 7.4
104.3 ± 8 .5
(n=15)
(n=16)
115 ± 7 .7
89.5 ± 8.8
No Carnitine Low Protein
(n=14)
(n=15)

Figure 4.15 data: Serum ammonia levels for all c ietary treatm ent groups.
Amm onia W k 8
Dietary Treatment
Ammonia Wk 2
(umol/L ± SE)
(um ol/L ± SE)
CLL
98.1 ± 12.4
128.3 ± 10 .9
(n=7)
(n=8)
CPL
110 ± 10.9
108.8 ± 12.4
(n=7)
(n=8)
CLF
95.2 ± 11.6
106.1 ± 10.2
(n=8)
(n=8)
CPF
98.7 ± 11.6
134.79 ± 10.2
(n=8)
(n=8)
91.3 ± 12.4
NLL
115.8 ±10.9
(n=7)
(n=7)
NPL
149 ± 10.2
118.6 ± 1 1 .6
(n=8)
(n=8)
NLF
87.7 ± 12.4
114.1 ±10 .9
(n=7)
(n=8)
NPF
90.0 ± 12.4
145.4 ±10.9
(n=8)
(n=7)
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Figure 4.16 data: Serum glucose levels for rats fed diet with or without
carnitine.
Dietary Treatment
Glucose Wk 2
Glucose W k 8
(mmol/l ± SE)
(mmol ± SE)
8.64 ± 0.24
8.66 ± 0.31
Carnitine
(n=30)
(n=32)
8.16 ± 0 .2 4
9.24 ± 0.31
No Carnitine
(n=31)
(n=30)

Figure 4.17 data: Serum glucose levels for rats fed high and low protein
diets.
Dietary Treatment
Glucose W k 8
Glucose W k 2
(mmol/l ± SE)
(mmol ± SE)
High Protein
9.41 ± 0.30
8.63 ± 0.23
(n=31)
(n=32)
Low Protein
8.17
± 0 .2 4
8.49 ± 0.31
(n=30)
(n=30)

Figure 4.18 data: Serum glucose levels of rats fed high and low protein with
or w ithout carnitine.
Glucose Wk 2
I Dietary treatm ent
Glucose W k 8
(mmol/l ± SE)
(mmol ± SE)
Carnitine High Protein
8.86 ± 0.44
9.09 ± 0.34
(n=16)
(n=15)
8.19 ± 0 .3 4
Carnitine Low Protein
8.47 ± 0.44
(n=16)
(n=15)
No Carnitine High Protein
9.97 ± 0.42
8.17 ± 0 .3 2
|
(n=16)
(n=16)
No Carnitine Low Protein
8.14 ± 0 .3 5
8.52 ± 0.45
(n=15)
(n=15)

|
I
I
I
I

I

Figure 4.19 data: Serum urea nitrogen levels for rats fed high and low
protein diets.________________________________________________
Dietary Treatment
Urea W k 2
Urea Wk 8
(mmol ± SE)
(mmol/l ± SE)
High Protein
7.77 ± 0.21
6.48 ± 0 .1 6
(n=32)
(n=31)
Low Protein
5.76 ± 0.22
5.53 ± 0 .1 6
(n=30)
(n=31)
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Figure 4.20 data: Serum urea nitrogen levels for rats fed diet with or without
carnitine.
Dietary Treatm ent
Urea W k 2
Urea W k 8
(mmol/l ± SE)
(mmol ± SE)
Carnitine
6.04 ± 0 .1 6
6.80 ± 0.21
(n=31)
(n=32)
No Carnitine
6.00 ± 0 .1 6
6.73 ± 0.22
(n=30)
(n=31)
Figure 4.21 data: Serum urea nitrogen levels for rats fed low and high fat.
Dietary Treatment
Urea W k 2
Urea W k 8
(mmol/l ± SE)
(mmol ± SE)
High Fat
6.27 ± 0.21
5.76 ± 0 .1 6
(n=32)
(n=31)
Low Fat
6.25 ± 0 .1 6
7.26 ± 0.22
(n=30)
(n=31)
Figure 4.22 data: Serum urea nitrogen levels for rats fed high and low fat
with or w ithout carnitine.
Dietary treatm ent
Urea W k 2
Urea W k 8
(mmol/l ± SE)
(mmol ± SE)
Carnitine High Fat
5.95 ± 0.22
6.53 ± 0.30
(n=16)
(n=16)
Carnitine Low Fat
6.14 ± 0 .2 2
7.06 ± 0.31
(n=15)
(n=16)
No Carnitine High Fat
5.58 ± 0.22
6.01 ±0.31
(n=15)
(n=16)
No Carnitine Low Fat
6.36 ± 0.22
7.46 ± 0.31
(n=15)
(n=15)

Figure 4.23 data: Serum urea nitrogen levels fo r rats fed high and low
protein and fat.______________________________________________
| Dietary treatm ent
Urea W k 2
Urea Wk 8
(mmol/l ± SE)
(mmol ± SE)
High Protein High Fat
6.00 ± 0.22
7.01 ± 0.30
(n=16)
(n=16)
High Protein Low Fat
7.00 ± 0.22
8.53 ± 0.31
(n=15)
(n=16)
Low Protein High Fat
5.52 ± 0.22
5.53 ± 0.31
(n=15)
(n=16)
Low Protein Low Fat
5.54 ± 0.22
5.98 ± 0.31
(n=15)
(n=15)
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Figure 4.24 data: Serum insulin levels for rats fed high and low protein
Insulin Wk 8
Insulin W k 2
Dietary Treatment
(u U/ml ± SE)
(MU/ml ± SE)
5.9 ± 0.5
High Protein
6.7 ± 0 .5
(n=16)
(n=13)
4.7 ± 0.5
Low Protein
5.4 ± 0.5
(n=13)
(n=15)
Figure 4.25 data: Serum insulin levels for rats fed high and low protein with
or w ithout carnitine.
Insulin Wk 8
| Dietary Treatment
Insulin W k 2
(MU/ml ± SE)
(uU/ml ± SE)
6.3 ± 0 .7
6.5 ± 0.7
Carnitine High Protein
(n=14)
(n=16)
4.4 ± 0.6
Carnitine Low Protein
5.7 ± 0.7
(n=16)
(n=16)
5.4 ± 0.7
No Carnitine High Protein
7.1 ± 0 .7
(n=16)
(n=15)
4.9 ± 0.7
No Carnitine Low Protein
5.2 ± 0 .8
(n=13)
(n=15)
Figure 4.26 data: Serum insulin levels for rats fed high and low fat with or
w ithout carnitine.
Insulin Wk 8
I Dietary Treatment
Insulin W k 2
(MU/ml
± SE)
(MU/ml ± SE)
6.6 ± 0 .7
5.0 ± 0.7
Carnitine High Fat
(n=16)
(n=15)
5.8 ± 0.7
Carnitine Low Fat
5.4 ± 0 .7
(n=16)
(n=15)
5.0 ± 0.7
No Carnitine High Fat
4.8 ± 0 .8
(n=14)
(n=15)
5.3 ± 0.7
No Carnitine Low Fat
7.4 ± 0 .7
(n=15)
(n=15)
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Figure 4.27 data: Serum insulin levels for rats fed high and low levels of
protein and fat.________________________________________________
Insulin Wk 8
Dietary Treatment
Insulin W k 2
(MU/ml
± SE)
(MU/ml ± SE)
High Protein High Fat
5.0 ± 0 .7
5.5 ± 0.7
(n=14)
(n=16)
6.9 ± 0.7
High Protein Low Fat
7.8 ± 0.7
(n=16)
(n=15)
5.1 ± 0 .7
Low Protein High Fat
5.8 ± 0.8
(n=14)
(n=16)
Low Protein Low Fat
4.3
± 0.7
5.0 ± 0 .7
(n=15)
(n=15)
—

-

Figure 4.28 data: Serum nonesterified fatty acids level fo r rats fed high and
low fat.
NEFA W k 2
NEFA Wk 8
Dietary Treatm ent
(pEq/L ± SE)
(pEq/L ± SE)
High Fat
636.7 ± 42.7
628.8 ± 42.5
(n=30)
(n=32)
Low Fat
820.1 ± 42.2
792.2 ± 43.4
(n=31)
(n=30)
Figure 4.29 data: Serum nonesterified fatty acid levels for rats fed diet with
or without carnitine.
] Dietary Treatment
NEFA W k 2
NEFA Wk 8
|
(pEq/L ± SE)
(pEq/L ± SE)
I Carnitine
753.3 ± 43.2
692.6 ± 43.4
(n=31)
(n=31)
j No Carnitine
695.6 ± 42.5
736.3 ± 42.7
(n=31)
(n=3)

I
I

Figure 4.30 data: HOAD activity for rats fed high and low
protein with or without carnitine._____________________
I Dietary Treatment
HOAD Activity
(pmol/g/min ± SE)
Carnitine High Protein
5.82 ± 0.70
(n=16)
Carnitine Low Protein
4.97 ± 0.68
(n=16)
5.44 ± 0.68
No Carnitine High Protein
(n=16)
6.77 ± 0.72
No Carnitine Low Protein
(n=14)
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Figure 4.31 data: Body composition analysis for rats fed diet with or without
carnitine
Fat %
Dietary
Protein %
M oisture %
Ash %
Treatment
(% ± SE)
(% ± SE)
(% ± SE)
(% ± SE)
Carnitine
21.42 ± 0 .8 2
56.72 ± 0.73
20.52 ±0.42
4.61 ± 0 .1 5
(n=32)
(n=32)
(n=32)
(n=32)
No Carnitine
19.89 ± 0 .8 5
57.30 ± 0.75
21.25 ±0.43
4.46 ±0.16
(n=30)
(n=30)
(n=30)
(n=30)
Figure 4.32 data: Body com position analysis for rats fed high and low fat
diets
Fat %
Dietary
Protein %
M oisture %
Ash %
Treatment
(% ± SE)
(% ± SE)
(% ± SE)
(% ± SE)
High Fat
54.2 ± 0.7
24.7 ± 0.8
20.3 ± 0.4
4.4 ± 0.2
(n=31)
(n=31)
(n=31)
(n=31)
Low Fat
16.7 ± 0 .8
21.5 ± 0 .4
59.8 ± 0.7
4.7 ± 0.2
(n=31)
(n=31)
(n=31)
(n=31)
Figure 4.33 data: Final body weight for rats fed high
and low fat diets.
Dietary Treatm ent
Final Body W eight
(Grams ± SE)
High Fat
342 ± 5
(n=31)
Low Fat
304 ± 5
(n=31)
I
Figure 4.34 data: Abdominal fat for rats fed diets with
o r without carnitine
1 Dietary Treatment
Abdominal Fat
1
(Grams ± SE)
| Carnitine
20.4 ± 1.1
I
(n=31)
I No Carnitine
18.4 ± 1 .2
(n=31)

I
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Figure 4.35 data: Abdominal fat as percent o f body weight fo r rats fed diet
with o r without carnitine.
Dietary Treatment
Abdominal Fat as % o f
Body W eight
(% ± SE)
Carnitine
6.2 ± 0.3
(n=32)
No Carnitine

5.5 ± 0 .3
(n=30)

Figure 4.36 data: Serum glucose levels for rats fed high and low fat before
(0 min) and after (120 min] glucose administration.
Dietary Treatm ent
Glucose 0 min
Glucose 120 min
(mmol/l ± SE)
(mmol/l ± SE)
High Fat
10.43 ± 0 .3 5
16.80 ±0.63
(n=32)
(n=31)
Low Fat
10.83 ±0.37
13.09 ±0.67
(n=32)
(n=28)

|
I
I
I
|

I

Figure 4.36 data: Serum insulin levels for rats fed high and low fat diets
before (0 min) and after (120 min) glucose adm inistration.
Dietary Treatment
Insulin 0 min
Insulin 120 min
(MU/ml ± SE)
(MU/ml ± SE)
High Fat
4.4 ± 0.6
4.8 ± 0.3
(n=32)
(n=32)
Low Fat
5.5 ± 0.6
3.3 ± 0 .3
(n=31)
(n=30)
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Figure 4.37 data: Serum glucose levels of rats fed high and low protein
before (0 m in) and after (120 min) glucose administration.___________
Dietary Treatm ent
Glucose 120 min
Glucose 0 min
(mmol/l ± SE)
(mmol/l ± SE)
High Protein
15.83 ±0.66
10.59 ±0.36
(n=29)
(n=32)
14.06 ±0.64
Low Protein
10.68 + 0.36
(n=30)
(n=31)
Figure 4.37 data: Serum insulin levels of rats fed high and low protein before
(0 min) and after (120 min glucose administration.
Insulin 120 min
j Dietary Treatm ent
Insulin 0 min
(MU/ml ± SE)
(p ll/m l ± SE)
High Protein
4.3 ± 0 .3
5.6 ± 0.6
(n=32)
(n=32)
Low Protein
3.8 ± 0.3
4.3 ± 0.6
(n=31)
(n=30)
Figure 4.38 data: Serum insulin levels for rats fed high and low protein with
or without carnitine before (0 min) and after (120 min) glucose
adm inistration.
Insulin 120 min
Dietary Treatm ent
Insulin 0 min
(MU/ml ± SE)
(MU/ml ± SE)
Carnitine High Protein
4.7 ± 0.4
10.7 ± 0 .8
(n=16)
(n=16)
Carnitine Low Protein
3.3 ± 0.4
3.5 ± 0 .8
(n=16)
(n=16)
No Carnitine High Protein
3.9 ± 0.4
4.9 ± 0 .8
(n=16)
(n=16)
No Carnitine Low Protein
4.2 ± 0.5
5.1 ± 0 .9
(n=15)
(n=14)
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Figure 4.38 data: Serum glucose levels for rats fed high and low protein with
or without carnitine before (0 min) and after (120 min) glucose
administration.
Glucose 120 min
I Dietary Treatment
Glucose 0 min
(mmol/L ± SE)
(mmol/L ± SE)
16.22 ± 0 .9 8
Carnitine High Protein
6.4 ± 0.54
(n=13)
(n=16)
13.90 ±0.88
Carnitine Low Protein
10.10 ± 0 .4 8
(n=16)
(n=16)
15.43 ±0.88
No Carnitine High Protein
10.48 ± 0 .4 8
(n=16)
(n=16)
11.26 ± 0 .5 2
14.22 ± 0 .9 5
No Carnitine Low Protein
(n=14)
(n=15)

Figure 4.39 data: Serum insulin levels for rats fed high and low protein and
fa t before (0 min) and after (120 min) glucose adm inistration.
Insulin 0 min.
Insulin 120 min.
I Dietary treatm ent
(pU/ml ± SE)
(pU/ml ± SE)
High Protein High Fat
4.4 ± 0.8
5.3 ± 0.5
(n=16)
(n=16)
High Protein Low Fat
3.3 ± 0.5
6.9 ± 0.8
(n=16)
(n=16)
Low Protein High Fat
4.4 ± 0.8
4.2 ± 0.5
(n=16)
(n=16)
Low Protein Low Fat
3.3 ± 0.5
4.1 ± 0 .9
(n=15)
(n=14)

Figure 4.39 data: Serum glucose levels fo r rats fed high and low protein and
fa t before (0 min) and after (120 min) glucose adm inistration.
Glucose 120 min.
R Dietary treatm ent
Glucose 0 min.
(mmol/L ± SE)
(mmol/L ± SE)
| High Protein High Fat
10.48 ± 0 .5 0
17.74 ±0.91
(n=15)
(n=16)
I High Protein Low Fat
13.92 ± 0 .9 5
10.69 ± 0 .5 2
(n=14)
(n=16)
I Low Protein High Fat
15.86 ±0.88
10.38 ± 0 .4 8
(n=16)
(n=16)
I Low Protein Low Fat
12.26 ± 0 .9 5
10.97 ± 0 .5 2
(n=14)
(n=15)
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